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Abstract 
  
 
 
General anaesthesia is an induced state that enables a person to endure surgical 
procedures without pain or recollection. There is substantial individual variability 
in the response to anaesthesia and in order to avoid adverse effects caused by 
either under- or over-sedation, anaesthetic drug administration must be tailored to 
suit the individual patient. This requires a means to monitor the depth of general 
anaesthesia. The electroencephalogram (EEG) records the electrical activity of the 
brain and enables effects of anaesthetic drugs on brain functioning to be 
monitored. Quantitative EEG monitors, such as the Bispectral (BIS) index 
monitor, process the raw EEG and provide a numerical output that is often used to 
measure the depth of general anaesthesia during surgery. Due to a number of 
factors including clinical conditions and genetic variability in the EEG, the BIS 
value can at times be misleading.  
To identify genetic variations associated with EEG phenotypes relevant to 
anaesthesia monitoring, an association analysis was performed for 34 single 
nucleotide polymorphisms (SNPs) in a sample of 125 surgical patients undergoing 
general, gynaecological or orthopaedic surgery. During surgery, patients were 
anaesthetised with the volatile anaesthetic agent desflurane, the depth of 
anaesthesia was measured using BIS monitoring and the raw was also EEG 
recorded. SNP genotyping was performed for 13 SNPs in five candidate genes; 
SGIP1, GABRA2, CACNA1G, HCN1 and HCN2, using the polymerase chain 
reaction and restriction fragment length polymorphism analysis. An additional 21 
SNPs in 15 genes involved in various inflammatory and other immune-related 
pathways were genotyped by Sequenom MassARRAY at the Australian Genome 
Research Facility. 
Six SNPs in five different genes were found to be associated with spindle 
amplitude (SGIP1, GABRA2, HCN1, IL1B and MYD88), and a further five SNPs 
were associated with either delta frequency (IL10), or end tidal desflurane 
concentration (ETDC) (CACNA1G, CRP, MYD88 and TGFB1). The strongest 
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associations were identified for a single SNP located in the 3' UTR of MYD88 
(rs6853). The rs6853 A/G genotype was associated with higher median spindle 
amplitude (p = 0.0040) and spindle amplitude relative to ETDC (p = 0.0006), and 
lower EDTC (p = 0.0095) than the A/A genotype. No rs6853 G/G homozygotes 
were identified in the study sample. 
MYD88 acts as an adaptor protein in the interleukin-1 receptor and toll-like 
receptor signalling pathways. Within the brain, cytokines are thought to act as 
neuronal modulators and influence neurotransmitter signalling and ion channel 
activity. The association of MYD88 with spindle amplitude, in conjunction with 
IL1B, suggests that cytokines may influence the EEG during general anaesthesia. 
Thus cytokine mediated regulation of neuronal activity is speculated to underlie 
the reported associations. All reported effect sizes were small (0.77- to 1.55-fold) 
and associated genes had four distinct types of function; ion channels, 
neurotransmitter signalling, endocytosis, and cytokine signalling. This suggests 
that numerous genes in different pathways, each with a small, possibly additive 
effect, are involved in regulating the EEG during general anaesthesia. 
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1 Chapter 1:  
Introduction and 
Literature Review 
  
 
 
 
1.1 General introduction  
Every year thousands of New Zealanders undergo operations that require the use 
of general anaesthesia to enable them to endure surgical procedures without pain 
or recollection. It is widely accepted that there is substantial variability in the 
quantity of anaesthetic agents required to induce adequate anaesthesia and that 
following surgery, the pain experienced by patients can be highly variable [1]. To 
ensure appropriate dosage of anaesthetic drugs and avoid adverse effects caused 
by either under- or over-sedation, a reliable and accurate method of monitoring 
the depth of anaesthesia is required. 
One tool that is now commonly used to monitor general anaesthesia during 
surgery is the electroencephalogram (EEG). The EEG records the electrical 
activity of the brain and reflects its rhythmic activity. EEG patterns reflect a 
person’s state of consciousness and can be used to assess the effects of 
anaesthetics on cortical activity – allowing the EEG to be used to gauge the depth 
of anaesthesia and assist anaesthetic administration. Various quantitative EEG 
(qEEG) monitors, such as the bispectral (BIS) index monitor, have been 
developed to process the raw EEG and provide a numerical output that is used to 
guide the titration of anaesthetics during surgery. Previous studies have reported 
the depth of anaesthesia, as measured by qEEG monitors, can influence post-
operative pain [2], and that the use of these monitors during surgery can reduce 
the risk of post-operative recall [3, 4].  
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This research is part of larger study aimed at determining the influence of the 
depth of anaesthesia, as measured by the BIS monitor, on post-operative pain 
levels. The BIS is a dimensionless numerical variable that ranges from 0-100 and 
reflects of consciousness. BIS monitors are commonly used in anaesthesia 
monitoring, however, due to factors including clinical conditions and genetic 
variability in the EEG, the BIS value can at times be misleading.  
Many features of brain oscillations are largely genetically determined, resulting in 
inter-individual differences in the EEG that can contribute to a misleading BIS 
value. While numerous studies have investigated genetic variations associated 
with the EEG in psychiatric disorders, variations influencing the EEG during 
general anaesthesia have not yet been investigated. The aim of this research was 
to investigate genetic variably in the form of single nucleotide polymorphisms 
(SNPs) associated with the EEG during general anaesthesia. As genetic 
differences can confound interpretation of the EEG, a better understanding of the 
genetic variability underlying individual EEG variability may lead to improved 
use of the EEG in anaesthesia monitoring and reduced post-operative pain. 
 
 
1.2 General anaesthesia 
General anaesthesia is a controlled and reversible state comprised of multiple 
components – sedation, amnesia, analgesia, and immobility – that enable a person 
to endure surgical procedures without pain or recollection. While the exact 
mechanisms of general anaesthesia are still poorly understood, a generalised 
decrease in cortical activity and the blockade of external sensory information 
transfer from the thalamus to the cortex is presumed to be involved [5]. 
Both genetic and clinical factors influence anaesthetic drug requirements and the 
response to anaesthesia [6], occasionally resulting in either under- or over-
sedation [7]. Under-sedation can potentially result in a patient remembering 
events from the surgery (post-operative recall), which can lead to psychological 
disturbances such as anxiety, nightmares and post-traumatic stress disorder [8-10]. 
The incidence of post-operative recall is estimated at 1-2 patients per 1000 [11-
13], however this risk is substantially increased during certain high risk 
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procedures, such as cardiac surgery [14] and caesarean section [15]. Over-
sedation can also compromise patient outcome and can potentially result in 
complications such as cardiovascular and respiratory suppression [7]. 
 
1.2.1 Monitoring the depth of general anaesthesia 
Because of the variability in the way individuals respond to anaesthesia, drug 
administration must be tailored to suit the individual patient. This requires 
monitoring the depth of anaesthesia and titrating anaesthetic agents to achieve a 
desirable level of sedation. 
Traditionally, anaesthetists monitored various physiological parameters such as 
respiration rate, heart rate, blood pressure and pupil size, to gauge the depth of 
anaesthesia (reviewed in [16]). The absence of responsiveness, while an important 
sign of adequate anaesthesia, is an unreliable predictor of the depth of anaesthesia, 
largely due to the administration of muscle relaxants that suppress movement 
without removing consciousness [13, 17]. Other techniques evolved to assist 
anaesthesia monitoring include the isolated forearm technique [18] and measuring 
the exhaled concentration of volatile anaesthetics (end tidal anaesthetic 
concentration (ETAC)). ETAC provides a measure of the alveolar concentration 
of anaesthetic agent which is thought to reflect levels in the brain. More recently, 
the EEG has been gaining popularity as a tool to monitor the depth of anaesthesia 
as it enables the effects of anaesthetics on cortical functioning to be monitored 
[19]. Incorporation of EEG monitoring with current monitoring techniques is 
suggested to better enable the patient’s level of sedation to be estimated [11, 19]. 
Better measurement of the depth of anaesthesia may lead to more appropriate 
administration of anaesthetic agents, subsequently reducing the potential for 
adverse effects caused by either over- or under-sedation. 
 
 
  
1 | Introduction and Literature Review  4 
 
 
 
1.3 The electroencephalogram 
The EEG provides a graphical representation of the spontaneous electrical activity 
of the brain. It was discovered in the 1920’s by Hans Berger who reported the first 
human EEG recording in 1929 [20]. Nowadays, the EEG is widely used in both 
research and clinical settings, including applications in psychiatry, diagnostics and 
anaesthesia monitoring. 
The EEG recording is obtained by placing electrodes on the scalp that detect the 
combined electrical activity of large numbers of neurons located primarily in the 
cerebral cortex [21]. Differences in voltage between pairs of electrodes at 
different sites on the head are measured and amplified, and the resultant EEG 
recording provides a graphical representation of these voltage differences over 
time (Figure 1.1). 
 
 
Figure 1.1: The human brain and EEG recording. 
Electrodes placed on the scalp measure the voltage difference between two locations on the 
head and the EEG recording provides a graphical representation of these voltage differences 
over time. 
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1.3.1 Genesis of the EEG signal 
The primary generators of the EEG signal are the large excitatory pyramidal (PY) 
neurons located in layers III, IV and V of the cerebral cortex [21]. The combined 
synchronous activity of large numbers of these neurons creates extracellular 
voltage fields that are able to be detected by scalp electrodes [21-23] .  
It is not axonal action potentials but rather synaptic activity in the dendrites of 
cortical PY neurons that provide the predominant source of the EEG signal [21, 
22]. Excitatory postsynaptic potentials (EPSPs) and inhibitory postsynaptic 
potentials (IPSPs), generate extracellular currents that are able to summate both 
temporally and spatially to produce local electric fields of both sufficient duration 
and strength to be detected by scalp electrodes [21, 24]. While synaptic activity 
provides the most significant source of the EEG signal, other non-synaptic sources 
can potentially contribute to extracellular current flow and therefore to the EEG 
signal. Non-synaptic contributors to the EEG signal include calcium mediated 
action potentials (Ca2+ spikes) and the after hyperpolarisation following Ca2+ 
spikes [21, 25]. Sodium action potentials (Na+ spikes) are usually of too short 
duration (<2 µs) to contribute to scalp recorded EEG, except during synchronous 
events such as epileptic activity [21, 24]. 
 
1.3.2 EEG rhythms  
The EEG reflects the rhythmic activity of the brain. Wave-like fluctuations occur 
when periodic sequences of synchronised action potential bursts generate EPSPs 
in large numbers of cortical PY cells that summate to produce major 
depolarisations, resulting in fluctuations in local field potentials that appear as 
oscillations in the EEG [24]. These oscillations are classified on the basis of 
frequency into five major classes of brain oscillations (Table 1.1).  
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Table 1.1: Brain oscillations categorised by frequency. 
Hz = hertz (number of oscillations per second).  
Wave category Frequency (Hz) 
Delta (δ) 0.5 - 4.0 
Theta (θ)  4.0 - 7.0 
Alpha (α) 7.0 - 13.0 
Beta (β) 13.0 - 30.0 
Gamma (γ) 30.0 - 80.0 
 
EEG oscillatory activity reflects the functional state of the brain and changes in 
both the signal frequency and amplitude are observed with different states. In the 
awake state and during rapid eye movement (REM) sleep, the EEG is 
predominated by low amplitude, high frequency, alpha and beta waves [22]. In 
these states rapid patterns are observed and the EEG is said to be desynchronised 
[26]. During non-REM (NREM) sleep and anaesthesia, there is a shift in the EEG 
signal from rapid low-amplitude, high-frequency activity, to high-amplitude, low-
frequency rhythmic activity (synchronised EEG) [26, 27]. Delta and spindle 
waves are particularly prominent features of the synchronised EEG [27] and these 
rhythms reflect important changes in thalamocortical activity (Section 1.3.3). 
Spindle waves are groups of waxing and waning 7 to 14 Hz oscillations that last 1 
to 3 seconds and recur every 3 to 10 seconds [28] (Section 1.4.3). These rhythmic 
oscillations are a hallmark of NREM sleep and are also an important feature of the 
EEG during general anaesthesia [29]. 
 
1.3.3 EEG patterns during general anaesthesia 
The anaesthetised EGG is similar to that seen during NREM sleep and is 
characterised by low frequency delta and theta waves, the loss of alpha and beta 
waves, and the appearance of spindle waves that become slower and longer as the 
depth of anaesthesia increases [5, 22]. The most important signs of anaesthesia are 
likely the absence of fast waves, and the presence of spindle waves superimposed 
against background of slow waves [22].  
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During both sleep and anaesthesia, the shift to synchronised EEG activity reflects 
important changes in thalamic activity. The thalamus acts as a gateway regulating 
the flow of information to the cortex [28] and a decrease in its activity is an 
important feature of loss of consciousness [22]. During waking, the thalamus is 
depolarised and in this state acts a relay station forwarding sensory information to 
the cortex. During slow wave sleep and anaesthesia the thalamus becomes 
hyperpolarised and in this state the transfer of information from the thalamus to 
the cortex is blocked [5, 29]. The appearance of spindle and delta waves on the 
EEG indicate thalamic hyperpolarisation, and thus the blockade of sensory 
information transfer through to the cortex [29]. 
 
 
1.4 Generation of synchronised EEG activity  
The synchronised EEG observed during sleep and anaesthesia results from 
rhythmic neuronal activity co-ordinated by sub-cortical pacemaker activity in the 
brain [26]. The main brain regions involved in the generation of synchronised 
EEG activity, such as spindle and delta waves, are the thalamus and the cerebral 
cortex [28], and the primary cell types involved are the thalamocortical (TC) 
neurons and the GABA-ergic thalamic reticular (TR) neurons of the thalamic 
reticular nucleus (TRN) [28]. Neurons in these structures have intrinsic oscillatory 
properties [26, 28, 30] and interactions with other neurons are thought to modulate  
this oscillatory activity [31]. Both the intrinsic properties of these neurons and 
their interactions are important for the generation of widespread rhythmic brain 
activity [32, 33]. 
Thalamic neurons can fire in two distinct firing modes: the ‘tonic mode’ (also 
known as the transmission mode) and the ‘burst mode’ (also known as the 
oscillatory mode) [34]. The desynchronised EEG occurs when thalamic neurons 
fire in the tonic mode. In this mode, TC neurons fire tonic Na+ spikes at 
depolarised membrane potentials and the thalamus acts as a relay station for 
sensory information to be forwarded to the cortex [27]. Accordingly, the tonic 
mode is generally associated with the awake state and also REM sleep [34]. The 
burst mode is associated with the synchronised EEG and occurs during NREM 
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sleep and anaesthesia. In the burst firing mode, thalamic neurons are 
hyperpolarised and fire in a uniform repetitive pattern and in this state, 
information transfer from the thalamus to the cortex is blocked [5, 29].  
The switch from the tonic mode to the burst mode of firing involves alterations in 
neurotransmitter release from the brainstem, resulting in hyperpolarisation of the 
resting membrane potential [27, 28, 35]. Hyperpolarisation activates a series of 
ionic currents that play an important role in the burst mode and the generation of 
synchronised EEG activity. Two highly important currents involved in the burst 
mode of firing are the low-threshold calcium current (It) and the 
hyperpolarisation-activated mixed cation current (Ih). These two currents are 
thought to operate in tandem to generate rhythmic burst firing in thalamocortical 
networks [27]. 
 
1.4.1 Low-threshold calcium current  
The low-threshold calcium current (It) is an inward flowing Ca2+ current that is 
active near the resting membrane potential and exhibits voltage dependent 
activation and inactivation [36]. This current was first identified in nervous tissue 
in the 1980’s following the discovery of low threshold spikes (LTS) in inferior 
olive and thalamic neurons by Llinás and colleagues (reviewed in [36]). It plays an 
important role in neuronal oscillations and cardiac and neuronal pacemaker 
activity [36, 37], and is implicated in various other processes including pain 
processing [38, 39] and fertilization [40]. It has also been associated with various 
disorders such as epilepsy [41], neuropathic pain [42], hypertension [43] and 
cardiac hypertrophy [44]. 
Underlying It are low voltage gated T-type Ca2+ channels (T-type Ca2+ channels, 
also known as low voltage activated Ca2+ channels). T-type Ca2+ channels are 
characterised by their low-voltage threshold for activation and inactivation, fast 
inactivation, selectivity for Ca2+, and tiny single channel conductance [37]. These 
channels activate around the resting membrane potential (about -65mV), are 
inactivated by membrane depolarisation and de-inactivated by membrane 
repolarisation [27, 37, 45]. 
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It is inactive at the more depolarised membrane potentials associated with the 
tonic firing mode [34]. During the burst firing mode, the resting membrane 
potential is more negative and It plays an important role in the generation of 
synchronised EEG activity by promoting LTS and rebound burst firing [46]. 
Rebound burst firing is the phenomenon whereby neurons can be triggered to fire 
after hyperpolarisation. This involves action potentials known as low threshold 
spikes that are generated from a membrane potential more negative than the Na+ 
spike threshold. Hyperpolarisation, such as that induced by the arrival of IPSPs, 
removes the inactivation of It and when the membrane potential returns to its 
resting level voltage dependent activation of It occurs. The activation of It results 
in a Ca2+ influx into the cell (Ca2+ spike) that depolarises the membrane to the 
point where Na+ channels are able to open, resulting in a burst of Na+ action 
potentials called rebound bursts (reviewed in [36]). 
 
1.4.2 Hyperpolarisation-activated mixed cation current  
The hyperpolarisation-activated mixed cation current (Ih) is an inwardly directed 
mixed Na+/K+ current that is activated by hyperpolarisation and closes at positive 
membrane potentials. cAMP is a direct modulator Ih of and acts to shift the 
activation curve toward more positive potentials [47]. Ih plays a central role in the 
generation and regulation of spontaneous rhythmic activity in both the brain and 
cardiac pacemaker cells, and also contributes to numerous other neuronal 
functions including working memory, motor learning, determination of the resting 
membrane potential and synaptic transmission (reviewed in [48, 49]). 
Misregulation of Ih is thought contribute to a number of neurological disorders 
including epilepsy and chronic pain (reviewed in [50]). 
Underling Ih are hyperpolarisation-activated cyclic nucleotide gated (HCN) 
channels. There are four HCN subunit isoforms (HCN1-4) and these assemble 
into either homo- or hetero-tetrameric Ih channels that form a pore across the cell 
membrane [51]. The four HCN subunit isoforms differ both in their activation 
kinetics [52] and degree of regulation by cAMP (reviewed in [49]). The co-
assembly of different HCN subunits to form heterotetrameric Ih channels 
substantially increases the functional diversity of these channels [51, 53, 54].   
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1.4.3 Spindle oscillations 
Spindles oscillations are bursts of 7 to 14 Hz oscillations that generally last 1 to 3 
seconds and recur every 3 to 10 seconds [28] (Figure 1.2). The appearance of 
these rhythmic oscillations on the EEG is a useful correlate for anaesthesia 
monitoring they indicate hyperpolarisation of the thalamus and a switch to the 
burst firing mode [5, 29].  
 
 
Figure 1.2: The EEG showing varying amounts of spindle activity.  
Image kindly supplied by Professor Jamie Sleigh (Department of Anaesthesiology, Waikato 
Clinical School, University of Auckland, Auckland, New Zealand). 
 
Spindle waves were first described by Loomis in the 1930’s [55]. They are 
primarily generated in the thalamus by a reciprocal interaction between TC and 
TR neurons [28, 56, 57] through the interplay of synaptic interconnections and 
intrinsic membrane properties [33]. Rhythmic cycles of action potential bursts in 
TR cells impose IPSPs on TC neurons via GABA-ergic synapses [33] that 
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hyperpolarise TC neurons, resulting in the de-inactivation of It and the subsequent 
activation of It during the repolarising phase [56, 57]. Activation of It generates 
LTS and rebound bursts in TC neurons, which then fire EPSPs back to TR 
neurons to restart the cycle [56, 57]. TC neurons also forward this activity onto 
the cortex, imposing EPSPs on PY neurons, that are visible in the EEG as spindle 
waves [28]. A small number of cells are involved in spindle wave initiation and 
they then spread into synchronised network oscillations through the progressive 
recruitment of neighbouring neurons [58]. Within the thalamus, TR cells are 
thought to play a central role in the initiation of spindle oscillations and also to act 
as the oscillatory pacemaker by setting TC firing at the spindle frequency 
(reviewed in [59]). 
The cortex is also thought to play an important role in the initiation, 
synchronization and termination of spindle oscillations [60, 61]. In addition to 
cortical inputs, spindle termination is thought to involve upregulation of Ih.  
LTS is accompanied by a rise in intracellular Ca2+. This increases cAMP levels 
leading to persistent Ih activation, which in turn depolarises TC cells sufficiently 
to inactivate the It current and thus end the spindle. Immediately following the 
spindle, intracellular Ca2+ remains high resulting in residual upregulation of Ih 
which is thought to determine the refractory period between spindles [62-64]. 
Blockage of Ih either by the application of Cs+ or the drug ZD7288 (a 
bradycardiac agent), has been demonstrated to abolish the spindle wave refractory 
period, resulting in the generation of continuous spindle oscillations [62].  
 
1.4.4 Delta oscillations  
Delta oscillations lie in the 0.5 to 3.5 Hz frequency range and are primarily 
associated with deep sleep [23]. These oscillations are also seen during general 
anaesthesia and are important correlates for anaesthesia monitoring as they 
indicate thalamic hyperpolarisation and blockade of sensory information transfer 
to the cortex [29]. 
The delta oscillation is an intrinsic rhythm generated in the thalamus in TC 
neurons at membrane potentials more negative than that required for spindle wave 
generation [32]. This rhythm involves the interaction of Ih and It at hyperpolarised 
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membrane potentials, resulting in the generation of spontaneous and self sustained 
oscillations in the delta frequency range [28]. At hyperpolarised membrane 
potentials, activation of It generates LTS and rebound burst firing causing a 
membrane depolarisation that deactivates Ih and inactivates It. Decline of the 
rebound burst creates a hyperpolarising overshoot, removing the inactivation of It 
and activating Ih. Ih then gradually depolarises the membrane leading to the 
activation of It – restarting of the cycle [65]. While the interaction between Ih and 
It is able to generate intrinsic delta rhythms in single TC neurons, the cortex is 
hypothesised to both potentiate the delta rhythm and synchronise thalamic 
neurons via thalamocortical networks, resulting in the appearance of delta waves 
in the EEG [66]. 
 
 
1.5 Using the EEG to monitor anaesthesia 
1.5.1 q EEG monitors and the BIS index 
A predictable series of changes occur in the EEG as a person transitions from 
fully awake to asleep, or as one becomes anaesthetised (Section 1.3.3). qEEG 
monitors algorithmically process the raw EEG to generate a numerical output 
known as a qEEG index that reflects state of consciousness [22]. The qEEG index 
is used to guide the titration of anaesthetic agents to achieve a number within a 
recommended range. These monitors are often used to estimate the depth of 
general anaesthesia and assess the risk of intra-operative recall during surgery [22]. 
Numerous indices are commercially available such as the BIS index (Aspect 
Medical Systems, Newton, MA), spectral entropy (GE Healthcare, Helsinki, 
Finland), and the cerebral state index (Danmeter, Odense, Denmark).  
The BIS index was first introduced in 1992 and is now the most widely used and 
investigated qEEG index [7]. The BIS monitor processes the raw EEG recorded 
from a single EEG channel measured on the patient’s forehead to derive the  
BIS value. The BIS index is a dimensionless numerical variable that provides a 
quantitative measure of cortical activity, allowing the effects of anaesthetics on 
consciousness, memory formation, and analgesia, to be assessed during surgery 
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[67] (reviewed in [68]). BIS values range from 0-100 and inversely reflect level of 
sedation; a BIS value of zero indicates the absence of brain activity (isoelectric 
EEG) whereas a value of 100 indicates full consciousness. BIS values of 40-60 
are generally recommended as a suitable target for surgery, and have been 
associated with a low probability of responsiveness and recall during general 
anaesthesia [69, 70]. When anaesthetic drug delivery was titrated within this range, 
the use of BIS monitors during surgery has been reported to lead to an 
approximately 80% reduction in the incidence of recall [3, 4], and also to promote 
faster emergence and improved post-operative recovery [71-73]. Furthermore, the 
BIS value has also been shown to correlate with the probability of movement in 
response to surgical incision [74, 75], however, this correlation becomes weaker 
when analgesics are used in conjunction with other anaesthetic agents [76]. 
 
1.5.2 Reliability of the BIS value 
While there are numerous studies demonstrating the use of BIS monitors in 
anaesthesia management to improve patient care, there are also reports in which 
the BIS value has been erroneous. For example, case reports document patients 
experiencing explicit intra-operative recall despite having BIS values <50 [77, 78]. 
While the above examples represent extreme cases, they highlight the fact that the 
BIS value can at times be misleading and cannot be relied on as a sole means to 
estimate anaesthetic depth. A number of factors can contribute to a misleading 
BIS value including various clinical conditions, electromyography artefacts and 
environmental artefacts such as interference from electronic devices (reviewed in 
[79]). Furthermore, the BIS value is not independent of the anaesthetic agent used 
whereby different drugs can elicit varying changes in the EEG [79]. 
In addition to various clinical and environmental factors that can affect the BIS 
value, BIS values also demonstrate significant variability between individuals 
potentially making it difficult to accurately use the BIS monitor to predict sedation 
level [80]. Between individuals there can be marked differences in the raw EEG, 
these differences are largely genetically determined [81] and can confound 
interpretation of the BIS value. For example, spindle wave patterns have been 
demonstrated to show considerable variability between individuals during normal 
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sleep [82] and clinical observations have shown that some patients lack spindle 
waves during general anaesthesia (unpublished observation).  
 
 
1.6 Genetics of human brain oscillations 
The EEG is relatively stable in individuals and high high-retest correlations are 
observed in healthy adults [83-85]. The majority of EEG characteristics are 
largely genetically determined [81], with genetic factors contributing strongly to 
important characteristics of the sleep, waking and anaesthetised EEG. Twin 
studies investigating heritability of the EEG have demonstrated higher 
concordance between monozygotic twins than dizygotic twins and unrelated 
individuals [86, 87], this is also observed in monozygotic twins raised apart [88]. 
EEG spectral power analysis has demonstrated high heritability for the various 
frequency bands; the average heritability of the alpha, beta, theta, and delta 
frequencies have been estimated to be 89%, 86%, 89% and 76%, respectively [89].  
Because of the stability and high heritability of the EEG, phenotypes based on 
measures of EEG power and amplitude represent useful correlates for genetic 
analysis. Accordingly, the EEG is often used as an endophenotype (an 
intermediate phenotype that is involved in the pathway between genotype and 
clinical outcome [90]) to study to genetic factors involved in psychiatric disorders. 
The use of the EEG as an endophenotype is thought to aid the search of genes 
associated with complex disorders as the EEG more closely reflects the function 
of genes that predispose to such disorders than clinical diagnosis and symptoms 
alone [91]. Using this approach, numerous studies have investigated genetic 
variations contributing to EEG variability in the context of disorders such as 
alcoholism [92-95] and schizophrenia/psychosis [96, 97]. This has led to the 
identification of numerous genes predicted to influence the resting EEG that may 
also be involved in predisposition to alcoholism, including SGIP1 [95], GABRA2 
[92, 98] and CRH-BP [93, 99] and HRT3B [94].  
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Despite the important clinical application of the EEG in anaesthesia monitoring, 
studies investigating genetic variation and the EEG during general anaesthesia 
have not been published to date.  
 
 
1.7 Anaesthesia, surgery and inflammation 
1.7.1 Inflammation 
Inflammation is an immune response characterised by five cardinal signs; rubor 
(redness), tumor (swelling), calor (heat) and dolor (pain) and functio laesa (loss 
of function). The inflammatory response plays an essential role in host defence 
and can be activated in response to pathogenic infection, tissue injury, or by 
immune stimulation. It is a dynamic process that consists of four main 
components; inflammatory inducers, sensors, mediators and target tissues [100]. 
As well as playing a vital role in the immune response to infection, inflammation 
is also a contributing factor to many chronic diseases including diabetes, 
osteoporosis and cardiovascular disease (reviewed in [101]). Inflammation is also 
thought to have a potential role in many central nervous system (CNS) diseases 
including epilepsy, neurodegenerative disorders, multiple sclerosis, and even 
some psychiatric disorders such as schizophrenia and depression [102, 103].  
 
1.7.2 Cytokines and immune system-to-brain communication  
Cytokines are small protein molecules involved in cell-cell signalling. They exert 
their effects by binding to specific receptors on target cells, activating intra-
cellular signalling cascades that regulate gene transcription. Cytokines play an 
important role as mediators of the inflammatory response, including regulating the 
production of other cytokines [104].  
During systemic inflammation, cytokines are secreted primarily by peripheral 
immune cells, such as macrophages and monocytes [105]. These cytokines, or 
their signals, are able to reach the CNS, thus there is bi-directional communication 
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between the brain and immune system [106]. Tumor necrosis factor (TNF) α, and 
the interleukins (IL) IL-1 and IL-6, are thought to be the primary mediators of 
immune system-to-brain communication [106]. Cytokines cannot freely cross the 
blood-brain barrier (BBB) but can reach the brain by passive transport through 
leaky areas of the BBB, active transport across the BBB [106]. Cytokine signals 
may also be transmitted via nerve fibres and humoral mechanisms [106]. 
Furthermore, cytokines are known to be expressed by various brain cells, 
including glial cells, astrocytes and neurons (reviewed in [107]).  
Within the brain, cytokines have been implicated in various aspects of normal 
brain functioning, including sleep regulation, neuroendocrine functioning and 
neuronal development [105], as well in pathological conditions such as seizure 
generation and epilepsy [108]. Numerous studies on rodents have reported 
elevated mRNA levels of TNFα, IL-1, IL-6, and the IL-1 receptor (IL-1R) 
following immune activation induced by peripheral endotoxin administration 
[109-114], suggesting that the systemic inflammatory response may affect brain 
functioning by inducing pro-inflammatory cytokine expression in the brain [109]. 
Accordingly, peripheral immune stimulation by endotoxin administration has 
been found to influence the sleep EEG and sleep patterns, resulting in increased 
delta activity during NREM sleep in rats [115] and humans [116], and increased 
alpha and beta activity in humans [117]. However, conflicting results have also 
been reported [118]. 
Increasing evidence suggests that cytokines may influence neurotransmitter 
signalling and ion channel activity in the brain to regulate neuronal excitability 
and synaptic plasticity (reviewed in [105, 119]). Although the exact mechanisms 
by which cytokines exert such effect remains unclear, post-translational 
modification has been suggested as one possible mechanism, as effects have been 
shown to occur rapidly within seconds or minutes of exposure. Effects have also 
been observed following prolonged exposure – suggesting cytokine mediated 
effects on gene expression [119]. 
 
  
1 | Introduction and Literature Review  17 
 
 
 
1.7.3 Surgery, anaesthesia and the inflammatory response 
Surgery is a highly invasive process that induces a systemic inflammatory 
response essential for tissue repair, pathogen elimination and the maintenance of 
homeostasis. The normal inflammatory response to surgery consists of 
immunological, hormonal and metabolic components and involves a balance 
between pro- and anti-inflammatory factors [120]. Initially, pro-inflammatory 
cytokines such as IL-1, IL-6 and TNFα, are released at the site of damage and 
induce immune activation and an inflammatory response. Inflammatory 
stimulation predominates for the first 36 hrs and over the next few days is 
balanced by a compensatory suppressive response that involves the release of 
anti-inflammatory cytokines including IL-10, IL-1R antagonist, and soluble TNF 
receptors [120]. The extent of the inflammatory response to surgery is usually 
well- controlled and appropriately balanced in healthy patients and is related to 
the invasiveness of the surgical procedure [120]. Dysregulation of this response 
can lead to post-operative complications such as sepsis, impaired wound healing 
and systemic inflammatory response syndrome [120].  
The inflammatory response to surgery is influenced by various factors such as 
genetics, age, other medications, pre-existing conditions and also anaesthetic 
drugs [121, 122]. The ability of anaesthetic agents to modulate inflammatory 
processes was first demonstrated over 100 years ago and during more recent 
decades, effects of various anaesthetics on the immune response have been widely 
studied both in vitro and in vivo (reviewed in [120, 122]). In general, anaesthetic 
agents are considered to have immuno-suppressive effects. Different anaesthetics 
modulate the inflammatory response to surgery either via direct effects on 
immune cells, or, indirectly by influencing the stress response, disturbing the 
balance between pro- and anti-inflammatory responses, resulting in a slight 
immune-suppression of limited duration.[122-124]. Although the exact nature and 
extent of these effects remain unclear, it is apparent that both the type of 
anaesthetic and the concentration administered influence the effects of 
anaesthetics on immune cells [120, 122]. Effects are generally considered to be 
small and clinically insignificant in healthy patients relative to the impact of 
surgical trauma [120], but may be of much greater clinical importance in patients 
with significant pre-existing conditions and elderly patients [122, 123].   
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1.8 Personalised medicine and pharmacogenomics 
Personalised medicine refers to the customisation of healthcare in which genetic 
and other information, such as biochemical measurements, are used to tailor 
medical practice and treatment to best suit the individual.  
One major area in which personalised medicine may lead to improved health care 
outcomes is in drug administration and prescription. There is a wide degree of 
heterogeneity in individual response to pharmaceuticals which can be due to 
numerous factors including age, sex, other clinical conditions, and inheritance [1, 
125, 126]. The disciplines of pharmacogenetics and pharmacogenomics 
(collectively referred to here as pharmacogenomics) study the genetic basis 
underling individual variation in drug response. Pharmacogenomic studies tend to 
focus on genetic variation in the form of SNPs (Section 1.8.1). Cancer 
chemotherapy provides an example of progress in pharmacogenomics that has led 
to improved treatment outcomes by allowing treatment to be customised based on 
the genetic profile of the tumor cells [127]. 
It is widely accepted that there is considerable variability in anaesthesia 
requirements and recovery from anaesthesia between patients. Along with various 
clinical factors, genetic variation also contributes to the pharmacology of 
anaesthetics and it is thought that multiple genes and gene variants underlie this 
variability [128]. The response to anaesthesia can be influenced by genetic 
differences in receptors and ion channels [6], as well as transport proteins and 
enzymes involved in drug metabolism [1]. These differences have important 
clinical implications for the anaesthetist [1], thus this area represents an important 
focus for pharmacogenomics research. While understanding the genetic variability 
contributing to anaesthetic response has clear implications for clinical practice, 
understanding the genetic variability associated with the EEG during general 
anaesthesia may augment advances in this area by improving anaesthesia 
monitoring.  
The identification of genetic variants associated with EEG traits of importance to 
anaesthesia monitoring, such as spindle and delta wave features, may lead to 
improved use of qEEG monitors in anaesthesia monitoring by allowing the 
incorporation of genetic data into the BIS or other algorithms, or through the 
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development of new algorithms. Improved monitoring in conjunction with 
personalised anaesthetic drug administration using pharmacogenomic information, 
may lead to improved anaesthetic administration and consequently better patient 
outcomes, potentially reducing side effects and post-operative pain. 
 
1.8.1 Single nucleotide polymorphisms 
SNPs are single base pair differences in the human genome present in >1% of the 
population. There an estimated ~7 million common SNPs with minor allele 
frequencies (MAF) >5%, and a further ~4 million with MAFs between 1 and 5% 
[129]. While allele frequencies of SNPs can vary considerably between 
populations, the majority of common SNPs are found in most major human 
populations [130]. SNPs account for the majority of variants in the human 
genome and are predicted to occur approximately once every 800-100 bp  
[131, 132]. 
Genome-wide association studies (GWAS) and candidate gene studies generally 
use common DNA variants in the form of SNPs to identify genes and genomic 
regions associated with particular traits or disease risk. GWAS test thousands of 
SNPs spread across the entire genome for potential associations, whereas 
candidate gene studies select a subset of SNPs in a gene, or genes, of interest to 
genotype and test for associations with the phenotype of interest. These studies 
have identified hundreds of loci associated with disease susceptibility, the vast 
majority of which are located in non-coding regions [133].  
SNPs in non-coding regions may have functional effects on phenotype if they 
occur in regulatory regions and affect levels of gene expression. Alternatively, 
associations of non-coding SNPs with disease may be due to linkage 
disequilibrium (LD) with functional SNPs either in non-coding or protein coding 
regions. LD refers to the non-random association of SNP loci on the same 
chromosome [134, 135]. Segments of the genome in high LD are unlikely to have 
been interrupted by recombination, and such segments are referred to as haplotype 
blocks. Within these blocks, SNP alleles correlate in a predictable way and limited 
combinations of alleles – known as haplotypes – are observed [134, 135]. 
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1.9 Study design  
This research applied a candidate gene type approach to identify SNPs associated 
with the EEG during general anaesthesia with desflurane (herein referred to 
simply as general anaesthesia). Participants were surgical patients who had the 
raw EEG recorded during surgery and the depth of anaesthesia measured using the 
BIS monitor. For each patient, a short EEG segment (epoch) was selected from 
the middle of the surgery for analysis. Five candidate genes were selected for 
inclusion in this study (Section 1.10) and two to three SNPs in each gene were 
chosen to be genotyped. Genotyping was performed using the polymerase chain 
reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis 
(collectively referred to as PCR-RFLP) (Section 2.2). Statistical analysis was used 
to test SNPs for associations with spindle and delta wave features, and with 
anaesthetic agent concentration.   
For the larger study this research was part of, a number of patient DNA samples 
were also sent to the Australian Genome Research Facility (AGRF, Brisbane, 
Australia) and genotyped for SNPs 15 different inflammatory and immune-related 
genes (Section 1.11). Genotyping results were provided for incorporation into this 
study and these SNPs were also tested for associations with the EEG. 
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1.10 Candidate genes 
Five candidate genes were specifically selected for inclusion in this study (Table 
1.2). The first two of these genes – SGIP1 and GABRA2 – were selected on the 
basis of results from previous association studies [92, 95] and on their 
physiological roles. The remaining three genes – CACNA1G, HCN1 and HCN2 – 
were chosen based on their roles in the generation of synchronised neuronal 
activity.  
 
Table 1.2: Basic information on candidate genes selected for inclusion in this study. 
Official 
Symbol Location Official name Role of gene product 
SGIP1 1p31.3 
SH3-domain GRB2-like 
(endophilin) interacting 
protein 1 
Involved in recycling 
receptors, ion channels and 
other membrane proteins in 
neuronal cells. 
GABRA2 4p12 
Gamma-aminobutyric 
acid (GABA) A receptor 
alpha 2 
Neurotransmitter receptor in 
the brain for the inhibitory 
neurotransmitter GABA.  
HCN1 5p12 
Hyperpolarisation-
activated cyclic 
nucleotide-gated 
potassium channel 1  
Mixed cationic ion channel in 
neuronal cells, underlies Ih. 
CACNA1G 17q22 
Calcium channel, 
voltage-dependent, T 
type, alpha 1G subunit  
T-type Ca2+ ion channel in 
neuronal cells, underlies It. 
HCN2 19p13.3 
Hyperpolarisation-
activated cyclic 
nucleotide-gated 
potassium channel 2  
Mixed cationic ion channel in 
neuronal cells, underlies Ih. 
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1.10.1 SGIP1  
The human gene SGIP1 encodes a highly conserved endocytic adaptor protein 
predominantly expressed in the brain known as SH3-domain GRB2-like 
(endophilin) interacting protein 1 (NCBI Gene ID: 84251) [136]. SGIP1 is located 
on the forward strand of chromosome 1 at 1p31.3, spans approximately 211 kb, 
and consists of 27 exons [136] (Figure 1.3) (Figure 2.2a). 
 
 
Figure 1.3: Location and genomic context of SGIP1. 
a. Chromosome 1 showing locus 1p31.3; b. Genomic region of 1p31.3 containing SGIP1 and 
neighbouring genes. (Figure based on NCBI human genome build 37.3). 
 
SGIP1 was first identified as a central regulator of energy homeostasis in 
Psammomys obesus, a polygenic rodent model of obesity [136]. The protein it 
encodes has been shown to as function as an endocytic protein [136], and a direct 
role for the splice variant SGIP1α in clathrin-mediated endocytosis (CME) has 
been demonstrated using knockdown, over-expression and co-localisation studies 
[137]. In neuronal cells, CME regulates the uptake of channels, transporters and 
other membrane proteins, and also mediates the internalization of several 
signalling receptors, thereby modulating signal transduction [138]. CME is also a 
central pathway for the recycling of synaptic vesicles at the nerve terminal 
following synaptic transmission [139].  
A recent GWAS by Hodgkinson et al. (2010) identified eight SNPs in SGIP1 
associated with resting theta power in Plains American Indians [95]. SGIP1 was 
1 | Introduction and Literature Review  23 
 
 
 
found to account for 8.8% of the variance in theta power in this sample, and for 
3.5% of the variance in a replicate US Caucasian sample. Several other genes 
involved in cell trafficking processes were also associated with the EEG at 
threshold or sub-threshold significance. Variability in such genes is suggested to 
influence neuronal membrane component uptake and recycling, consequently 
influencing neuronal excitability [95], which is then reflected in the EEG.  
 
1.10.2 GABRA2  
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in 
the mammalian brain (Stephenson 1988). GABA exerts its inhibitory effects by 
binding to one of three types of receptors; GABAA, GABAB and GABAC. 
GABAA receptors are ligand-gated chloride ion channels that mediate the majority 
of fast synaptic inhibition in the brain [140]. These receptors are assembled from a 
combination of five subunits from six different subunit classes; α, β, γ, ε, ρ and µ 
[140]. Different combinations of these subunits confer different physiological and 
pharmacological properties increasing the diversity of GABAA receptors [140]. 
GABAA receptors are been proposed as targets for many general anaesthetics 
(reviewed in [141]). Nearly all general anaesthetics have been demonstrated to 
potentiate GABA-ergic currents, and generally at higher doses to activate GABAA 
receptors in the absence of GABA [141]. 
There are six members of the α subunit class (α1- α6) and the majority of GABAA 
receptors contain α subunits as well as β and γ. In humans, the GABAA α2 
subunit is encoded for by the gene GABRA2 (NCBI Gene ID: 2555). GABRA2 is 
comprised of 10 exons, spans approximately 140 kb and is located amongst a 
cluster of GABAA receptor genes on the reverse strand of chromosome 4 at 4p12 
[142] (Figure 1.4) (Figure 2.2b). GABRA2 mRNA is subject to both alternative 
splicing and alternative promoter use, leading to the production of numerous 
isoforms with varying levels of expression throughout the brain [143].  
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Figure 1.4: Location and genomic context of GABRA2. 
a. Chromosome 4 showing locus 4p12; b. 1.5 mb region on 4p12 containing the GABAA 
receptor gene cluster harbouring GABRA2. (Figure based on NCBI human genome build 37.3). 
 
GABRA2 variability has previously been associated with increased beta power in 
the resting EEG [92, 144]. The association of GABRA2 with the EEG was first 
identified in a study by Edenberg et al. (2004) using the EEG as an 
endophenotype to investigate the genetics of alcohol dependency [92]. Numerous 
candidate gene studies have reported associations between GABRA2 variation and 
alcohol dependence and related phenotypes, and this gene is now considered a 
confirmed locus for susceptibility to alcohol dependency (reviewed in [145]). The 
association of GABRA2 with both the beta frequency band and alcohol 
dependence has lead to the hypothesis that GABRA2 variability might influence 
susceptibility to alcohol dependence by modulating neuronal excitability [92].  
Based on the role of GABA-ergic signalling spindle wave generation (Section 
1.4.3); the role of GABAA receptors as targets for many general anaesthetics; the 
previously identified association of GABRA2 with beta frequencies; and the 
postulated role of this gene in regulating neuronal activity, it is hypothesised that 
GABRA2 variability might also influence anaesthetic response and the EEG 
during general anaesthesia. 
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1.10.3 CACNA1G  
The human gene CACNA1G encodes the T-type Ca2+ channel subunit α1G, also 
known as Cav3.1 (NCBI Gene ID: 8913). CACNA1G maps to chromosome 17 at 
17q22, spans approximately 66.5 kb on the forward strand and consists of 38 
exons [146, 147] (Figure 1.5) (Figure 2.2d). CACNAG1 is subject to extensive 
alternative splicing that is both developmentally regulated [148] and tissue 
specific [149]. Alternative splicing of CACNA1G transcripts serves to increase the 
diversity of T-type Ca2+ channels and has been shown to modify channel gating 
properties [148, 150]. 15 sites of transcript variation have been identified: 11 sites 
of alternative splicing in the open reading frame, two alternative 5' UTR promoter 
sites and two alternative 3' UTR polyadenylation sites [146, 148].  
 
 
Figure 1.5: Location and genomic context of CACNA1G. 
a. Chromosome 17 showing locus 17q22; b. ~200 kb region of 17q22 containing CACNA1G 
and neighbouring genes. (Figure based on NCBI human genome build 37.3). 
 
T-type Ca2+ channels belong to the voltage gated Ca2+ channel (Cav) family, 
which includes both low (T-type) and high (L-, P/Q-, N- and R-types) voltage 
activated members. The different members of this family mediate the different 
voltage regulated Ca2+ currents. Cav channels are heteromultimers and the channel 
subtype is determined solely by the principle pore forming α1 subunit [151].  
The various α1 subunits are encoded for by Cav channel α1 subunit gene family 
which contains three subfamilies (Cav1-3) that arose by an ancient gene 
duplication [152]. 
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CACNA1G belongs to the Cav3 gene subfamily which encodes the T-type α1 
subunits. There are two other genes in this subfamily; CACNA1H and CACNA1I, 
which encode the α1H (Cav3.2) and α1I (Cav3.3) subunits, respectively. The three 
T-type α1 subunits each have different biophysical properties (reviewed in [153]) 
and the expression pattern of the three Cav3 genes is unique and complementary 
to a great extent [154]. The α1G subunit is predominantly expressed in the brain, 
with particularly high levels of expression observed in the thalamus [147, 149, 
154].  
T-type Ca2+ channels mediate It and this current plays an important role in the 
generation of synchronised EEG activity, including delta and spindle waves 
(Sections 1.4.4 and 1.4.3). The importance of Cav3.1 channels in the generation 
synchronised EEG activity has been demonstrated in mice lacking functional 
Cav3.1. Within the thalamus, Cav3.1 channels are the primary generators of LTS 
[153]. LTS and burst firing has been shown to be absent in TC neurons of 
CACNA1G-/- mice [155], accordingly, these mice show altered slow wave EEG 
activity during natural sleep and under urethane anaesthesia, with both a loss of 
spindle oscillations and decreased delta activity compared to wild type mice [156].  
Because of the important role of It in the generation of synchronised EEG activity; 
the role of Cav3.1 channels in promoting LTS in the thalamus; and the altered 
slow wave EEG activity observed in CACNA1G-/- mice, variability in CACNA1G 
is suggested to potentially underlie some of the variability in the EEG observed 
under general anaesthesia. 
 
1.10.4 HCN1 and HCN2  
The human gene HCN1 encodes the hyperpolarisation-activated cyclic nucleotide-
gated channel subunit 1 (HCN1), also known as brain cyclic nucleotide gated 1 
(BCNG-1). HCN1 is located in a relatively gene poor region on the reverse strand 
of chromosome 5 at 5p12, spans approximately 437 kb and is comprised of 8 
exons (NCBI Gene ID: 348980) (Figure 1.6) (Figure 2.2c). HCN2 encodes the 
hyperpolarisation-activated cyclic nucleotide-gated channel subunit 2 (HCN2), 
also known as brain cyclic nucleotide gated 2 (BCNG-2). HCN2 is located on the 
forward strand of chromosome 19 at 19p13.3, consists of 8 exons and spans 
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approximately 27 kb (NCBI Gene ID: 610) (Figure 1.7) (Figure 2.2e). The protein 
products of these genes are 890 (HCN1) and 189 (HCN2), amino acids long and 
alternative splicing variants have not been identified for either gene (Ensembl: 
ENSG00000164588 (HCN1) and ENSG00000099822 (HCN2)). 
HCN1 and HCN2 were first discovered and cloned in the late 1990’s along with 
the other two members of the HCN gene family, HCN3 and HCN4 [157-159]. In 
the brain, HCN channels mediate the important pacemaker current Ih (Section 
1.4.2). Ih plays a key role in delta wave generation (Section 1.4.4) and is thought 
to be involved in regulating the periodicity of spindle waves (Section 1.4.3). 
 
 
Figure 1.6: Location and genomic context of HCN1. 
a. Chromosome 5 showing location of locus 5p12; b. 2 mb region of 5p12-5p11 containing 
HCN1 and neighbouring genes. (Figure based on NCBI human genome build 37.3). 
 
 
Figure 1.7: Location and genomic context of HCN2. 
a. Chromosome 19 showing location of locus 19p13.3; b. ~140 kb region of 19p13.3 
containing HCN2 and neighbouring genes. (Figure based on NCBI human genome build 37.3). 
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Expression of the HCN gene family has been well studied at both the transcript 
and protein levels in the mouse and rat brain. All four genes have been found to 
be expressed in the brain and multiple isoforms can be expressed in the same cell 
[52, 160]. HCN2 is widely distributed throughout the brain and is particularly 
highly expressed in the thalamus and brain stem. HCN1 shows a more localised 
distribution and is predominantly expressed in the neocortex, hippocampus and 
cerebellum [158, 160-162]. There is considerable overlap in the expression of 
HCN1 and HCN2 [160], and sub-cellular localization of these subunits has also 
been shown with the highest channel density found in the distal dendrites of 
neuronal cells [161, 163].  
Using HCN2-/- mice, Ludwig et al. (2003) have demonstrated that Ih in TC neurons 
is predominately generated by HCN2, and that HCN2 plays a vital role  
in determining the resting membrane potential of these cells [164]. HCN2-/- TC 
relay neurons were found to exhibit a near total loss of Ih and fired in the burst 
mode rather than the tonic mode as observed in wild type cells [164]. While 
HCN2 channels appear to play a critical role in regulating neuronal excitability in 
TC neurons, HCN1 channels appear to fulfil this role in PY neurons. The 
dendrites of HCN1−/− PY neurons have been demonstrated to display a loss of Ih 
resulting in enhanced excitability, suggesting a crucial role for HCN1 in the 
generation of Ih and the regulation of excitability in PY neurons [165]. These 
observations also correspond well with expression data showing that HCN1 is the 
most predominantly expressed HCN gene in the cortex, and HCN2 in the 
thalamus [160]. 
HCN channels have also been implicated as potential targets of anaesthetics. 
Volatile anaesthetics have been demonstrated to inhibit Ih in brainstem motor 
neurons [166, 167], and intravenous anaesthetics to inhibit Ih in thalamic and TC 
relay neurons [168, 169]. The inhibition of Ih by volatile anaesthetics involves a 
hyperpolarising shift in the voltage dependence of activation and a decrease in 
current amplitude; these effects represent actions on the HCN1 and HCN2 
subunits, respectively [170].  
Based on the essential role of Ih in the generation of synchronised EEG; the 
effects of HCN1 and HCN2 knockout on PY and TC neurons, respectively; and 
the role of HCN channels as anaesthetic targets, it is speculated that variability in 
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either HCN1 and/or HCN2 may influence the generation of synchronised EEG 
activity and be associated with differences in the EEG during general anaesthesia. 
 
 
1.11 Inflammatory genes 
Several candidate genes involved in various inflammatory and other immune-
related pathways were investigated for associations with post-operative pain for 
the larger study this research was part of. The majority of these genes are involved 
in cytokine signalling and inflammatory pathways and therefore this set of genes 
will be collectively referred to as ‘inflammatory genes’. SNPs in or near 15 
inflammatory genes were selected and genotyped by researchers at AGRF (Table 
1.3), and genotyping information was provided for incorporation into the present 
study.  
Based on the role of cytokines in immune-to-brain communication and their 
ability to modulate ion channels in the brain and influence neuronal excitability 
(Section 1.7.2), variability in genes involved in these signalling pathways might 
also influence the EEG during general anaesthesia.  
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Table 1.3: Information on candidate inflammatory genes 
Information on genes involved in various inflammatory and immune pathways selected for 
genotyping by AGRF. Ch. = chromosome; TLR = toll-like receptor signalling. 
Official 
Symbol Ch. Official Name Function 
IL6R 1 Interleukin 6 Receptor Cytokine receptor 
CRP 1 C-reactive protein, pentraxin-related 
Involved in various host defence 
functions 
IL10 1 Interleukin 10 Anti-inflammatory cytokine 
IL1B 2 Interleukin 1 beta Pro-inflammatory cytokine 
MYD88 3 Myeloid Differentiation Primary Response Gene (88) 
Signal transducer in IL-1 & TLR 
signalling pathways 
IL2 4 Interleukin 2 Pro-inflammatory cytokine 
TLR2 4 Toll Like Receptor 2 TLR signalling 
TNF 6 Tumor Necrosis Factor Pro-inflammatory cytokine 
OPRM1 6 Opioid Receptor, Mu 1 Opioid receptor 
IL6 7 Interleukin 6 Pro-inflammatory cytokine 
LY96 8 Lymphocyte Antigen 96 TLR signalling 
TLR4 9 Toll Like Receptor 4 TLR signalling 
CASP1 11 Caspase 1 Protease. Activates inactive IL-1 precursor. Can promote apoptosis. 
BDNF 11 Brain-Derived Neurotrophic Factor Nerve growth factor 
TGFB1 19 Transforming growth factor, beta 1  Anti-inflammatory cytokine 
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1.12 Research objectives 
The main objective of this study was to identify genetic polymorphisms 
associated with brain oscillations during general anaesthesia. The identification of 
such variants may improve our understanding of genetic factors influencing the 
EEG during general anaesthesia and may help provide a genetic explanation for 
clinical observations, such as the absence of spindles in some patients. This may 
lead to improved understanding of how genetic variability can influence the BIS 
value, and lead to improved use of the BIS index in anaesthesia monitoring. 
 
1.12.1 Aim  
The primary aim of this research was to identify genetic variants in the form of 
SNPs associated with human brain oscillations as recorded by the EEG during 
general anaesthesia in specifically selected candidate genes and various 
inflammatory and immune-related genes. 
 
1.12.2 Hypotheses 
Hypothesis One 
Polymorphisms in, or near, the candidate genes; SGIP1, CACNA1G, GABRA2 
HCN and HCN2, will influence brain oscillations as recorded by the EEG during 
general anaesthesia. A null hypothesis proposes that brain oscillations during 
general anaesthesia are not affected by variation in, or near, these genes. 
Hypothesis Two 
Polymorphisms in, or near, inflammatory pathway and related genes may affect 
human brain oscillations as recorded by the EEG during general anaesthesia. A 
null hypothesis proposes that variability in or near inflammatory and related genes 
will not influence brain oscillations during general anaesthesia. 
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2 Chapter 2:  
Materials and Methods 
  
 
 
 
2.1 Samples 
This research was part of larger study investigating post-operative pain levels and 
use of the BIS monitor to measure the depth of anaesthesia during surgery. Ethical 
approval was obtained from the Northern X Ethics Committee (reference number 
NTX/09/06/047) and from the University of Waikato School of Science and 
Engineering Human Research Ethics Committee (reference number 103).  
Participants undergoing general, gynaecological or orthopaedic surgery were 
recruited from Waikato Hospital and North Shore Hospitals. Written consent was 
obtained from each participant and basic personal and medical details were 
recorded including age, sex, ethnicity, and operation type.  
During surgery, patients were anaesthetised with the volatile anaesthetic agent 
desflurane. The depth of anaesthesia was estimated with BIS monitoring, and 
anaesthesia was titrated to achieve a BIS value within a given range. The raw 
EEG was also recorded intra-operatively and processed by the anaesthetist 
following surgery. For each patient, the anaesthetist selected a 60 sec EEG epoch 
recorded during the middle of the surgery that was representative of the EEG 
throughout. Median BIS value, median delta amplitude and frequency, median 
spindle amplitude and frequency, and median end tidal desflurane concentration 
(ETDC), were determined for the selected epoch. Quantitative processed EEG and 
ETDC data was then provided by the anaesthetist in spreadsheet format. 
1 ml of peripheral whole blood was obtained at surgical closure by a medical 
doctor and was placed in a collection tube containing 4 ml of a 5 M guanidinium 
isothiocyanate (GITC) solution (Appendix 6.1) [171]. This was transported from 
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the hospital to the Molecular Genetics Laboratory at the University of Waikato 
(C.2.03) and stored at room temperature until DNA extraction. 
 
2.1.1 Isolation of genomic DNA from blood 
Total genomic DNA was extracted from each blood sample using the following 
protocol:  
1 ml of the blood/GITC solution was placed in a labelled 1.7 ml eppendorf tube 
and 100 µl of 3 M sodium acetate and 0.7 ml of phenol:chloroform was added. 
The tube was shaken vigorously and placed on a rotator wheel for 15 min, 
followed by centrifugation at 13,000 rpm for 15 min at 4ºC. The aqueous layer 
containing the DNA was transferred to new labelled tube using a transfer pipette. 
An additional extraction was then performed using the same procedure as above, 
with an equal volume of chloroform in place of phenol:chloroform. 
Following extraction, an equal volume of isopropanol was added and the tube was 
inverted a few times then left on ice for 15 min to allow the DNA to precipitate. 
After precipitation, the tube was centrifuged at 13,000 rpm for 15 min at 4ºC and 
the supernatant discarded. The precipitate was then washed with 1 ml 70% 
ethanol and centrifuged at 13,000 rpm for 5 min at 4ºC. The supernatant was 
removed and discarded using a transfer pipette, and any residual ethanol was 
briefly spun down in a centrifuge and removed using an autopipette. Any 
remaining ethanol was evaporated by leaving the tube to stand at room 
temperature for a short period. Finally, 50 µl of TE buffer (Appendix 6.1) was 
added to re-suspend the pellet and samples were stored at 4˚C until required. 
 
2.1.2 Cetyltrimethylammonium bromide DNA cleanup  
For DNA samples that failed to amplify, a cleanup of extracted DNA using 
cetyltrimethylammonium bromide (CTAB) was trialled to improve the quality of 
the DNA sample for PCR. 
In this protocol, 50 µl of the extracted DNA solution was placed in a clean 1.7 ml 
eppendorf tube and diluted with TE buffer to a final volume of 570 µl. 30 µl of  
30% SDS was then added and the tube was incubated for 1 hr at 37°C. After 
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incubation, 100 µl of 5 mM NaCl was added, followed by 80 µl CTAB/NaCl  
(Appendix 6.1). Tubes were incubated at 65°C for 10 min, and the DNA was then 
extracted using an equal volume of chloroform. The tube was shaken vigorously 
then placed on a rotator wheel for 15 min, followed by centrifugation at 13,000 
rpm for 15 min at 4ºC. The aqueous layer containing the DNA was transferred to 
new labelled tube and an equal volume of isopropanol was added to precipitate 
the DNA. Following DNA precipitation, the tube was centrifuged at 13,000 rpm 
for 15 min at 4ºC and the supernatant discarded. The pellet was washed with 1 ml 
70% ethanol and centrifuged at 13,000 rpm for 5 min at 4ºC. The supernatant was 
removed and discarded, and any residual ethanol was briefly spin down in a 
centrifuge and removed. The tube was left to stand at room temperature for a short 
period to evaporate any remaining ethanol, and the pellet was then re-suspended 
in 25 µl of TE buffer. 
 
2.1.3 Column DNA extraction 
DNA recovery kits (Zymoclean Gel DNA Recovery KitTM) were used to further 
purify DNA samples that failed to amplify. This kit is designed to extract DNA 
from agarose gel slices and it is also capable of extracting DNA from TE buffer. 
Three volumes of the supplied ADB BufferTM were added to each volume of 
DNA solution in a 1.7 ml eppendorf tube and this was incubated at 37°C for 10 
min. The solution was then transferred to a Zymo-Spin ITM column placed in a 
collection tube, and centrifuged for 1 min at 13,000 rpm. The flow through was 
discarded and 200 µl of the supplied wash buffer was added to the column. This 
was then centrifuged for 30 sec at 13,000 rpm, the flow through discarded, and the 
wash step repeated. The column was then placed in a new 1.7 ml tube and 
depending on the amount and starting concentration of DNA solution, 20 - 40 µl 
of TE buffer was added directly to the column. The column was then centrifuged 
at 13,000 rpm for 1 min to elute the DNA. 
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2.1.4 DNA quantification 
DNA was quantified in ng/µl and purity assessed by the 260/280 ratio using a 
Nanodrop ND-1000 spectrophotometer. A 260/280 ratio of 1.8 – 2.0 was 
considered ideal, indicating a sample free from protein, RNA, phenol or other 
contaminants. Working DNA samples were prepared by diluting a small amount 
of stock DNA solution with TE buffer to a concentration of approximately  
100 ng/µl 
 
 
2.2 Genotyping of candidate genes by PCR-RFLP 
PCR-RFLP assays were custom designed to genotype 13 SNPs in five candidate 
genes; SGIP1, GABRA2, CACNA1G, HCN1 and HCN2 (Table 2.1). Briefly, for 
each genotyping assay customised designed primer pairs were first used to 
amplify a small genomic region containing the SNP of interest by PCR. PCR 
products were then digested with a restriction enzyme specific to the assay that 
would either cut, or not cut, the product depending on the allele present at the 
SNP loci of interest. Digested PCR products were separated by agarose gel 
electrophoresis and visualised under UV light, allowing genotype to be 
determined from the banding pattern present (Figure 2.1). 
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Figure 2.1: Diagram outlining PCR-RFLP genotyping method. 
The restriction enzyme will either cut, or not cut, the PCR product depending on the SNP 
allele present. In the example shown, the A allele is cut (indicated by a solid black triangle) 
into a small and medium sized fragments, and the C allele is uncut. The rate at which DNA 
fragments migrate through the agarose gel depends on their size, allowing digestion product 
fragments to be separated and genotype to be determined from the fragmentation pattern. 
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2.2.1 SNP selection 
Two to three SNPs in each candidate gene were selected for genotyping by PCR-
RFLP (Table 2.1). 
Three intronic SNPs in each of SGIP1 and GABRA2, were chosen for genotyping 
based on results from previous association studies [92, 95]. SNPs in the remaining 
three genes – CACNA1G, HCN1 and HCN2 – were selected using database 
information to identify SNP loci with potential functional effects on gene 
regulation or splicing. Selected SNPs were also required to have a MAF of at least 
15%. Databases utilised were the UCSC Genome Browser (http:// 
genome.ucsc.edu. Assembly: Feb 2009, GRCh37/hg19) [172], the ECR Browser 
(http://ecrbrowser.dcode.org/) [173], NCBI dbSNP (http://www.ncbi.nlm.nih.gov/ 
snp/), and the International HapMap project (http://hapmap.ncbi.nlm.nih.gov. 
Project data: Phase II+III, #27, Feb 09, Caucasian population) [174]. 
Table 2.1 provides summary information on all 13 SNPs genotyped by PCR-
RFLP, including MAFs for the HapMap Caucasian population (sample of 
Caucasians of European descent (CEU)), and Figure 2.2 shows the position of 
SNPs genotyped in each candidate gene.  
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Table 2.1: Information on SNPs genotyped by PCR-RFLP. 
1 Position of SNP in Human Reference Sequence build 37.3.  
2 MAF for the HapMap Caucasian population, unless otherwise indicated. * MAF for pilot 
HapMap Caucasian population. ¥ MAF for pilot HapMap Yoruban population. 
“from 3'/5'” indicates approximate distance of SNP from gene 3'/5' end.  
Ch. =  Chromosome. SNPs are listed in order of chromosomal position. Data retrieved April 
2012 from NCBI dbSNP. 
 
Gene SNP Location Position1  Alleles MAF2 
SGIP1 rs10889635 Intronic 65184790 (Ch.1) A/G 0.442 (G) 
 rs6681460 Intronic 65232536 (Ch.1) A/G 0.451 (A) 
 rs2146904 Intronic 65269889 (Ch.1) A/G 0.390 (A) 
GABRA2 rs572227 ~250 bp from 3' 45569517 (Ch.4) G/A 0.456 (A) 
 rs279845 Intronic 45647787 (Ch.4) A/T 0.473 (A) 
 rs279841 Intronic 45658827 (Ch.4) A/G 0.446 (A) 
HCN1 rs13361609 ~1.5 kb from 5' 45650903 (Ch.5) C/T 0.341 (C) 
 rs13187565 ~10 kb from 5'  45660979 (Ch.5) G/T 0.456 (T) 
CACNA1G rs7501581 ~1.5 kb from 5' 44004613 (Ch.17) C/G 0.400 (G)* 
 rs8066527 Intronic (near 44060878 (Ch.17) C/T 0.300 (T)* 
  splice site)    
 rs8066269 Exonic (missense) 44069812 (Ch.17) G/T 0.153 (T)¥ 
HCN2 rs7254543 ~4 kb from 5' 585805 (Ch. 19) A/C 0.221 (A) 
 rs873634 ~1.5 kb from 5' 588305 (Ch. 19) G/T 0.195 (G) 
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Figure 2.2: Structure of candidate genes showing position of SNPs genotyped by  
PCR-RFLP.  
a. SGIP; b. GABRA2; c. HCN1; d. CACNA1G; and e. HCN2. Ch. = chromosome.  
(Created using data from the UCSC Genome Browser and NCBI Gene (Reference sequence 
GRCh37.p5 Primary Assembly) (http://www.ncbi.nlm.nih.gov/gene)). 
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2.2.2 PCR-RFLP assay design 
PCR-RFLP assays were designed for each SNP using the NCBI dbSNP database 
and the free online tools WatCut (watcut.uwaterloo.ca/watcut/watcut/ 
template.php), Primer3 (version 0.4.0) (http://frodo.wi.mit.edu/primer3/) Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/). 
WatCut was first used to identify restriction enzymes that would cleave only one 
variant sequence, thereby enabling the two SNP alleles to be distinguished. The 
300 bp sequence flanking each side of the SNP was retrieved from NCBI dbSNP 
and this sequence was used to design specific primer pairs using Primer3  
(Table 2.2). 
Primer pairs were designed to flank the SNP of interest, with the 3' end of each 
primer ideally being at least 30 bp from the restriction enzyme cut site in order to 
make restriction digest fragments easy to distinguish. Where required, artificial 
restriction enzyme cut sites were created by incorporating a mismatch near, but 
not directly next to, the 3' end of either the forward or reverse primer. This results 
in the incorporation of a new base near the SNP and the mismatch site artificially 
generates a sequence in the PCR product that is recognised by a specific 
restriction enzyme for one allele but not the other. Expected PCR products for 
each allele were then input into NEBcutter V2.0 and a custom digest was 
performed using the restriction enzyme specific to the assay to determine expected 
fragment sizes and banding pattern. 
To reduce the probability of non specific priming, Primer-BLAST was used to 
check the specificity of each primer pair against the human genome. Primer 
binding regions were also checked for known polymorphisms using the UCSC 
Genome Browser. 
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2.3 PCR protocols 
2.3.1 Standard PCR 
For each PCR-RFLP assay, PCR was first used to amply a short segment of DNA 
containing the SNP of interest using specifically designed primers (Table 2.2). 
20 µl PCR reactions were prepared for each sample containing 0.5 units (U) HOT 
FIREPol® DNA polymerase (Solis BioDyne), the supplied buffer at x1 
concentration, 2.0 mM MgCl2, 250 µM dNTPs and 0.2 µM of each primer. 
Approximately 100 ng of extracted DNA was added to each reaction tube, 
excluding the negative control.  
PCR thermal cycling parameters were as follows:  
1. Initial denaturation and DNA polymerase activation: 95°C for 15 min 
2. Denaturation: 95°C for 20 sec 
3. Annealing: Ta°C for 30 sec  
4. Elongation: 72°C for 30 sec 
5. Repeat steps 2-4 for 34 more cycles 
6. Final elongation: 72°C for 1 min 
The annealing temperature (Ta) used was specific for each primer pair (Table 2.2). 
To determine the annealing temperature for each reaction, the annealing 
temperature was initially set approximately 5°C below the average melting 
temperature (Tm) for the primer pair. This was then either slightly modified if 
needed to either reduce non-specific priming or improve yield. Final annealing 
temperatures used in PCR-RFLP assays are shown in Table 2.2.  
This protocol was used for all SNPS with the exception of SNP rs8066527 and 
rs7254543. For these two SNPs the optimum annealing temperature was first 
determined by gradient PCR (Section 2.3.2) and a touchdown PCR protocol was 
then trialled and used for genotyping (Section 2.3.3). 
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Table 2.2: PCR reaction information for SNPs genotyped by PCR-RFLP. 
 Mismatches incorporated to create artificial restriction enzyme sites are shown in lower case. 
A touchdown protocol was used for SNPs rs8066527 and rs7254543, (Ttd)1 = final touchdown 
temperature (Section 2.3.3). 
SNP Primer sequence (5'-3') Product size (bp) Ta 
rs10889635 F: AGGAGAAATACTTGGGCCAACC 364 60˚C 
 R: TGACCTACATTCTCAGTGACGC   
rs6681460 F: GAGGAAGATCTAGGATACAGCCACT 193 60˚C 
 R: GAAGGTTCTGTGCCTTGATTACAcC   
rs2146904 F: CTCTAGATGCACCCTGTATATTTACTGTTgA 201 60˚C 
 R: AAGCAGTGACCGGACATGTAATCTT   
rs572227 F: TTACGGGTGCTGGAGACTG 234 60˚C 
 R: TGCCAATTAACTGCCCTTCT   
rs279845 F: TGCCATGTTTGCTACAGGTT 213 60˚C 
 R: CTCTCCTTGCAAAAACACAGAG   
rs279841 F: CCCTCTTGTCTCTACTCATAcA 174 50˚C 
 R: AGCTAGAAAACTGGCTCAACCT   
rs13361609 F: ATCTCCCTTGCGCTCTTGAA 192 48˚C 
 R: CAGGGCAAGATTCTCTTTGA   
rs13187565 F: CTACCAACAAAGAGGCCATT 222 48˚C 
 R: GAACTGTGGAGTTTTGTAAACTGgTA   
rs7501581 F: GTGGTGCAGCCTTAGGAGAG 196 55˚C 
 R: AAGCACTCTCCCAACACTTG   
rs8066527 F: AGCAGCCCCAGGTAGGcG 169 60˚C 
 R: AAGATGATACCCACCCTCAAGG  (Ttd)
1 
rs8066269 F: CCTCGCTTTGCTCGTCTACT 239 55˚C 
 R: AACACAGGCTACTACCAGCA   
rs7254543 F:  GGCCCTCTCCTCCCTgTA 194 55˚C 
 R:  TCTCATGCTAGCAGCCTCTCT  (Ttd)1 
rs873634 F: GCTGAAGGGGGTCTTTTTATG 199 55˚C 
 R: CACAGCCCTCCTTGTGACTT   
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2.3.2 Gradient PCR  
To avoid the non-specific priming observed in test reactions for SNPs rs8066527 
and rs7254543, gradient PCR was used to determine the optimum annealing 
temperature. 
110 µl PCR reactions were prepared containing 0.5 U HOT FIREPol® DNA 
polymerase (Solis BioDyne), the supplied buffer at x1 concentration, 2.0 mM 
MgCl2, 250 µM dNTPs and 0.2 µM of each primer. 10 µl of this reaction mixture 
was transferred into a clean PCR tube as the negative control. Approximately 500 
ng of extracted DNA was added to the remaining 100 µl and this was then 
aliquoted into 10 individual PCR tubes. PCR was performed using an annealing 
temperature gradient for step 3, with the negative control placed at an intermediate 
annealing temperature. 
Thermal cycling parameters for gradient PCR were as follows:  
1. Initial denaturation and DNA polymerase activation: 95°C for 15 min 
2. Denaturation: 95°C for 20 sec 
3. Annealing temperature gradient: 51°C to 62°C for rs8066527  
45°C to 55°C for rs7254543 
4. Elongation: 72°C for 30 sec 
5. Repeat steps 2-4 for 34 more cycles 
6. Final elongation: 72°C for 1 min 
PCR products were separated by gel electrophoresis on 1 – 1.5% agarose/sodium 
borate (SB) gels and visualised under UV light (Section 2.4). The optimum 
annealing temperature was determined by visual inspection of product yield and 
non-specific amplification at each annealing temperature. 
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2.3.3 Touchdown PCR 
For SNPs rs806627 and rs7254543, a touchdown PCR protocol was trialled and 
applied for PCR-RFLP assays to reduce non-specific priming.  
In this modified PCR protocol, the annealing temperature of the early cycles was 
set higher than the expected annealing temperature and was subsequently reduced 
by 1°C per cycle until a desired ‘touchdown’ temperature (Ttd) was reached. The 
touchdown temperature was then used as the annealing temperature for the 
remaining cycles. Final touchdown temperatures used for PCR-RFLP are shown 
in Table 2.3.  
PCR reactions were set up as for standard PCR (Section 2.3) and thermal cycling 
parameters were set as follows: 
Phase one: 
1. Initial denaturation and DNA polymerase activation: 95°C for 15 min 
2. Denaturation: 95°C for 20 sec 
3. Annealing: Ttd + 10°C for 30 sec, reduced by 1°C per cycle 
4. Elongation: 72°C for 30 sec 
5. Repeat steps 2 - 4 for 9 more cycles until Ttd reached 
Phase two: 
1. Denaturation: 95°C for 20 sec 
2. Annealing: Ttd for 30 sec 
3. Elongation: 72°C for 30 sec 
4. Repeat steps 1 - 3 for 34 more cycles 
5. Final elongation: 72°C for 1 min 
 
Table 2.3: Touchdown PCR reaction information. 
 Mismatches incorporated to create artificial restriction enzyme sites are shown in lower case. 
Ttd = touchdown temperature. 
SNP Primer sequence (5'-3') Product size (bp) Ttd 
rs8066527 F: AGCAGCCCCAGGTAGGcG 169 60˚C 
 R: AAGATGATACCCACCCTCAAGG   
rs7254543 F:  GGCCCTCTCCTCCCTgTA 194 55˚C 
 R:  TCTCATGCTAGCAGCCTCTCT   
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2.3.4 Spiked PCR 
To determine if the failure of some samples to amplify by PCR was due to the 
presence of inhibitors, spiked PCR reactions were used. 
20 µl PCR reactions were prepared containing 0.5 U HOT FIREPol® DNA 
polymerase (Solis BioDyne), the supplied buffer at x1 concentration, 2.0 mM 
MgCl2, 250 µM dNTPs and 0.2 µM of the forward and reverse primers for SNP 
rs13187456. Approximately 100 ng of DNA from a sample known to amplify was 
added to each reaction tube, excluding the negative control. An additional 100 ng 
of DNA from a sample that failed to amplify was then added to each tube 
excluding the negative and positive controls.   
PCR thermal cycling parameters were as follows:  
1. Initial denaturation and DNA polymerase activation: 95°C for 15 min 
2. Denaturation: 95°C for 20 sec 
3. Annealing: 48 °C for 30 sec  
4. Elongation: 72°C for 30 sec 
5. Repeat steps 2-4 for 34 more cycles, for a total of 35 cycles. 
6. Final elongation: 72°C for 1 min 
Gel electrophoresis (Section 2.4) using 1% agarose/SB gels, was used to 
determine if amplification was successful. Successful amplification of the positive 
control and failed amplification of spiked reactions would indicate the presence of 
an inhibitor in the DNA solution used to the spike the PCR. 
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2.4 Agarose gel electrophoresis 
PCR and restriction enzyme digest products were separated on 1 – 2.5% (w/v) 
agarose/SB gels containing ethidium bromide, in x1 SB running buffer (Appendix 
6.1) run at 100 V, using an Owl gel electrophoresis separation system. 5 - 10 µl of 
each sample was first mixed with a gel loading buffer (Appendix 6.1) and then 
loaded into a well. Gels were run for as long as required to achieve a desired level 
of resolution. Products were then visualised under UV light on a trans-illuminator 
(Life Technologies, Gibco BRL UV Trans-illuminator, TFX-35M) and a 100 bp 
ladder (Solis BioDyne) was used to estimate product/fragment size. 
 
 
2.5 Restriction enzyme digests 
PCR products were digested with 1 - 2 U of restriction enzyme specific to the 
assay and the total reaction volume was bought up to 25 µl by addition of the 
supplied restriction enzyme buffer and Milli-Q water. Where specified by the 
enzyme manufacturer, digestion reactions were supplemented with bovine serum 
albumin (BSA) at 100 µg/ml. Digestion reactions were performed in a shaking 
incubator (Eppendorf, thermomixer comfort) at 900 rpm at the optimum 
temperature, with the exception of rs13361609, which was incubated in an MJ 
Research PCT-200 Peltier Thermal Cycler. Table 2.4 provides information on 
restriction enzyme digest conditions and expected fragment sizes of digestion 
products. 
The genotype of each sample was able to be inferred from the sizes and pattern of 
digested PCR product fragments using agarose gel electrophoresis (Section 2.4). 
The percentage of agarose used in gels varied depending on the size of the 
diagnostic fragments. Digestions cleaving small fragments (<40 bp) were run on 
2–2.5% agarose/SB gels to obtain finer resolution, whereas digestions removing 
larger fragments were able to be separated on 1–1.5% agarose/SB gels (Table 2.4). 
 
2 | Materials and Methods  47 
 
 
 
Table 2.4: Restriction enzyme digest information. 
Restriction enzyme and number of units used in each assay are given along with incubation 
temperature, expected fragment sizes and the percentage of agarose used in gels. 
* Supplemented with BSA at a concentration of 100 µg/ml. 
SNP Restriction Enzyme Incubation  
Fragment sizes 
(bp) 
Agarose 
(%) 
rs10889635 XbaI  (2 U)* 37˚C for 2 hrs A  201/163 G  364 1.0 
rs6681460 MnlI (2 U) 37˚C for 2 hrs A  160/33 G  193 2.0 
rs2146904 BclI  (2 U) 50˚C for 2 hrs A  172/29 G  201 2.0 
rs572227 DraIII  (2 U)* 37˚C for 2 hrs G  120/114 A  234 1.0 
rs279845 HinfI  (2 U) 37˚C for 2 hrs A  173/40   T  213 1.5 
rs279841 NspI  (2 U)* 37˚C for 2 hrs G  150/24 A  174 2.0 
rs13361609 TaiI (1 U) 65˚C for 6 hrs C  143/49 T  192 1.5 
rs13187565 RsaI  (2 U) 37˚C for 1 hr G  197/25 T  222 2.0 
rs7501581 Tsp451 (1 U)* 65˚C for 4 hrs G  142/54 C  196 1.5 
rs8066527 CfoI (2 U)* 37˚C for 1 hr C  151/18 T  169 2.5 
rs8066269 AluI  (2 U) 37˚C for 1 hr T  149/39/38/13 G  187/39/13 1.5 
rs7254543 Hpy166II (2 U) 37°C for 1hr A  176/18 C  194 2.5 
rs873634 HaeIII (2 U) 37˚C for 2 hrs G  82/74/43 T  156/43 2.0 
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2.6 Sequencing 
To confirm that the correct genomic fragment had been amplified, one sample for 
each PCR-RFLP assay was sequenced in both the forward and reverse directions. 
Samples were first amplified by PCR and the PCR product was then cleaned up 
and used as the sequencing template. 
 
2.6.1 Template preparation 
40 µl PCR reactions were prepared containing 1U HOT FIREPol® DNA 
polymerase (Solis BioDyne), the supplied buffer at x1 concentration, 2 mM 
MgCl2, 250 µM dNTPs and 0.2 µM of each primer. 10 µl of the reaction was 
aliquoted into a separate tube as a negative control and approximately 150 ng of 
extracted DNA was added to the remaining 30 µl as a template. PCR cycling 
parameters and annealing temperatures were the same as those used for PCR-
RFLP assays (Section 2.3; Table 2.2). 
Following thermal cycling, 5 µl of each PCR reaction was separated by gel 
electrophoresis on 1% agarose/SB gels (Section 2.4) and the DNA ladder was 
used to estimate both product size and DNA concentration.  
The remaining 25 µl of PCR product was then cleaned up for sequencing using 
Exonuclease I and Alkaline Phosphatase. These enzymes remove any remaining 
primers and free dNTPs, respectively. 10 U Exonuclease I (Fermentas) and 1 U 
rAPid Alkaline Phosphatase (Roche) was added to each PCR reaction, tubes were 
vortexed and then incubated for 15 min at 37°C, followed by a 15 min incubation  
at 85°C.  
Solutions were then sent to the University of Waikato Sequencing Facility 
(Hamilton, New Zealand) for sequencing using an Applied Biosystems 3130xl 
Genetic Analyzer. Each PCR product was sequenced in both the forward and 
reverse direction using the appropriate forward and reverse PCR primers as 
sequencing primers. 
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2.6.2 Sequence analysis  
Sequencing reaction results were provided in FASTA format along with a printout 
of the electropherogram. The electropherogram printout was used to examine the 
quality of the read and determine reliable start and end points for the  
sequence. The free online software FASTA Sequence Comparison 
(http://fasta.bioch.virginia.edu/fasta_www2/) was used to align forward and 
reverse sequences for each primer pair and a final sequence was determined for 
each PCR product. Any mismatches in the alignment were checked using the 
electropherogram printout. Final sequences were entered into NCBI nucleotide 
BLAST (BLASTN 2.2.26+) (http://blast.ncbi.nlm.nih.gov/) [175], to search the 
human genome for similar sequences, allowing confirmation that the correct 
region had been amplified. The position and genotype of the SNP of interest in 
each sequence was also determined from the electropherogram and checked 
against genotyping results.  
 
 
2.7 Genotyping of inflammatory genes by 
MassARRAY  
21 SNPs in or near 15 different genes involved in various inflammatory and 
related pathways were selected for genotyping by researchers at AGRF (Table 1.3, 
Table 2.5). 100 samples were sent to AGRF and were genotyped for these SNPS 
with custom-designed multiplex analysis using Sequenom MassARRAY 
technology (iPlex Gold).  
Completed genotyping data was provided in an excel spreadsheet along with 
calculated genotype and allele frequencies. This data was then paired with EEG 
and other patient data. 
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Table 2.5: Information on SNPs genotyped by MassARRAY at AGRF. 
1 Position of SNP in Human Reference Sequence build 37.3.  
2 MAF for the HapMap Caucasian population.  
“from 5' ” indicates approximate distance of SNP from gene 5' end.  
Synom. = Synonymous coding SNP. Ch. =  Chromosome. Data retrieved April 2012 from 
NCBI dbSNP. 
Gene SNP Location Position1 Alleles MAF2 
IL6R rs8192284 Exonic (missense) 154426970 (Ch.1) A/C 0.354 (C) 
CRP rs2794521 ~600 bp from 5' 159685096 (Ch.1) C/T 0.317 (C) 
IL10 rs1800871 ~800 bp from 5' 206946634 (Ch.1) C/T 0.173 (T) 
 rs1800896 ~1 kb from 5' 206946897 (Ch.1) A/G 0.469 (A) 
IL1B rs1143634 Exonic (synom.) 113590390 (Ch.2) C/T 0.208 (T) 
 rs1143627 ~30 bp from 5' 113594387 (Ch.2) C/T 0.363 (C) 
 rs16944 ~500 bp from 5' 113594867 (Ch.2) A/G 0.358 (A) 
MYD88 rs6853 3' UTR 38184370 (Ch.3) A/G 0.115 (G) 
IL2 rs2069762 ~200 bp from 5' 123377980 (Ch.4) G/T 0.232 (G) 
TLR2 rs3804100 Exonic (synom.) 154625409 (Ch.4) C/T 0.051 (C) 
TNF rs1800629 ~200 bp from 5' 31543031 (Ch.6) A/G 0.173 (A) 
OPRM1 rs1799971 Exonic (missense) 154360797 (Ch.6) A/G 0.155 (G) 
IL6 rs10499563 ~6 kb from 5' 22760488 (Ch.7) C/T 0.195 (C) 
LY96 rs11466004 Exonic (missense) 74941275 (Ch.8) C/T 0.028 (T) 
TLR4 rs4986790 Exonic (missense) 120475302 (Ch.9) A/G 0.035 (G) 
 rs4986791 Exonic (missense) 120475602 (Ch.9) C/T 0.045 (T) 
BDNF rs6265 Exonic (missense) 27679916 (Ch.11) A/G 0.195 (A) 
CASP1 rs554344 ~1 kb from 5' 104895197 (Ch.11) C/G 0.192 (C) 
 rs580253 Exonic (synom.) 104900488 (Ch.11) C/T 0.192 (T) 
TGFB1 rs11466314 ~450 bp from 5' 41860236 (Ch.19) A/G 0.021 (A) 
 rs1800469 ~500 bp from 5' 41860296 (Ch.19) C/T 0.288 (T) 
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2.8 Analysis of genotyping data 
Raw genotyping results from PCR-RFLP assays and MassARRAY were input 
into Microsoft Office Excel spreadsheet along with corresponding EEG trait 
values for each sample. Within the excel document, separate sheets were used to 
format data to be exported to Haploview, SNPAnalyzer 1.2A and the statistical 
software NCSS. 
 
2.8.1 Haploview 
The free software Haploview [176] was used to check SNPs for adherence to the 
Hardy Weinberg equilibrium (HWE), to examine patterns of LD between SNPs, 
and to estimate haplotypes and their frequencies. SNP genotyping data was 
converted to a tab-delimited text file for importation into Haploview as specified 
in the user’s manual. Fields requiring pedigree and case-control information were 
filled with a zero.  
Haploview was also used to construct LD plots and to infer haplotypes and their 
frequencies for selected genes using HapMap Caucasian data. Data was imported  
directly into the Haploview software using the download feature in Haploview, 
and by specifying the chromosome and start and end points in kb. 
 
2.8.2 SNPAnalyzer 1.2A 
The expectation-maximization (EM) algorithm in the free online software 
SNPAnalyzer 1.2A (http://snp.istech.info/istech/board/detail.jsp) was used to 
reconstruct three SNP haplotypes for SGIP1, GABRA2 and IL1B. For importation 
into SNPAnalyzer 1.2A, genotyping data was converted to a tab-delimited text 
file as specified in the user’s manual. 
 
 
  
2 | Materials and Methods  52 
 
 
 
2.8.3 Association analysis: NCSS 
The statistical software NCSS was used to perform statistical tests to examine 
associations between SNPs and quantitative EEG traits. All statistical tests 
performed were non-parametric tests as these methods do not require data to be 
normally distributed. 
Summary statistics and histograms were produced for all EEG traits and ETDC 
and the Shapiro-Wilk W test was used to determine if variability was normally 
distributed. Linear regression analysis was performed to examine correlations 
between different EEG traits and the BIS value, and between the EEG and ETDC. 
Kruskal-Wallis one-way analysis of variance (KW-ANOVA) was used to identify 
SNPs with potential associations with the EEG or ETDC, and box and whisker 
plots enabled data to be visualised categorised by genotype. KW-ANOVA was 
performed for each SNP, with each EEG trait, to identify SNPs with a significant 
difference in the median between genotypes.  
SNPs that were putatively associated with the EEG or ETDC (p < 0.05) were 
further examined. Mann-Whitney U tests were used to identify SNP genotypes 
with significant differences in the median and to test SNPs for associations with 
the EEG and ETDC in recessive, dominant, and over-dominant models. The 
dominant, recessive and over-dominant models are tests for the minor allele; if “D” 
is the major allele and “d” is the minor allele the dominant model compares  
[dd + dD] vs. DD, the recessive model compares dd vs. [dD + DD], and the over-
dominant model compares dD vs. [dd + DD]. To determine effect sizes, fold 
differences were calculated for each comparison by dividing the median value for 
one genotype by the median for the other. 
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3 Chapter 3: 
Results 
  
 
 
 
3.1 Participants 
137 participants undergoing general, gynaecological, or orthopaedic surgery were 
recruited and the raw EEG was recorded for 125 patients who were therefore 
retained for inclusion in the present study.  
The age range of participants in this study was 17 – 67 years (mean = 42.3 years) 
and 82% were female (Table 3.1). The high proportion of female participants was 
largely due the high proportion of gynaecological patients (51%) recruited. Of the 
remaining patients (general and orthopaedic), there was also a higher proportion 
of females (62%) than males (38%).  
 
Table 3.1: Basic summary information on study participants (n = 125). 
NZ Euro. = New Zealand European; Poly/M = Polynesian and Maori; N/S = Not Specified; 
Gynae. = Gynaecological; Ortho. = Orthopaedic.  
Gender Ethnicity Surgery type 
M F NZ Euro. Asian Poly/M N/S General Gynae. Ortho. 
23 102 96 10 18 1 46 64 15 
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3.2 EEG Data and anaesthetic administration  
EEG signal processing was performed by the anaesthetist on a selected 60 sec 
epoch recorded during the middle of surgery. The median was determined for the 
following EEG traits; spindle amplitude, spindle frequency, delta amplitude and 
delta frequency (n = 125) (N.B. logarithmic transformation applied to spindle and 
delta amplitude). Median BIS value (n = 100) and ETDC (n = 122) were also 
determined for the selected epoch. Processed data was supplied in spreadsheet 
format, and spindle amplitude relative to ETDC (relative spindle amplitude) was 
calculated using the supplied data (Equation 3.1) (n = 122).   
Spindle amplitude = Relative spindle amplitude (Equation 3.1) 
   ETDC  
Summary statistics were calculated for all EEG traits and ETDC using  
the statistical software NCSS. The distribution of each variable was visualised 
using histograms (Figure 3.1), and distributions were tested for normality  
using the Shapiro-Wilk W test. Spindle and ETDC showed a normal distribution  
(p > 0.05) whereas normality was rejected for BIS value (p = 0.0014), spindle 
frequency (p = <0.0001), delta frequency (p = <0.0001), delta amplitude  
(p = 0.0047) and relative spindle amplitude (p = 0.0099). 
Table 3.2: Summary statistics for quantitative EEG data and ETDC. 
Min. = minimum; Max. = maximum; Med. = median; Std.Dev. = standard deviation. 
Variable Min. Max. Range Med. Mean Std. Dev. n 
ETDC (%) 2.12 9.46 7.34 5.46 5.58 1.31 122 
BIS value 22 81 59 39 40 11.27 100 
Delta amplitude 
(Log(µV)) 3.36 10.22 6.86 5.83 5.89 0.99 125 
Delta frequency (Hz) 0.50 2.25 1.75 0.63 0.71 0.26 125 
Spindle amplitude 
(Log(µV)) 0.19 3.23 3.04 1.86 1.83 0.63 125 
Spindle frequency (Hz) 7.13 16.50 9.38 9.38 9.73 2.02 125 
Relative spindle 
amplitude 0.034 0.844 0.811 0.339 0.357 0.173 122 
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Figure 3.1: Histograms showing distributions of EEG data and ETDC. 
a. ETDC; b. BIS value; c. Delta amplitude; d. Delta frequency; e. Spindle amplitude;  
f. Spindle frequency; g. Relative spindle amplitude.  
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3.2.1 EEG correlation analysis 
Scatter plots and linear regression analyses were used to analyse relationships 
between ETDC, BIS value, and EEG traits (Figure 3.2). Were required, data was 
transformed using the square root or Log10 of the dependent variable in order to 
meet the necessary assumptions of the linear regression model. The full results 
from this analysis are presented in Appendix Table 6.2. 
A weak correlation was observed between BIS value and ETDC (r = -0.227,  
p = 0.023) (Figure 3.2a). Modest correlations were observed between spindle 
amplitude and ETDC (r = -0.467, p = <0.0001), and delta amplitude and BIS 
value (r = -0.469, p = <0.0001) (Figure 3.2b,d). Weak correlations were also 
observed between delta amplitude and ETDC (r = 0.265, p = 0.0032) (Figure 
3.2c).  
 
 
Figure 3.2: Scatter plots and regression lines showing relationships between EEG traits, 
BIS value and ETDC.  
a. BIS value and ETDC; b. Spindle amplitude and ETDC; c. Delta amplitude and ETDC;  
d. Delta amplitude and BIS value.  
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3.3 Isolation of genomic DNA  
Prior to the beginning of this study, DNA had already been extracted from 
approximately 110 samples using a phenol:chloroform extraction method (Section 
2.1.1). As part of the current project, DNA was extracted from the remaining 
samples.  
Using the phenol:chloroform extraction protocol, DNA that reliably amplified by 
PCR was able to be obtained for >90% of samples. For a small number of samples, 
PCR was either completely or frequently unsuccessful, requiring further 
purification steps to obtain higher quality DNA. A CTAB cleanup method was 
first trialled to improve the quality of samples that failed to amplify (Section 
2.1.2). This method was unsuccessful (Section 3.3.1), and using spiked PCR 
(Section 2.3.4) it was determined that the failure of some samples to amplify was 
likely due to the presence of an inhibitor in the DNA solution (Section 3.3.2). A 
column DNA extraction using a commercial kit (Zymoclean Gel DNA Recovery 
KitTM) was then trialled to remove any inhibitors (Section 2.1.3). This kit 
successfully extracting DNA from samples that failed to amplify (Section 3.3.3), 
and was used to further purify samples if required. The final protocol used for the 
isolation and purification of DNA from blood samples is shown in the flow chart 
below (Figure 3.3). 
 
Figure 3.3: Flow chart outlining final protocol used for isolation 
and purification of genomic DNA for PCR-RFLP assays. 
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3.3.1 CTAB Cleanup  
An additional DNA cleanup protocol using CTAB (Section 2.1.2) was trialled for 
three DNA samples that frequently failed to amplify (samples IDs; 23, 34, 75). 
Briefly, 50 µl of the originally isolated DNA was incubated with SDS, NaCl and 
CTAB. Following incubation, DNA was re-extracted with chloroform and then 
precipitated using isopropanol and re-suspended in 25 µl of TE. 
This protocol was found to markedly increase the 260:230 ratio with minimal 
effect on the 260:280 ratio (Table 3.3). On average, approximately two-thirds of 
the DNA was recovered. While the CTAB method was found to improve the 
quality of DNA samples as determined by 260:230 ratio, these three samples still 
failed to amplify during PCR.  
 
Table 3.3: Nanodrop results showing the effect of CTAB cleanup on DNA quality. 
Nanodrop readings from DNA samples isolated from blood and from the same samples after  
clean up using CTAB. 
Sample ID 
Before CTAB cleanup After CTAB cleanup 
260:280 260:230 ng/µl 260:280 260:230 ng/µl 
23 1.78 1.52 104 1.82 2.25 130 
34 1.83 1.83 273 1.84 2.26 480 
75 1.84 1.67 65 1.81 2.17 73 
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3.3.2 Spiked PCR 
Spiked PCR reactions were used to determine if the failure to amplify during PCR 
was due to presence of inhibitors. Four PCR reactions were prepared using a 
sample known to amplify and three of these were spiked with DNA from sample 
numbers 23, 34 and 75 and the remaining reaction was left unspiked as a positive 
control. PCR reactions failed when spiked with DNA from samples 23, 34 and 75, 
whereas the positive unspiked control successfully amplified, demonstrating that 
the failure of these samples to amplify was likely due to the presence of a 
contaminant in the DNA solution (Figure 3.4). 
 
 
Figure 3.4: Gel image of spiked PCR results. 
Spiked PCR reaction products separated on a 1% agarose/SB gel. Pos = positive control,  
Neg = negative control. PCR reactions spiked with DNA from samples 23, 34 and 75 failed to 
amplify, whereas the positive unspiked control successfully amplified.  
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3.3.3 Column DNA extraction 
The three samples used for CTAB cleanup were used to trial an additional 
purification using a Zymoclean Gel DNA Recovery KitTM (Section 2.1.3). This kit 
uses a column to absorb DNA from a buffer solution, and once DNA was 
absorbed the column was washed twice and the DNA eluted with TE buffer.  
Following column purification with this kit, all three samples successfully 
amplified during PCR. 260:280 ratios were slightly improved, however, 260:230 
ratios decreased (Table 3.4). A substantial reduction in the total amount of DNA 
in solution was also observed, with approximately only half the DNA being 
recovered.   
Following this result, any DNA samples frequently failing to amplify by PCR 
were re-purified from the original solutions using the Zymoclean Gel DNA 
Recovery KitTM with the omission of the CTAB protocol. Using this approach, 
DNA was able to be obtained from 123 samples that reliably amplified and gave 
results for at least 10 of the 13 genotyped SNPs.  
 
Table 3.4: Nanodrop results showing the effect of column extraction (Zymoclean Gel 
DNA Recovery KitTM) on DNA quality. 
260:280 and 260:230 ratios and DNA concentration are shown for three samples cleaned up 
using CTAB before and after column extraction. Approximately 50% of total DNA was lost 
during extraction (DNA concentration shown does not reflect the extent of this loss as 
differing amounts of starting DNA solution and TE buffer for elution were used depending on 
the amount and concentration of starting DNA solution). 
Sample ID Before column purification After column purification 
260:280 260:230 ng/µl 260:280 260:230 ng/µl 
23 1.82 2.25 130 1.85 1.48 26.1 
34 1.84 2.26 480 1.90 1.63 28.5 
75 1.81 2.17 73 1.91 1.77 34 
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3.4 PCR optimisation 
For all PCR reactions, the annealing temperature was initially set approximately  
5°C below the average primer Tm and if required this was adjusted slightly to 
improve amplification or reduce non-specific priming. This approach was 
successful for establishing the annealing temperature to be used for the majority 
of PCR-RFLP assays. Due to poor priming specificity, the optimum annealing 
temperature for primer pairs designed to amplify rs8066527 (CACNA1G) and 
rs7254543 (HCN2) was first determined by gradient PCR and then a touchdown 
protocol was trialled and implemented to improve priming specificity. 
 
3.4.1 Gradient PCR 
The optimum annealing temperature for rs8066527 and rs7254543 was 
determined by gradient PCR (Section 2.3.2). The annealing temperature gradient 
ranged from 51.0°C to 62.1°C for rs8066527, and from 45°C to 55.2°C for 
rs7254543.  
For rs8066527, an annealing temperature of approximately 55°C was determined 
to give maximal yield of the correct PCR product but substantial levels of non-
specific priming were still observed (Figure 3.5). Even at annealing temperatures 
as high as 62°C, >5°C higher than the lowest Tm of the primer pair, non-specific 
priming still occurred. 
For rs7254543 annealing temperature had a little effect on yield of the correct 
product (Figure 3.6). At annealing temperatures below 52°C substantial non-
specific priming still occurred, and at higher annealing temperatures (53.1 – 
55.2°C) non-specific priming was markedly reduced but still weakly visible. 
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Figure 3.5: Gel electrophoresis image showing gradient PCR results for rs8066527 
(CACNA1G). 
PCR products were separated on a 1.5% agarose/SB gel. The correct product band is indicated 
with a white arrow. Neg = negative control. 
 
 
 
Figure 3.6: Gel electrophoresis image showing gradient PCR results for rs7254543 
(HCN1). 
PCR products were separated on a 1% agarose/SB gel. The correct product band is indicated 
with a white arrow. Neg = negative control. 
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3.4.2 Touchdown PCR 
A touchdown PCR protocol was trialled and implemented for primer pairs 
rs8066527 and rs7254543 to reduce non-specific priming and to improve yield 
(Section 2.3.3). At the higher annealing temperatures in the early cycles, only very 
specific binding occurs, allowing for enrichment of the correct product over any 
non-specific products. Using the lower touchdown temperature for the remaining 
cycles serves to increase the yield of the desired product [177, 178]. 
For rs8066527 two touchdown temperatures were trialled; 55°C, as this annealing 
temperature was found to give maximum yield of the correct PCR product, and 
60°C which resulted in reduced non-specific product but also slightly reduced 
product yield (Figure 3.5). A 55°C touchdown temperature was found to increase 
product yield relative to the standard protocol and as a result only 30 cycles for 
phase two were required to give a desirable yield, but, non-specific priming was 
not reduced (Figure 3.7). Increasing the touchdown temperature to 60°C was 
found to reduce non-specific priming, and when 35 cycles were performed for 
phase two a desirable product yield was obtained.  
For rs7254534 a touchdown temperature of 50°C was trialled. This temperature 
resulted in the elimination of non-specific priming and a suitable product yield for 
PCR-RFLP when 35 cycles were performed for phase two (Figure 3.19 shows 
final PCR-RFLP assay using a 50°C touchdown temperature). 
Based on the results from these trials, touchdown protocols were used for PCR in 
PCR-RFLP assays for rs8066527 and rs7254534. A 55°C touchdown temperature 
was used for rs8066527, 50°C for rs7254534, and 35 cycles for phase two of 
thermal cycling for both reactions. 
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Figure 3.7: Gel electrophoresis image showing touchdown PCR results for rs8066527 
(CACNA1G). 
A standard PCR protocol for rs8066527 using an annealing temperature of 55°C (Ta = 55°C), 
compared with touchdown protocols using touchdown temperatures of 55°C (x30 cycles for 
phase two) (Ttd = 55°C), and 60°C (x35 cycles for phase two) (Ttd = 60°C). Neg = negative 
control. 
 
 
3.5 PCR-RFLP assays 
Briefly, PCR was first used to amplify a small genomic region (169-364 bp) 
containing the SNP of interest using custom designed primers. PCR products were 
digested with a restriction enzyme specific to the assay at the optimum 
temperature for that enzyme and digested PCR products were separated by gel 
electrophoresis and visualised by UV trans-illumination. A 100 bp DNA ladder 
was used to estimate the size of the fragments and the genotype of each sample 
was determined from the fragmentation pattern (Section 2.2-2.5). 
PCR-RFLP assays were successfully designed and optimised that enabled 
genotyping for each of the 13 selected SNPs. Figures 3.8-3.20 show example gel 
image results from each PCR-RFLP assay. Primer-dimer was observed for some 
primer pairs, however, this did not seem to have significant impact on 
amplification efficiency, nor did it impair genotyping.  
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Figure 3.8: Example gel electrophoresis image of PCR-RFLP results for r10889635 
(SGIP1). 
Lane 1 – 100 bp ladder; lanes 3, 7 – A/A homozygous; lanes 2, 6, 9 – G/G homozygous;  
lanes 4, 5, 8 – A/G heterozygous; lane 10 – negative control. Products separated on a 1% 
agarose/SB gel. 
 
 
 
 
Figure 3.9: Example gel electrophoresis image of PCR-RFLP results for rs6681460 
(SGIP1). 
Lane 1 – 100 bp ladder; lanes 4, 5, 7 – A/A homozygous; lanes 3, 8, 9 – G/G homozygous; 
lanes 2, 6 – A/G heterozygous; lane 10 – negative control. Products separated on a 2% 
agarose/SB gel. 
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Figure 3.10: Example gel electrophoresis image of PCR-RFLP results for rs2146904 
(SGIP1). 
Lane 1 – 100 bp ladder; lanes 2, 4, 5, 7, 8 – A/A homozygous (weak amplification for lane 7, 
PCR-RFLP was repeated for this sample and confirmed genotype); lanes 3, 6 – G/G 
homozygous; lanes 9, 10, 11 – A/G heterozygous; lane 12 – negative control. Products 
separated on a 2% agarose/SB gel. 
 
 
 
 
Figure 3.11: Example gel electrophoresis image of PCR-RFLP results for rs572227 
(GABRA2). 
Lane 1 – 100 bp ladder; lanes 2, 8, 9 – G/G homozygous; lanes 3, 6 – A/A homozygous;  
lanes – 4, 7, 11 – A/G heterozygous; lanes 5, 10 – no amplification; lane 12 – negative control. 
Products separated on a 1% agarose/SB gel. 
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Figure 3.12: Example gel electrophoresis image of PCR-RFLP results for rs279845 
(GABRA2). 
Lane 1 – 100 bp ladder; lanes 5, 10 – A/A homozygous; lanes 3, 4, 6 – T/T homozygous; 
lanes 2, 9, 11 – A/T heterozygous; lanes 7, 8 – no amplification; lane 12 – negative control. 
Products separated on a 1.5% agarose/SB gel. 
 
 
 
 
Figure 3.13: Example gel electrophoresis image of PCR-RFLP results for rs279841 
(GABRA2). 
Lane 1 – 100 bp ladder; lanes 6, 8 – G/G homozygous; lane 2 – A/A homozygous;  
lanes  3, 5, 7 – A/G heterozygous; lane 4 – no amplification; lane 12 – negative control. 
Products separated on a 2% agarose/SB gel. 
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Figure 3.14: Example gel electrophoresis image of PCR-RFLP results for rs13361609 
(HCN1). 
Lane 1 – 100 bp ladder; lanes 6, 7 – C/C homozygous; lanes 2, 4, 9, 10, 11 – T/T homozygous; 
lanes 3, 5, 8 – C/T heterozygous; lane 12 – negative control. Products separated on a 1.5% 
agarose/SB gel. 
 
 
 
 
Figure 3.15: Example gel electrophoresis image of PCR-RFLP results for rs13187565 
(HCN1). 
Lane 1 – 100 bp ladder; lanes 3, 4, 5, 6, 8 – G/G homozygous; lane 10 – T/T homozygous; 
lanes 2, 7, 9, 11 – G/T heterozygous; lane 12 – negative control. Products separated on a 2% 
agarose/SB gel. 
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Figure 3.16: Example gel electrophoresis image of PCR-RFLP results for rs750581 
(CACNA1G). 
Lane 1 – 100 bp ladder; lanes 3, 7, 8, 11 – G/G homozygous; lanes 4, 5 – C/C homozygous; 
lanes – 2, 6, 9, 10 G/C heterozygous; lane 12 –  negative control. Products separated on a  
1.5% agarose/SB gel. 
 
 
 
 
Figure 3.17: Example gel electrophoresis image of PCR-RFLP results for rs8066527 
(CACNA1G). 
Lane 1 – 100 bp ladder; lanes 4, 5, 7 – C/C homozygous; lanes 6, 9 – T/T homozygous;  
lanes 2, 3, 8,10, 11 – C/T heterozygous; lane 12 – negative control. Products separated on a 
2.5% agarose/SB gel. 
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Figure 3.18: Example gel electrophoresis image of PCR-RFLP results for rs8066269 
(CACNA1G). 
Lane 1 – 100 bp ladder; lane 2 – undigested sample; lanes 3 to 10 – G/G homozygous;  
lane 11 – negative control. Products separated on a 1.5% agarose/SB gel. 
 
 
 
 
Figure 3.19: Example gel electrophoresis image of PCR-RFLP results for rs7254543 
(HCN2). 
Lane 1 – 100 bp ladder; lane 2 – A/A homozygous; lanes 4, 5, 6, 7, 8 – C/C homozygous; 
lanes 3, 9, – G/T heterozygous lane 10 – negative control. Products separated on a 2.5% 
agarose/SB gel. 
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Figure 3.20: Example gel electrophoresis image of PCR-RFLP results for rs873634 
(HCN2). 
Lane 1 – 100 bp ladder; lanes 7, 9, 11 – G/G homozygous; lanes 2, 10 – T/T homozygous; 
lanes 3, 4, 5, 6, 8 – G/T heterozygous; lane 12 – negative control. Products separated on a 2% 
agarose/SB gel. 
 
 
3.6 Conformation by sequencing 
To ensure that the correct region had been amplified for each PCR-RFLP assay, 
one sample was sequenced in the forward and reverse directions for all primer 
pairs (Section 2.6). DNA sequences were then input into NCBI BLAST and 
queried against the human genome (all assemblies) (Figure 3.21). All primer pairs 
were found to amplify the correct genomic region and SNP genotypes determined 
by PCR-RFLP corresponded with sequencing results for all sequenced samples 
(Appendix 6.4). 
 
Molecule type: nucleic acid 
Query Length: 363 
Database Name: Genome (all assemblies) 
Description: Homo sapiens build 37.3 genome database 
(reference assembly GRCh37.p5 [GCF_000001405.17] and alternate 
assemblies HuRef [GCF_000002125.1] and CRA_TCAGchr7v2 
[GCF_000002135.2])  
Program: BLASTN 2.2.26+ 
Figure 3.21: BLAST search parameters used to check alignment of PCR products 
against the human genome. 
3 | Results  72 
 
 
 
3.7 Genotyping results 
3.7.1 PCR-RFLP genotyping results 
Following completion of PCR-RFLP assays, genotyping results were input into a 
Microsoft Excel spreadsheet. Raw genotyping results for PCR-RFLP are shown in 
Appendix Table 6.3.  
Excel was used to determine the number of samples successfully genotyped for 
each PCR-RFLP assay and to assist calculations of MAF and genotype 
frequencies (Table 3.5). Of the 125 samples included in this study, genotyping 
results were obtained for 95-100% of samples for each individual SNP, with the 
exception of rs8066269. For rs8066269 only 25 samples were genotyped and all 
were found to be homozygous for the G allele. Excluding rs8066269, MAFs 
ranged from 0.238 – 0.419 (mean = 0.367) and minor genotype frequencies from 
0.074 - 0.234 (mean = 0.156). 
 
3.7.2 MassARRAY genotyping results 
100 DNA samples included in this study were genotyped with custom-designed 
multiplex analysis using Sequenom MassARRAY technology (iPlex Gold) at 
AGRF. Completed genotyping data was provided in excel format and then paired 
with EEG and other patient data. Raw genotyping data is shown in Appendix 
Table 6.4.  
Of the 100 samples genotyped by Sequenom MassARRAY, genotypes were 
determined for 88-99% of samples for each individual SNP (Table 3.6). Two 
SNPs (rs11466314 and rs11466004) were found not to be polymorphic in  
this sample and were therefore excluded from further analysis. All three 
genotypes were present for 16 of the remaining SNPs, and no patients were found 
to be homozygous for the minor allele for SNPs rs3804100, rs4986790 and 
rs4986791. Of the 19 polymorphic SNPs, MAFs ranged from 0.036 to 0.429 
(mean = 0.215) and minor genotype frequencies from 0.000 to 0.192 (mean = 
0.068). 
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Table 3.5: Summary of genotyping results for SNPs genotyped by PCR-RFLP. 
Gene  SNP n Genotype frequencies MAF 
SGIP1 rs10889635 124 0.169 (G/G) 
0.4768 
(A/G) 
0.355 
(A/A) 0.407 (G) 
 rs6681460 123 0.170 (A/A) 
0.407 
(A/G) 
0.423 
(G/G) 0.374 (A) 
 rs2146904 124 0.170 (A/A) 
0.427 
(A/G) 
0.403 
(G/G) 0.383 (A) 
GABRA2 rs572227 125 0.152 (A/A) 
0.472 
(A/G) 
0.376 
(A/G) 0.388 (A) 
 rs279845 125 0.168 (A/A) 
0.496 
(A/T) 
0.336 
(A/T) 0.416 (A) 
 rs279841 123 0.146 (A/A) 
0.472 
(A/G) 
0.382 
(G/G) 0.382 (A) 
HCN1 rs13361609 122 0.074 (C/C) 
0.328 
(C/T) 
0.598 
(T/T) 0.238 (C) 
 rs13187565 124 0.234 (T/T) 
.371 
(G/T) 
0.395 
(G/G) 0.419 (T) 
CACNA1G rs7501581 125 0.152 (G/G) 
0.432 
(C/G) 
0.416 
(C/C) 0.368 (G) 
 rs8066527 123 0.155 (T/T) 
0.398 
(C/T) 
0.447 
(C/C) 0.354 (T) 
 rs8066269 25 0.000 (T/T) 
0.00 
(G/T) 
1.00 
(G/G) 0.000 (T) 
HCN2 rs7254543 119 0.151 (A/A) 
0.336 
(A/C) 
0.513 
(C/C) 0.319 (A) 
 rs873634 122 0.131 (G/G) 
0.443 
(G/T) 
0.426 
(T/T) 0.352 (G) 
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Table 3.6: Summary of genotyping results for SNPs genotyped by MassARRAY at 
AGRF. 
Gene  SNP n Genotype frequencies MAF  
IL6R rs8192284 97 0.175 (C/C) 
0.371 
(A/C) 
0.454 
(A/A) 0.361 (C) 
CRP rs2794521 97 0.082 (C/C) 
0.320 
(C/T) 
0.598 
(T/T) 0.242 (C) 
IL10 rs1800871 99 0.101 (T/T) 
0.343 
(C/T) 
0.556 
(C/C) 0.273 (T) 
 rs1800896 99 0.192 (G/G) 
0.475 
(A/G) 
0.333 
(A/A) 0.429 (G) 
IL1B rs1143634 99 0.020 (T/T) 
0.232 
(C/T) 
0.747 
(C/C) 0.136 (T) 
 rs1143627 97 0.134 (C/C) 
0.495 
(C/T) 
0.371 
(T/T) 0.381 (C) 
 rs16944 99 0.121 (A/A) 
0.515 
(A/G) 
0.364 
(G/G) 0.379 (A) 
MYD88 rs6853 98 0.000 (G/G) 
0.153 
(A/G) 
0.847 
(A/A) 0.077 (G) 
IL2 rs2069762 93 0.151 (G/G) 
0.419 
(G/T) 
0.430 
(T/T) 0.360 (G) 
TLR2 rs3804100 99 0.010 (C/C) 
0.172 
(C/T) 
0.818 
(T/T) 0.096 (C) 
TNF rs1800629 99 0.020 (A/A) 
0.192 
(A/G) 
0.788 
(G/G) 0.116 (A) 
OPRM1 rs1799971 99 0.020 (GG) 
0.253 
(AG) 
0.727 
(AA) 0.146 (G) 
IL6 rs10499563 88 0.011 (C/C) 
0.239 
(C/T) 
0.750 
(T/T) 0.131 (C) 
LY96 rs11466004 90 0.000 (T/T) 
0.000 
(C/T) 
1.000 
(C/C) 0.000 (T) 
TLR4 rs4986790 97 0.000 (G/G) 
0.072 
(A/G) 
0.928 
(A/A) 0.036 (G) 
 rs4986791 98 0.000 (T/T) 
0.112 
(C/T) 
0.888 
(C/C) 0.056 (T) 
BDNF rs6265 99 0.051 (A/A) 
0.232 
(A/G) 
0.717 
(G/G) 0.167 (A) 
CASP1 rs554344 98 0.031 (C/C) 
0.286 
(C/G) 
0.684 
(G/G) 0.173 (C) 
 rs580253 98 0.041 (T/T) 
0.235 
(C/T) 
0.724 
(C/C) 0.158 (T) 
TGFB1 rs11466314  98 0.000 (A/A) 
0.000 
(A/G) 
1.000 
(G/G) 0.000 (A) 
 rs1800469 99 0.131 (T/T) 
0.475 
(C/T) 
0.394 
(C/C) 0.369 (T) 
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3.8 Haploview 
The software Haploview was used to check for adherence to HWE, calculate LD 
between SNPS, and to estimate haplotypes and their frequencies.  
For importation into Haploview, raw genotyping data was formatted as specified 
in the user manual and then converted into tab-delimited text files. Two separate 
Haploview input files were created; one providing information on SNPs 
genotyped by PCR-RFLP and the other on SNPs genotyped by MassARRAY. 
Each file contained information on sample number, gender, and genotype for each 
study participant. Fields were filled with a zero where pedigree information or 
case control status was required. An excerpt of the Haploview importation file for 
SNPs genotyped by PCR-RFLP is shown in Figure 3.22. 
 
 
Figure 3.22: Excerpt of Haploview input file. 
Information is shown for on sample numbers 1-5 for SGIP1 SNPs. Column A – pedigree 
name; B – sample ID number; C – father's ID number; D – mother's ID number; E – gender (1 
= male, 2 = female); F – affection status; G – genotypes for rs10889635, rs6681460 and 
rs2146904 (0 = unknown, 1 = A, 2 = C, 3 = G, T = 4).  
 
3.8.1 Adherence to HWE  
Haploview was used to test each SNP for adherence to HWE as a quality control 
measure. For any given SNP, the sum of the major and minor allele frequencies (p 
and q, respectively) equals one (equation 3.2). If a SNP is in HWE then the 
observed genotypes are a simple function of the major and minor allele 
frequencies (Equation 3.3).  
p + q = 1  (Equation 3.2)  
p2 + 2pq + q2 = 1 (Equation 3.3) 
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If observed genotype frequencies deviate significantly from those predicted by 
Equation 3.3 then that SNP is not in HWE. Haploview compares observed 
heterozygosity with that predicted, and any significant deviations (p < 0.05) 
indicate that SNP is not in HWE.  
All of the SNPs genotyped by MassARRAY, and 11 of the 13 SNPs genotyped by 
PCR-RFLP, were found to adhere to HWE (p > 0.05). For two SNPs, rs13187565 
and rs7254543, observed heterozygosity deviated significantly from expected  
(p = 0.0117 and p = 0.0219, respectively) (Appendix; Table 6.5). Adherence to 
HWE was therefore rejected for these SNPs and they were excluded from further 
analysis. 
 
3.8.2 LD and haplotype estimation 
LD values for SNP loci in the same gene were calculated in Haploview. Both D’ 
and r2 values were calculated, and LD plots were generated for genes in which 
three or more SNPs were genotyped.  
D’ provides a measure of the recombinational history between SNPs. D’ = 1.00 
indicates two SNP loci have not been separated by recombination (complete LD), 
D’ values <1.00 indicate linkage has been disrupted by recombination, and D’ = 0 
implies complete independence between loci. r2 is the correlation co-efficient and 
provides information on both LD and allele frequencies. r2 = 1 indicates SNPs 
have been separated by recombination and also have the same allele frequencies 
(perfect LD), thus the allele present at one SNP loci perfectly predicts the allele 
present at the other. Based on D’, SNP loci were assigned as either being in high 
(D’ ≥ 0.90), moderate (D’ ≥ 0.70) or weak (D’ < 0.70) LD. LD data was also 
obtained directly from the HapMap database for the HapMap Caucasian 
population (phase II+III, #27, Feb 09) for comparison with results obtained in the 
present study.  
Haploview was used to infer three-SNP haplotypes and estimate haplotype 
frequency (HF) for each gene containing three genotyped SNPs (SGIP1, GABRA2 
and IL1B). Haplotypes with HF ≥ 0.05 were considered common and HF < 0.05  
as rare. LD plots, haplotypes, and haplotype frequencies, were also inferred for 
the HapMap Caucasian population for several of the genes included in this study 
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(Appendix; 6.6). Data was downloaded directly into Haploview using the 
HapMap download feature (Version 3, Release 27, CEU population – herein 
referred to as V3/R27/CEU). 
 
3.8.2.1 SNPs genotyped by PCR-RFLP  
D’ values ranged from 0.155 to 0.961 (mean = 0.791), and r2 from 0.008 to 0.817 
(mean = 0.624), for pairs of SNP loci in the same gene (Table 3.7). The highest D’ 
values were observed between SNPs located in GABRA2. SNPs in both SGIP1 
and GABRA2 were found to be in moderate to high LD whereas weak LD was 
observed between SNPs in CACNA1G. Haploview identified eight three-SNP 
haplotypes for SGIP1 and six for GABRA2 (Figure 3.23c-d). Two common 
haplotypes were observed in both genes, along with six rare haplotypes in SGIP1, 
and four in GABRA2. 
 
 
Figure 3.23: LD plots and haplotypes for genes genotyped by PCR-RFLP. 
LD plots constructed in Haploview for a. SGIP1; and b. GABRA2. The value in each square 
corresponds level of LD between SNP loci in D’, for example, a value of 94 corresponds to  
D’ = 0.94. Dark red squares indicate high levels of LD.  
Haplotypes and their estimated frequencies inferred in Haploview for d. SGIP1  
(1 = rs10889635, 2 = rs6681460, 3 = rs2146904); and e. GABRA2 (1 = rs572227, 2 = 279845, 
3 = rs279841). 
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Table 3.7: LD values for SNP loci in the same gene genotyped by PCR-RFLP. 
Haploview results determined for this study are shown (Genotyped) along with LD data for 
the HapMap Caucasian population. Distance between loci for each SNP pair is also shown. 
N/D = no HapMap data. 
Gene SNP 1 SNP 2 
Genotyped HapMap Distance 
(bp) D' r2 D' r2 
SGIP1 rs10889635 rs6681460 0.942 0.761 1.000 0.960 47746 
  rs10889635 rs2146904 0.888 0.713 0.957 0.878 85099 
  rs6681460 rs2146904 0.927 0.817 1.000 1.000 37353 
GABRA2 rs572227 279845 0.809 0.583 0.876 0.710 78270 
  rs572227 279841 0.854 0.705 0.882 0.777 89310 
  279845 279841 0.961 0.780 0.959 0.850 11040 
CACNA1G rs7501581 rs8066527 0.155 0.008 N/D N/D 56265 
 
 
3.8.2.2 SNPs genotyped by MassARRAY  
Between pairs of SNP loci in the same gene genotyped by MassARRAY, D’ 
values ranged from 0.790 to 1.000 (mean = 0.931), and r2 from 0.060 to 0.857 
(mean = 0.488) (Table 3.8). Complete LD (D’ = 1) was observed between SNPs 
in IL10, TLR4, CASP1 and between one pair of SNP in IL1B. The three SNPs in 
IL1B were found to be in moderate to strong LD (Figure 3.24a). Four three-SNP 
haplotypes; two common and two rare, were identified for IL1B (Figure 3.24b).  
 
 
Figure 3.24: LD plots and haplotypes for IL1B. 
a. LD plot for IL1B. The value in each square corresponds level of LD between two SNP loci 
in D’, for example, a value of 79 corresponds to D’ = 0.79 and empty squares correspond to  
D’ = 1. Dark red squares indicate high levels of LD. b. IL1B haplotypes and their estimated 
frequencies (1 = rs1143634, 2 = rs1143627, 3 = rs16944). 
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Table 3.8: LD values for SNP loci in the same gene genotyped by MassARRAY. 
Haploview results determined for this study are shown (Genotyped) along with LD data for 
the HapMap Caucasian population. Distance between SNP loci for each SNP pair is also 
shown.  
Gene SNP 1 SNP 2 
Genotyped HapMap Distance 
(bp) D' r2 D' r2 
IL10 rs1800871 rs1800896 1.000 0.282 1.000 0.255 263 
IL1B rs1143634 rs1143627 0.795 0.063 0.551 0.064 3997 
  rs1143634 rs16944 0.790 0.060 0.538 0.058 4477 
  rs1143627 rs16944 1.000 0.978 1.000 0.982 480 
TLR4 rs4986790 rs4986791 1.000 0.689 1.000 0.742 300 
CASP1 rs554344 rs580253 1.000 0.857 1.000 1.000 5291 
 
 
3.9 Halplotype phasing 
The EM algorithm in SNPAnalyzer 1.2A was used to estimate haplotypes and 
infer haplotype phase for three-SNP haplotypes in SGIP1, GABRA2 and IL1B. 
Raw unphased data was formatted as specified in the user’s manual and converted 
into tab-delimited text files for input in SNPAnalyzer 1.2A. Input files contained 
information on SNP ID, sample ID and genotype (Figure 3.25). Any samples with 
incomplete genotyping data for the gene of interest were excluded from this 
analysis. 
 
 
Figure 3.25: Excerpt of SNPAnalyzer 1.2A input file for SGIP1. 
Row one provides information on SNP ID, and subsequent rows list sample ID followed by 
genotypes for each SNP. 
 
The EM algorithm identified the same three-SNP haplotypes constructed by 
Haploview and provided similar frequency estimates for SGIP1 and GABRA2 
(Table 3.9a-b). For IL1B, the EM algorithm identified one additional rare 
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haplotype (CCG, HF = 0.005) and frequency estimates for the remaining four 
IL1B haplotypes were similar for both Haploview and EM (Table 3.9c).   
 
Table 3.9: EM constructed haplotypes and their estimated frequencies.  
a. SGIP1; b. GABRA2; and c. IL1B. 
a. SGIP1 
Haplotypes HF 
b. GABRA2 
Haplotypes HF 
c. IL1B 
Haplotypes HF 
 
 AGG 0.550  GTG 0.528  CTG 0.485  
 GAA 0.351  AAA 0.350  CCA 0.371  
 GGG 0.040  GAG 0.049  TTG 0.134  
 AGA 0.020  ATG 0.041  TCA 0.005  
 AAG 0.012  GAA 0.024  CCG 0.005  
 AAA 0.008  GTA 0.008    
 
 GAG 0.008    
 
  
 
 GGA 0.008    
 
  
 
 
Haplotype phase was also inferred for each sample using the EM algorithm in 
SNPAnalyzer 1.2A, and the probability of each haplotype call was also 
determined. A probability threshold of 90% was chosen for accepting the 
haplotype call and considering phase resolved. Overall, probabilities ranged from 
37-100% (mean = 76%) and only 57%, 51% and 51% of haplotypes calls met the 
90% threshold for SGIP1, GABRA2 and IL1B, respectively (Appendix; Table 6.7). 
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3.10 Association analysis 
The software NCSS was used to perform statistical tests to examine associations 
between SNPs and quantitative EEG traits and ETDC. Because spindle frequency, 
delta amplitude and BIS value failed tests for normality, only non-parametric 
statistical tests were performed. 
 
3.10.1 Association of SNPs in candidate genes 
Of the 13 SNPs genotyped by PCR-RFLP, 10 passed quality control checks on 
MAF and adherence to HWE (Section 3.8.1) and were tested for associations with 
the EEG. KW-ANOVA identified associations with either the EEG or ETDC for 
four SNPs located in or near four different genes (p < 0.05). Two SNPs were 
found to associate with spindle amplitude; rs6681406 (SGIP1) and rs279841 
(GABRA2). rs6681406 (SGIP1) was also associated with relative spindle along 
with rs873634 (HCN2). A single SNP, rs7501581 (CACNA1G) was found to be 
associated with ETDC (Table 3.10). 
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Table 3.10: Association of SNPs genotyped by PCR-RFLP with ETDC and the EEG. 
SNPs were tested for associations with ETDC and the EEG using KW-ANOVA. p-values for each test are shown and significant p-values are marked with a single  
(p < 0.05) or double (p < 0.01) asterisk. n1 = number of samples tested for association with EEG traits excluding relative spindle amplitude (Relative spindle);  
n2 = number of samples tested for association with ETDC and relative spindle amplitude. 
Gene SNP ETDC Delta amplitude 
Delta 
frequency  
Spindle 
amplitude 
Spindle 
frequency 
Relative 
spindle  n1 n2 
SGIP1 rs10889635 0.0811 0.8439 0.9393 0.1332 0.5794 0.0715 124 121 
  rs6681460 0.1144 0.6770 0.7231 0.0362* 0.7778 0.0357* 123 120 
  rs2146904 0.3684 0.3826 0.7475 0.2210 0.8189 0.2237 124 121 
GABRA2 rs572227 0.9726 0.7549 0.9319 0.8308 0.2104 0.9335 125 122 
  rs279845 0.1925 0.4287 0.7060 0.1034 0.0637 0.0838 125 122 
  rs279841 0.1643 0.8264 0.7933 0.0427* 0.0836 0.0674 123 120 
HCN1 rs13361609 0.3434 0.4488 0.6217 0.6851 0.7335 0.4962 122 119 
CACNA1G rs7501581 0.0097** 0.2120 0.7041 0.3645 0.6478 0.0889 125 122 
  rs8066527 0.6222 0.9922 0.5267 0.6929 0.2286 0.6225 123 120 
HCN2 rs873634 0.1109 0.7936 0.2860 0.1406 0.9137 0.0474* 122 119 
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3.10.1.1 Associations with spindle amplitude 
Three SNPs in or near three different genes – SGIP1, GABRA2 and HCN2 – were 
found to be associated with spindle amplitude and/or relative spindle amplitude 
(Figure 3.26). For each of these SNPs, the strongest associations were observed in 
recessive models, and the minor allele was associated higher median spindle 
amplitude (Table 3.11, Table 3.12). 
 
 
Figure 3.26: Association of SNPs genotyped by PCR-RFLP with spindle amplitude and 
relative spindle amplitude.  
Association of a. rs6681460 (SGIP1) with spindle amplitude; b. rs279841 (GABRA2) with 
spindle amplitude; c. rs6681460 with relative spindle amplitude; and d. rs873634 (HCN2) 
with relative spindle amplitude. Box and whisker plots show median, minimum, maximum, 
and upper and lower quartiles for each genotype. The mean is marked with a cross and black 
circles denote outliers. Significant differences in median are indicated with a single asterisk  
(p < 0.05) (Appendix; Table 6.9, Table 6.10). 
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Table 3.11: Individual SNP effects on spindle amplitude for associated SNPs genotyped 
by PCR-RFLP. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are marked with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs6681406 R A/A  21 2.18 (1.93-2.43) 1.25 0.0103* 
(SGIP1)  A/G + G/G 102 1.75 (1.56-1.93)   
 D A/A + A/G  71 1.93 (1.75-2.16) 1.09 0.4440 
  G/G 52 1.77 (1.50-1.99)   
 OD A/A + G/G 73 1.93 (1.73-2.08) 1.10 0.2322 
  A/G 50 1.75 (1.51-1.98)   
rs279841 R A/A  18 2.32 (1.95-2.44) 1.28 0.0124* 
(GABRA2)  A/G + G/G 105 1.81 (1.62-1.97)   
 D A/A + A/G  76 1.94 (1.73-2.11) 1.07 0.3040 
  G/G 47 1.81 (1.54-2.06)   
 OD A/A + G/G  65 1.95 (1.71-2.16) 1.08 0.4412 
  A/G 58 1.80 (1.61-1.99)   
 
 
 
Table 3.12: Individual SNP effects on relative spindle amplitude for associated SNPs 
genotyped by PCR-RFLP. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are marked with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs6681406 R A/A  20 0.48 (0.32-0.53) 1.50 0.0102* 
(SGIP1)  A/G + G/G 100 0.32 (0.26-0.35)   
 D A/A + A/G  69 0.34 (0.28-0.42) 1.00 0.4478 
  G/G 51 0.34 (0.23-0.42)   
 OD A/A + G/G 71 0.35 (0.29-0.43) 1.13 0.2359 
  A/G 49 0.31 (0.24-0.35)   
rs873634 R G/G 16 0.43 (0.34-0.53) 1.34 0.0207* 
(HCN1)  GT + TT 103 0.32 (0.27-0.35)   
 D G/G + GT 68 0.34 (0.27-0.43) 1.03 0.9829 
  TT 51 0.33 (0.26-0.42)   
 OD G/G + TT 67 0.35 (0.31-0.43) 1.21 0.1068 
  GT 52 0.29 (0.24-0.41)   
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3.10.1.2 Associations with ETDC 
Only one SNP genotyped by PCR-RFLP – rs7501581 (CACNA1G) – was found to 
associate with ETDC. rs7501581 G/G homozygotes were found to have a  
1.29-fold higher median ETDC than C/G heterozygotes (p = 0.0075), and C/G 
heterozygotes a 0.88-fold lower median ETDC than C/C homozygotes  
(p = 0.0383) (Appendix; Table 6.11). The strongest association was observed in 
the over-dominant model (p = 0.0071) and a weaker association was also 
observed the recessive model (p = 0206) (Table 3.13).  
 
 
Figure 3.27: Associations of rs7501581 (CACNA1G) with ETDC. 
Box and whisker plot shows median, minimum, maximum, and upper and lower quartiles for 
each genotype, the mean is marked with a cross and black circles indicate outliers. Significant 
differences in median are indicated with a single (p < 0.05) or double asterisk (p < 0.01) 
(Appendix; Table 6.11). 
 
 
Table 3.13: Effects of rs7501581 (CACNA1G) on ETDC. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are indicated with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs7501581 R G/G 19 6.39 (4.96-7.36) 1.19 0.0206* 
  C/G + C/C 103 5.38 (4.91-5.63)   
 D G/G + C/G  71 5.34 (4.81-5.74) 0.95 0.3189 
  C/C 51 5.62 (5.04-6.03)   
 OD G/G + C/C  70 5.79 (5.35-6.18) 1.17 0.0071** 
  C/G 52 4.95 (4.56-5.49)   
3 | Results  86 
 
 
 
EDTC is in part controlled by the anaesthetist, therefore it was suggested 
rs7501581 might influence the relationship between BIS value and ETDC. A 
scatter plot of BIS value vs. ETDC categorised by rs7501581 in the over-
dominant model, showed an effect of rs7501581 on the relationship between 
ETDC and BIS value (Figure 3.28), however, linear regression analysis found this 
to be non-significant (Appendix; Table 6.12). There was evidence of a negative 
relationship between BIS value and ETDC for C/G heterzygotes (r = 0.349,  
p = 0.0058) but not for the C/C + G/G homozygous group (r =-0.076, p = 0.6458). 
This linear regression analysis was also performed on rs7501581 in the recessive 
and dominant models. The difference in intercept or slope of the regression line 
between the groups was found not to be statistically significant in either of these 
models (Appendix; Table 6.12) 
 
 
Figure 3.28: Scatter plot and regression lines showing relationship between BIS value 
and ETDC categorised by rs7501581 (CACNA1G) genotype in the over-dominant model. 
Solid black circles denote C/C + G/G homozygous patients, and black outlined circles C/G 
heterozygotes. Solid black line shows the relationship between BIS value and ETDC for C/C 
+ G/G homozygotes, and dashed black line for C/G heterozygotes. 
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3.10.2 Association of SNPs in inflammatory genes 
KW-ANOVA identified seven SNPs in or near five inflammatory genes 
associated with the EEG or ETDC (p < 0.05) (Table 3.14). A single SNP in 
MYD88 (rs6853) had the strongest association with the EEG of all SNPs 
genotyped in this study and was associated with spindle amplitude (p = 0.0040), 
relative spindle amplitude (p = 0.0006) and ETDC (p = 0.0095). Two SNPs in 
IL1B (rs1143627 and rs16944) were also associated with spindle amplitude  
(p = 0.0198 and p = 0.0222, respectively), and a single SNP in IL-10 (rs1800896) 
associated with delta frequency (p = 0.0176). In addition to rs6853, a further two 
SNPs in separate genes were associated with ETDC; rs2794521 in CRP  
(p = 0.0381), and rs1800469 in TGFB1 (p = 0.0367).  
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Table 3.14: Association of SNPs genotyped by MassARRAY with ETDC and the EEG. 
SNPs were tested for associations with ETDC and the EEG using KW-ANOVA. p-values for each test are shown and significant p-values are marked with a single  
(p < 0.05) or double (p < 0.01) asterisk. n1 = number of samples tested for association with EEG traits excluding relative spindle amplitude (Relative spindle);  
n2 = number of samples tested for association with ETDC and relative spindle amplitude. 
Gene SNP ETDC Delta amplitude 
Delta 
frequency 
Spindle 
amplitude 
Spindle 
frequency 
Relative 
spindle  n1 n2 
IL6R rs8192284 0.6726 0.7905 0.8512 0.6971 0.2381 0.6474 97 96 
CRP rs2794521 0.0381* 0.6964 0.7739 0.1236 0.6254 0.0530 97 96 
IL10 rs1800871 0.4878 0.8088 0.5213 0.8982 0.4650 0.8995 99 98 
  rs1800896 0.8142 0.2057 0.0176* 0.1671 0.9287 0.2590 99 98 
IL1B rs1143634 0.2900 0.2371 0.1925 0.2192 0.1262 0.1251 99 98 
  rs1143627 0.0698 0.3828 0.8601 0.0198* 0.3021 0.0269* 97 96 
  rs16944 0.1222 0.1818 0.9619 0.0222* 0.1595 0.0432* 99 98 
MYD88 rs6853 0.0095** 0.0984 0.6288 0.0040** 0.6148 0.0006** 98 97 
IL2 rs2069762 0.5595 0.3935 0.8795 0.6212 0.7916 0.4635 93 92 
TLR2 rs3804100 0.6630 0.3026 0.9578 0.2643 0.4670 0.6599 99 98 
TNF rs1800629 0.1039 0.3886 0.7375 0.5477 0.2966 0.4918 99 98 
OPRM1 rs1799971 0.9141 0.9206 0.8920 0.7330 0.4115 0.8699 99 98 
IL6 rs10499563 0.1020 0.4094 0.9372 0.1091 0.3271 0.0522 88 87 
TLR4 rs4986790 0.4767 0.6256 0.5489 0.6963 0.8344 0.8491 97 96 
  rs4986791 0.4596 0.8527 0.7698 0.8175 0.1860 0.5772 98 97 
BDNF rs6265 0.9877 0.3893 0.7122 0.1214 0.9622 0.3737 99 98 
CASP1 rs554344 0.8532 0.6344 0.0632 0.6753 0.0516 0.8497 98 87 
 rs580253 0.5243 0.8996 0.4892 0.1489 0.1832 0.1652 98 97 
 TGFB1 rs1800469 0.0367* 0.3946 0.3352 0.2887 0.4170 0.2668 99 98 
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3.10.2.1 Association of MYD88 with spindle amplitude and 
ETDC 
rs6853G (minor allele) was only observed in heterozygotes and was found to be 
associated with increased spindle amplitude, increased relative spindle amplitude, 
and decreased ETDC (Table 3.14, Figure 3.29). rs6853 A/G heterozygotes had a 
1.39-fold higher median spindle amplitude (p = 0.0040), 1.69-fold higher median 
relative spindle amplitude (p = 0.0006)  and  0.88-fold lower median ETDC  
(p = 0.0095) than A/A homozygotes (Appendix; Table 6.9, Table 6.10, Table 
6.11). Because no rs6853 G/G homozygotes were identified in this sample, tests 
for SNP effects in the various models were unable to be performed. 
 
 
Figure 3.29: Association of rs6853 (MYD88) with spindle amplitude and ETDC. 
Association of rs6853 with a. spindle amplitude; b. relative spindle amplitude; and c. ETDC. 
Box and whisker plots show median, minimum, maximum, and upper and lower quartiles for 
each genotype, the mean is marked with a cross and black circles denote outliers. Highly 
significant differences in median are indicated with a double asterisk (p < 0.01). 
 
Based on histograms showing the distribution of spindle amplitude (Figure 3.1d), 
spindle amplitude was classified as either low (< 1.0 µV), moderate (1.0 µV to  
2.5 µV) or high (> 2.5 µV), and distributions were compared between genotypes. 
Overall, approximately 80% of patients fell into the moderate group and the 
remaining were classified as either low or high. 40% of A/G heterozygotes fell 
into the high category compared with only 7.3% of A/A homozygotes, and no 
A/G heterozygotes fell into the low category compared with 8.4% of A/A 
homozygotes (p = 0.0013) (Table 3.15).   
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Table 3.15: Cross tabulation showing distribution of rs6853 (MYD88) genotypes with 
spindle amplitude categorised as either low, medium or high. (p = 0.0013). 
rs6853  
Genotype 
Low 
(< 1.0 µV) 
Medium 
(1.0 to 2.5 µV) 
High 
(> 2.5 µV) 
A/A 7 (8.4%) 70 (84.3%) 6 (7.3%) 
A/G 0 (0.0%) 9 (60.0%) 6 (40.0%) 
 
A scatter plot of spindle amplitude vs. ETDC, categorised by rs6853 genotype, 
showed that patients with the A/G genotype tended to cluster together at high 
spindle amplitude and low ETDC (Figure 3.30a). The relationship between 
spindle amplitude and ETDC was also influenced by rs6853 genotype. There was 
evidence of a negative relationship between ETDC and spindle amplitude for A/G 
heterozygotes (p = 0.0001), but not for A/G heterozygotes (Appendix; Table 6.13), 
and there was a significant difference in the intercept between A/G and G/G 
genotypes (p = 0.0087). No significant effects of rs6853 genotype on the 
relationship between BIS value and ETDC were observed (Figure 3.30b, 
Appendix; Table 6.13).  
 
 
Figure 3.30: Scatter plots showing relationships between a. Spindle amplitude and 
ETDC, and b. BIS value and ETDC, categorised by rs6853 (MYD88) genotype. 
Solid black circles denote A/A homozygous patients and black outlined circles A/G 
heterozygotes. Regression lines are also shown; solid black line shows the relationship 
between variables for A/A homozygotes, and dashed black line for A/G heterozygotes. 
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3.10.2.2 Associations with spindle amplitude 
In addition to rs6853, KW-ANOVA identified two SNPs near IL1B – rs1143627 
and rs16944 – associated with spindle amplitude and relative spindle amplitude 
(Table 3.14). For both SNPs, the strongest associations with spindle amplitude 
and relative spindle were observed in the over-dominant model. Weaker 
associations were also observed in the recessive model for spindle amplitude, and 
in the dominant model for relative spindle amplitude (Table 3.16, Table 3.17). 
 
 
Figure 3.31: Association of IL1B SNPs with spindle amplitude. 
a. Association of rs1143627 with spindle amplitude; b. rs16944 and spindle amplitude; c. 
rs1143627 and relative spindle amplitude; d. rs16944 and relative spindle amplitude. Box and 
whisker plots show median, minimum, maximum, and upper and lower quartiles of spindle 
amplitude for each genotype, the mean is marked with a cross and black circles indicate 
outliers. Significant differences in median are indicated with a single asterisk (p < 0.05) 
(Appendix; Table 6.9, Table 6.10).  
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Table 3.16: Individual IL1B SNP effects on spindle amplitude. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are indicated with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs1143627 R C/C  13 1.54 (1.13-1.75) 0.84 0.0495* 
  C/T + T/T 84 1.84 (1.62-1.99)    
 D C/C + C/T  61 1.83 (1.62-2.11) 1.08 0.1900 
  T/T 36 1.69 (1.32-1.93)    
 OD C/C + T/T 49 1.62 (1.39-1.79) 0.82 0.0092** 
  C/T 48 1.97 (1.68-2.25)    
rs16944 R A/A 12 1.47 (1.13-1.75) 0.80 0.0491* 
  A/G + G/G 87 1.83 (1.62-1.97)    
 D A/A + A/G 63 1.83 (1.62-2.04) 1.08 0.1917 
  G/G 36 1.69 (1.32-1.93)    
 OD A/A + G/G 48 1.58 (1.33-1.79) 0.84 0.0110* 
  A/G 51 1.89 (1.71-2.25)    
 
 
Table 3.17: Individual IL1B SNP effects on relative spindle amplitude. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are indicated with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs1143627 R C+C  13 0.27 (0.16-0.44) 0.82 0.3015 
  C/T + T/T 83 0.33 (0.28-0.35)   
 D C/C + C/T  61 0.34 (0.28-0.44) 1.31 0.0395* 
  T/T 35 0.26 (0.20-0.34)   
 OD C/C + T/T 48 0.27 (0.21-0.34) 0.77 0.0072** 
  C/T 48 0.35 (0.29-0.49)   
rs16944 R A/A 12 0.27 (0.16-0.44) 0.84 0.3402 
  A/A + A/G 86 0.32 (0.27-0.35)   
 D A/A + A/G 63 0.34 (0.28-0.42) 1.31 0.0499* 
  G/G 35 0.26 (0.20-0.34)   
 OD A/A + G/G 47 0.26 (0.21-0.34) 0.76 0.0122* 
  A/G 51 0.34 (0.29-0.47)   
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3.10.2.3 Associations with delta frequency 
A single SNP near IL10 (rs1800896) associated with delta frequency (p = 0.0176). 
Mann-Whitney U tests identified a significant difference between the A/G and 
G/G genotypes (p = 0.0055), and no significant differences were observed 
between either the A/A and A/G or the A/A and G/G genotypes (Figure 3.32) 
(Appendix; Table 6.14) Associations were observed in both the over-dominant  
(p = 0.0096) and recessive models (p = 0.0154).  
 
 
Figure 3.32: Association of rs1800896 (IL10) with delta frequency. 
Box and whisker plot showing median, minimum, maximum, and upper and lower quartiles 
of delta frequency for each genotype, the mean is marked with a cross. Significant differences 
in median are indicated with a double asterisk (p < 0.01) (Appendix; Table 6.14). 
 
 
Table 3.18: Effect of rs1800896 (IL10) on delta frequency. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are indicated with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs1800896 R A/A 19 0.50 (0.50-0.63) 0.72 0.0154* 
(IL10)  A/G + G/G 80 0.69 (0.63-0.75)   
 D A/A + A/G 66 0.63 (0.63-0.75) 1.00 0.4711 
  G/G 33 0.63 (0.50-0.75)   
 OD A/A + G/G 52 0.63 (0.50-0.63) 0.84 0.0096** 
  A/G 47 0.75 (0.63-0.88)   
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3.10.2.4 Associations with ETDC 
In addition to rs6853, two other SNPs genotyped by MassARRAY were 
associated with ETDC – rs2794521 near CRP (p = 0.0381) and rs1800469 near 
TGF1B (p = 0.0367). 
rs2794521C (minor allele) was associated with higher median ETDC and the 
strongest association was observed in the dominant model (p = 0.0119) (Table 
3.19). A significant difference in median ETDC was observed between the 
rs2794521 C/T and T/T genotypes (p = 0.0306), with a 1.15-fold higher median 
ETDC observed in C/T heterozygotes relative to T/T homozygotes.  
For rs1800469, a significant difference in mean ETDC was identified between the 
C/C and T/T genotypes (p = 0.0126) (Figure 3.33b). rs1800469T (minor allele) 
was associated with lower median ETDC with the strongest association observed 
in the recessive model (p = 02151) (Table 3.19).   
 
 
Figure 3.33: Association of a. 2794521 (CRP) and b. rs1800469 (TGFB1) with ETDC. 
Box and whisker plots show median, minimum, maximum, and upper and lower quartiles for 
each genotype, the mean is marked with a cross. Significant differences in median are 
indicated with a single asterisk (p < 0.05) (Appendix; Table 6.11). 
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Table 3.19: Individual SNP effects on ETDC for associated SNPs genotyped by 
MassARRAY. 
R = recessive model; D = dominant model; OD = over-dominant model. Significant p-values 
are indicated with a single (p < 0.05) or double (p < 0.01) asterisk. 
SNP Model Genotype/s n Median (95% CI) Fold Diff. p-value 
rs2794521 R C/C  8 5.78 (4.71-7.96) 1.04 0.1785 
(CRP)  C/T + T/T 88 5.58 (5.18-6.03)   
 D C/C + C/T 39 5.83 (5.57-6.67) 1.13 0.0119* 
  T/T 57 5.18 (4.80-5.62)   
 OD C/C + T/T 65 5.39 (4.88-5.81) 0.90 0.0650 
  C/T 31 5.96 (5.57-6.68)   
rs1800469 R T/T 13 4.71 (4.26-5.67) 0.82 0.0215* 
(TGF1B)  T/T + C/T 85 5.74 (5.39-6.10)   
 D T/T + C/T 59 5.40 (4.80-5.83) 0.91 0.0685 
  C/C 39 5.95 (5.39-6.66)   
 OD T/T + C/C 52 5.60 (5.18-6.18) 1.00 0.8226 
  C/T 46 5.58 (4.82-6.10)   
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4 Chapter 4: 
Discussion 
  
 
 
 
4.1 Genotyping results 
Observed MAFs for all genotyped SNPs (excluding rs8066269) fell within ±0.16 
of the corresponding MAF for the HapMap Caucasian population. SNPs 
rs7254543 and rs2069762 deviated the most from the HapMap MAF (+0.157 and 
+0.128, respectively). The differences in MAF between this sample and the 
HapMap are likely attributable to ancestral differences. The HapMap Caucasian 
population sample consists of Utah residents of northern and western European 
descent. The sample in the present study was of mixed descent; 77% of patients 
identified themselves as being of European ancestry and remainder as either 
Maori, Polynesian, or Asian.  
For rs8066269, the MAF for the HapMap pilot Yoruban population was 0.157, 
and no frequency information was available for a Caucasian population. 25 
samples were genotyped for rs8066269 and all were found to have the G/G 
genotype. Genotyping was not continued for this SNP as it was predicted that 
even if the A allele was identified in this sample, the low frequency would 
considerably limit statistical power in the association analysis.    
Of the 34 SNPs included this study, two (rs13187565 and rs7254543) failed 
quality control tests for adherence to HWE and were therefore excluded from 
further analysis. The failure of SNPs to adhere to HWE can suggest problems in 
the dataset such as population stratification [179] or genotyping errors [180, 181]. 
Three SNPs (rs8066269, rs11466314 and rs11466004) were also found not to be 
polymorphic in this sample and were excluded from further analysis.  
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4.1.1 LD and haplotype phasing 
Moderate to high levels of LD were observed for the majority of SNP loci in the 
same gene (SGIP1, GABRA2, CACNA1G, IL10, IL1B, TLR4 and CASP1) (Table 
3.7, Table 3.8). Plots of LD, as either D’ or r2, against distance between SNP loci, 
showed that LD tended to decrease only marginally with increasing distance 
(Figure 4.1) (Table 3.7, Table 3.8). All SNP pairs in complete LD were located 
within 5 kb of one another, however, high LD was observed for SNPs located as 
far as 48 kb apart, and moderate LD for SNP pairs as far as 89 kb apart. r2 values 
showed the same general trend as D’, with the exception that low r2 values were 
observed for some SNP pairs even in very close proximity (<1 kb) (Figure 4.1b). 
D’ provides a measure of recombinational history whereas r2 measures both 
recombinational history and allele frequencies between two loci. High r2 values 
indicate that SNPs have similar allele frequencies and are unlikely to have been 
separated by recombination. The average haplotype block size in European and 
Asian populations has previously been estimated to be around 20 kb, however, 
over half of the human genome is predicted to lie in a smaller number of large 
haplotypes blocks (>30 kb) [134]. Therefore it is not unexpected for SNPs nearly 
50 kb apart to be in high LD. 
 
 
Figure 4.1: Relationship of LD with physical distance. 
a. LD measured in D’; b. LD measured in r2. 
 
LD values determined in the present study were compared with the HapMap 
Caucasian population (Table 3.7, Table 3.8). Deviation from HapMap D’  
values ranged from -0.073 to +0.252 (mean = +0.017), and r2 values from -0.119 
to +0.027 (mean = -0.081). Differences in LD patterns between this sample  
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and the HapMap Caucasian population are suggested to in part be attributable  
to differences in ancestry. D’ values can also be influenced by small  
sample size. However, small samples tend to lead to upwards fluctuations in D’ 
[134, 135] and D’ values were generally lower in this study than for the  
HapMap Caucasian population. 
The EM algorithm in SNPAnalyzer 1.2A was investigated as a tool to resolve 
haplotype phase for three-SNP haplotypes in SGIP1, GABRA2 and IL1B. The EM 
algorithm identified the same haplotypes as Haploview and one additional rare 
haplotype for IL1B, but the probability of over half of all haplotype calls for 
individual samples was below the desired threshold (90%). Because of the overall 
poor probability of calls, haplotype phase was not considered adequately resolved 
and haplotypes assignments were not used in the association analysis. It is 
suggested that the poor probability of the haplotype assignment is the result of a 
combination of small sample size, the low number of SNPs included in each 
haplotype, and only moderate LD between some SNP pairs. 
Three-SNP haplotypes constructed in Haploview for SGIP1, GABRA2 and IL1B, 
for this study were compared with haplotypes for the HapMap Caucasian 
population (Appendix; Table 6.8). For SGIP1, two additional rare haplotypes 
were identified in this study that are absent in HapMap Caucasians, and for 
GABRA2 one additional rare haplotype was identified. As this study included 
participants of mixed ancestry, the additional rare haplotypes may have been 
contributed by participants of non-European descent, or alternatively, may be the 
result of genotyping errors. One of the requirements of performing a haplotype 
analysis is the need for a very low error rate as genotyping errors can create 
artificial rare haplotypes that are not truly present in the population [134]. Errors 
in PCR-RFLP genotyping can potentially arise as a result of incomplete digestion 
[182], or as result of polymorphisms in the primer binding region [183]. In order 
to reduce the likelihood of such errors, primer binding regions were checked for 
known polymorphisms using the UCSC Genome Browser; the ratio of band 
intensity was assessed for each sample; and any samples that gave unclear results 
were re-genotyped. It is also important to note that the haplotypes identified by 
Haploview are inferred using statistical algorithms, thus the haplotypes identified 
by the software are probable and may not represent the actual haplotypes present. 
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4.2 BIS value and ETDC 
In accordance with previous studies, BIS value was found to decrease with 
increasing ETDC [184]. The correlation between EDTC and BIS value was weak 
(r = -0.2271, p = 0.0230). Other studies have also reported poor correlations 
between BIS value and ETAC of volatile anaesthetics [185, 186], furthermore, 
this relationship has been found to be significantly affected by age [187].  
Two patients were found to have unexpectedly high median BIS values (81 and 
79), which considered alone, would indicate inadequate anaesthesia. Both patients 
however were unconscious and ETDC values were within a suitable range for 
surgical anaesthesia. The high BIS values observed are likely to be artifactual, and 
highlight the fact that BIS value can be at times be misleading and cannot be 
relied on as a sole means to estimate anaesthetic depth. It is also important to note 
that these BIS values do not correspond to the median intra-operative BIS, but 
rather to a single a 60 sec EEG epoch recorded in the middle surgery. 
 
 
4.3 Genetic associations with the EEG and EDTC 
KW-ANOVA identified a total of nine SNPs located in eight different genes 
associated with the EEG or ETDC at p < 0.05, three of which were associated at  
p < 0.01. These are summarised in Table 4.1. 
The associated SNPs were located in genes with four distinct types of function; 
ion channels, neurotransmitter signalling, endocytosis, and cytokine signalling. 
This is interpreted to suggest different pathways are involved in regulating the 
EEG during general anaesthesia. Sections 4.4 and 4.5 discuss the reported 
associations in more detail and the relevance of these associations to the EEG 
during general anaesthesia. 
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Table 4.1: Summary table of SNPs associated with the EEG or ETDC (p < 0.05).  
Highly significant p-values (p < 0.01) are marked with an asterisk. 
Gene SNP Phenotype p-value 
SGIP1 rs6681460 Spindle amplitude 0.0362 
  Relative spindle amplitude 0.0357 
GABRA2 rs279841 Spindle amplitude 0.0427 
CACNA1G rs7501581 ETDC 0.0097* 
HCN2 rs873634 Relative spindle amplitude 0.0474 
CRP rs2794521 ETDC 0.0381 
Il10 rs1800896 Delta Frequency 0.0176 
IL1B rs1143627 Spindle amplitude 0.0198 
  Relative spindle amplitude 0.0269 
 rs16944 Spindle amplitude 0.0222 
  Relative spindle amplitude 0.0432 
MYD88 rs6853 Spindle amplitude 0.0040* 
  Relative spindle amplitude 0.0006* 
  ETDC 0.0095* 
TGF1B rs1800469 ETDC 0.0367 
 
 
4.3.1 The multiple testing problem 
One difficulty with performing KW-ANOVA tests on all SNPs for all EEG traits 
and ETDC, is the multiple testing problem – the more simultaneous statistical 
tests performed the greater the likelihood of the null hypothesis being falsely 
rejected. The approach taken resulted in a total of 174 individual KW-ANOVA 
analyses being performed, which at an alpha level of 0.05 would be expected to 
result in 8-9 false positive results. 
It is important that any adjustments for multiple comparisons finds a balance 
between decreasing the probability of false positives without over inflating the 
risk of false negatives, as this can result in important associations being over 
looked. One of the most commonly used methods to correct for multiple testing is 
the Bonferroni correction [188]. This method reduces the probability of false 
positives, however, it is often considered too conservative, particularly when 
variables are highly dependent [189].  
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The standard Bonferroni correction adjusts the significance threshold (α) based on 
the number of tests performed (n) (Equation 4.1).  
α/n = adjusted α  (Equation 4.1)  
Using Equation 4.1, the Bonferroni correction gives an adjusted significance 
threshold value of α = 0.0003 for this study. At this threshold no SNPs reach 
statistical significance.   
Several SNPs in this study were found to be in high LD as measured by r2 values, 
indicating that SNPs alleles are highly correlated. Moderate correlations were also 
observed between ETDC and spindle amplitude, and ETDC and delta amplitude. 
Therefore, within this data set, variables are not fully independent and the 
Bonferroni correction may indeed be too conservative. Rather than applying a 
correction for multiple testing, a lower significance level of α = 0.01 is suggested 
as possibly more appropriate for this study. Using a significance threshold of  
α = 0.01 only two SNPs (rs7501581 and rs6853) in this study achieve statistical 
significance and a further seven can be considered sub-threshold (p = 0.01 - 0.05). 
Additionally, while p-values measure the statistical significance of the result they 
do not provide a measure of effect sizes. A test may have a highly significant  
p-value yet this does not imply that the extent of effect is of biological or clinical 
importance, thus this also needs to be considered when evaluating the significance 
of association results. 
 
 
4.4 Associations of candidate genes with the EEG 
and ETDC 
4.4.1 SGIP1  
SGIP1 encodes a protein involved in CME that plays an important role in the 
recycling of synaptic vesicles, channels, transporters and other membrane proteins 
in neuronal cells (Section 1.10.1). The present study identified a single SNP in 
SGIP1 (rs6681406) associated with spindle amplitude at sub-threshold 
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significance (p = 0.362). The rs6681406 A/A genotype was found to be associated 
both with higher spindle amplitude (p = 0.0103) and relative spindle amplitude  
(p = 0.0102) in recessive models of effect. Effect sizes were only small, with  
1.25- and 1.50-fold increases in median spindle amplitude and relative spindle 
amplitude, respectively, for A/A homozygous patients compared with carriers of 
the G allele.  
rs6681406 is one of eight intronic SNPs previously associated with resting theta 
power in a GWAS of Plains American Indians by Hodgkinson et al. (2010) [95]. 
A recent study by Derringer and colleagues failed to replicate the association of 
any of these eight SNPs in a large European (n = 757) and an African sample  
(n = 309) [190], or for the combined data set. The failure to replicate was 
primarily attributed to differences in ancestry, in part resulting from differences in 
allele frequency or LD [190]. Of the eight significant SNPs identified by 
Hodgkinson et al. (2010), three were genotyped in this study, and only one was 
found putatively associated with the EEG. The failure to identify associations with 
the EEG for the other two SNPs (rs10889635 and rs2146904) may be the result of 
the difference in EEG phenotypes analysed in this study or ancestry differences. 
Participants in the present study data were of mixed, but predominantly European 
ancestry, and associations with delta and spindle oscillations were examined, but 
not with theta and alpha power. 
The putative association of rs6681406 with spindle amplitude identified in the 
present study, in conjunction with the previously identified association with theta 
power [95], supports the earlier hypothesis that SGIP1 may have broader effects 
on the EEG not solely limited to a single frequency band. Other loci that may 
regulate the EEG across the frequency spectrum have previously been identified, 
for example convergence of linkage peaks to alpha, beta and theta EEG power 
have been found on chromosome 5q13-14 [93].  
All three SGIP1 SNPs genotyped were intronic SNPs of unknown function and 
the underlying cause of the association of rs6681406 with spindle amplitude or 
ETDC is unknown. Association of intronic variants with disease of other 
phenotypes is often thought to be due to their being in LD with functional SNPs. 
Another possibility underlying associations of non-coding variants, such as 
rs6681406, is that they might alter the regulation of gene expression, for example, 
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by affecting transcription factor binding, RNA splicing, or via microRNA 
(miRNA) mediated gene regulation.  
One mechanism by which SGIP1 variation is suggested to influence the EEG, is 
through altered ion channel or receptor recycling by CME. Ion channel recycling 
plays an important role in the regulation of ion channels and their respective 
currents and CME has been directly shown to play a role in the regulation of 
various ion channels, including voltage gated potassium channels in neuronal cells 
[191]. Both over expression and knockdown of SGIP1 have been shown to inhibit 
endocytosis [137], thus variability in the function or expression levels of SGIP1 
between individuals might also affect endocytosis and the efficiency of receptor 
and channel turnover or neurotransmitter uptake, thereby influencing neuronal 
activity. This in turn may potentially manifest not only as variability in the theta 
frequency band but extend to other EEG frequencies.  
 
4.4.2 GABRA2  
Three SNPs in GABRA2 were genotyped by PCR-RFLP and tested for 
associations with the EEG and anaesthesia administration. Only one of these 
SNPs, rs279841, was associated with the EEG at sub-threshold significance  
(p = 0.0427) and no associations were identified for rs572227 and rs279845. 
rs279841A was associated with increased spindle amplitude and A/A 
homozygous patients had a 1.28-fold higher median spindle amplitude than 
carriers of the G allele (p = 0.0124). 
rs279841 has previously been associated with alcohol dependency [92] and beta 
power in the resting EEG [92, 192]. Numerous other SNPs in GABRA2 have also 
been associated with these phenotypes and associations with alcohol dependency 
replicated in various studies (reviewed in [145]). The association of GABRA2 
variants with both alcohol dependency and increased beta power has led to the 
hypothesis that GABRA2 may influence risk for alcohol dependence by 
modulating neuronal activity [92]. While associations with beta power were not 
tested for in this study, the identification of a putative association with spindle 
amplitude suggests GABRA2 variability might also influence other frequency 
bands.  
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Functional GABRA2 SNP(s) have not yet been identified [171]. In all of the 
studies linking GABRA2 with alcohol dependency or beta activity, only non-
coding variants have been associated with either phenotype, suggesting that 
GABRA2 variation may influence neuronal excitability by affecting gene 
regulation. Haughey and colleagues (2008), have previously reported differing 
GABRA2 mRNA levels in the post-mortem prefrontal cortex between GABRA2 
genotypes, however, the difference in expression level between genotypes 
observed was less than two-fold [171]. Three SNPs in perfect LD; rs573400 in the 
3' UTR, rs279871 in intron 7, and rs279858 – a synomynous coding SNP, were 
associated with mRNA GABRA2 levels, leading the authors to speculate that 
GABRA2 genotype may be involved in predetermining GABAA receptor subunit 
assembly and/or function [171].  
The three SNPs genotyped in the current study are located in a 113 kb haplotype 
block beginning upstream of the gene 3′ end and spanning a large portion of 
GABRA2 (Appendix; Figure 6.27). LD data was available for the HapMap 
Caucasian population for two of the three SNPs (rs573400 and rs279858) 
associated with GABRA2 mRNA levels by Haughey et al. (2008). rs279841 is 
located in the same haplotype block and is in high LD with both of these SNPs 
(Table 4.2) (Appendix; Figure 6.27), prompting the suggestion that differential 
gene regulation may underlie the putative association identified in this study. It is 
unknown if rs279841 has a direct effect on gene expression itself, or whether its 
association is due to it being in high LD with an as yet unidentified functional 
SNP in this haplotype block.  
 
Table 4.2: LD between rs279841 and SNPs previously associated with GABRA2 
mRNA levels in the pre-frontal cortex by Haughey et al. (2008) [171]. 
SNP 1 SNP 2 D' r2 
rs573400 rs279858 1.0 0.934 
rs573400 rs279841 0.93 0.835 
rs279858 rs279841 1.0 0.902 
 
The GABRA1 gene encodes the GABAA receptor α1 subunit and presents another 
particularly viable candidate gene for association with the EEG during general 
anaesthesia. In the thalamus, α2 subunit expression is high during embryonic 
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development, and during postnatal development α2 is replaced by the α1 subunit 
[193]. Within the adult brain, the α2 subunit exhibits a localised distribution with 
preferential expression in the forebrain and cerebellum, and limited expression in 
the thalamus. Conversely, the α1 subunit is widely distributed and is highly 
expressed in thalamic neurons [194-196]. The incorporation of different α 
subunits into GABAA receptors effects neuronal excitability by influencing the 
kinetics of deactivation of GABA-induced current, with faster decay time 
observed in receptors containing the α1 subunit than those containing α2 [197]. 
Genetic variability affecting expression levels of the different α subunits, might 
affect the relative abundance of each which in turn might to lead to differences in 
neuronal excitability due to differences in GABAA receptor kinetics. 
 
4.4.3 CACNA1G  
T-type Ca2+ channels underlie the It current which plays an important role in the 
generation of both spindle and delta waves (Sections 01.4.3 and 1.4.4). A single  
T-type Ca2+ channel gene – CACNA1G – was investigated for associations with 
the EEG and ETDC in this study. Of the three CACNA1G SNPs genotyped, an 
association was only found for rs7501581 with ETDC (p = 0.0097). rs7501581 
was selected based on MAF and its position upstream of the gene 5' end. SNPs in 
this region may affect gene regulation if they occur at transcription factor binding 
sites, or alternatively, might be in LD with SNPs with regulatory or other 
functional effects. 
Associations of rs7501581 with ETDC were identified in both the recessive  
(p = 0.0206) and over-dominant models (p = 0.0071). It was suggested rs7501581 
variability might affect the relationship between EDTC and the BIS value, 
however linear regression analysis found no significant effect of rs7501581 on 
this relationship in any of the effect models (Appendix; Table 6.12).  
CACNA1G was selected as a candidate gene based on the role of It in the 
generation of synchronised EEG activity, and on previously reported findings 
showing  altered slow wave EEG activity in CACNA1G-/- mice [155]. α1G is also 
strongly expressed within the thalamus in thalamic relay neurons [154]. In 
addition to its role in the generation of synchronised EEG activity, Cav3.1 is 
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implicated in pain signalling, sleep-wake cycles and absence epilepsy (reviewed 
in [41]). Interestingly, the results in this study suggest an association with ETDC, 
and no associations were identified between CACNA1G and the EEG. 
Associations of polymorphisms in any of the T-type Ca2+ genes with anaesthesia 
have not been reported to date. 
Various general anaesthetics have previously been demonstrated to reversibly 
block It in vitro at clinically relevant concentrations in a dose dependent manner 
[198-201], and isoflurane has also been reported to inhibit LTS in TC neurons 
[202]. While the clinical effect of It blockade by certain anaesthetics is unclear 
[198], such results lend support for the putative association identified in the 
present study. Conversely, in a study by Petrenko et al. (2007) examining  
the effects of volatile anaesthetics on CACNA1G-/- mice, the hypnotic and 
immobilizing effects of volatile anaesthetics were not altered in CACNA1G-/-  
mice, however, KO mice took longer to develop hypnosis, suggesting T-type  
Ca2+ channels might be involved in the induction of anaesthesia by volatile 
anaesthetic agents [203]. 
 
4.4.4 HCN1 and HCN2 
Aside from a weakly significant association identified for rs873634 (HCN1)  
(p = 0.0474), HCN1 and HCN2 were not found to be associated with the EEG  
or ETDC.  
There are over 900 SNPs in or near each of these genes listed in NCBI dbSNP. In 
the present study, just two SNPs located upstream of the gene 5' end were 
genotyped for each gene, and only one SNP in each gene passed quality control 
checks for inclusion in the association analysis. All four SNPs selected in these 
genes were chosen based on MAF and their location upstream of the gene 5' end. 
As the vast majority of HCN1 and HCN2 polymorphisms have not been tested for 
associations, the failure to identify associations for HCN2, and the identification 
of only one weak association for HCN1, does not imply that variability in these 
genes does not influence the EEG or ETDC. 
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4.5 Associations of inflammatory genes with the 
EEG and ETDC 
For the inflammatory gene set, only one gene – MYD88 – was found to be 
associated with the EEG at p < 0.01, and a further three genes were associated at 
sub-threshold significance. MYD88 is involved in the IL-1R signalling pathway 
and was found to be associated with spindle amplitude and ETDC. Interestingly 
IL1B, which signals via IL-1R, was also associated with spindle amplitude at sub-
threshold significance. Other than MYD88, no other genes involved in IL-1R 
mediated signalling were included in this study and no associations were 
identified for genes involved in toll-like receptor (TLR) signalling. Associations 
with the EEG or ETDC were also identified for SNPs in Il10 (delta frequency,  
p = 0.0176), CRP (ETDC, p = 0.0381), and TGFB1 (ETDC, p = 0.0367).  
All associated SNPs were located in non-coding regions upstream of the gene 5' 
end and different gene regulation is predicted to underlie the identified 
associations (Sections 4.5.2-4.5.4). The cytokine genes IL1B and IL10, along with 
MYD88, were the most strongly associated with the EEG and these genes and 
their relevance to the EEG are discussed in more detail in the following sections. 
 
4.5.1 Relevance of associations to the EEG 
Systemic inflammation is mirrored by an inflammatory response in the brain  
involving an increase in the levels of pro-inflammatory cytokines [108]. Within 
the brain, cytokines are thought to act as neuronal modulators and have been 
demonstrated to influence ion channel and receptor function, thus regulating 
neuronal activity (reviewed in [119]).  
Controlled changes in brain cytokine levels induced by systemic inflammation are 
thought to play an important role in mediating the behavioural changes required 
for recovery from infection or trauma (sickness behaviour) [106, 204]. Chronic 
changes in or disregulation of brain cytokine levels can lead to more adverse 
clinical symptoms [106], and have previously been associated with bipolar- 
disorder [205], and implicated in the pathophysiology of major depression, 
schizophrenia and Alzheimer’s disease (reviewed in [206]). The results from the 
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current study are interpreted to suggest that genetically determined variability in 
cytokine levels/signalling may influence the EEG during general anaesthesia. This 
effect is presumed to be mediated via cytokine modulation of ion channel or 
receptor activity, potentially involving upregulation of brain cytokine levels in 
response to surgical trauma. 
In particular, the presently reported results suggest that IL1B and MYD88 
variability may underlie some of the variability in spindle wave activity observed 
during general anaesthesia. IL1B encodes IL-1β, a key pro-inflammatory cytokine 
that belongs to the IL-1R ligand family. IL-1β is primarily produced by 
macrophages, monocytes and endothelial cells, and is also constitutively 
expressed in the brain at low levels, along with its receptor IL-1R (reviewed in 
[207]). MYD88 encodes the cytosolic adaptor protein – MyD88 – which acts a 
signal transducer in the IL-R and TLR mediated signalling pathways [208-210]. 
These homologous pro-inflammatory signalling pathways play important roles in 
mammalian host defences in both the innate and adaptive immune responses [211]. 
Upon activation, IL-1R interacts directly with MyD88 which activates signalling 
via IRAK (interleukin-1 receptor-associated) kinases and TRAF6 (TNF receptor 
associated factor 6) leading to NF-κB activation, and subsequently pro-
inflammatory cytokine production and an inflammatory response [103, 212]. 
In addition regulating the inflammatory response in peripheral immune cells, IL-
1β also has important effects on brain functioning and is thought to act as a 
primary mediator of immune system-to-brain communication [106]. In vitro 
studies investigating the electrophysiological effects of IL-1β on neuronal cells 
have demonstrated IL-1β can influence voltage dependent calcium currents and 
GABA-ergic signalling via GABAA receptors in certain cell types, as well TRPV1 
(transient receptor potential vanilloid 1) and glutamate receptors (reviewed in 
[119, 213]). For example, IL-1β has been demonstrated to inhibit GABAA 
receptor mediated currents in hippocampal neurons in vitro [214], and also to 
reduce voltage-dependent Ca2+ currents mediated by N-type Ca2+ channels in 
cultured cortical neurons [215]. Furthermore, several studies have reported the 
effects of IL-1β on neuronal cells to be dose-dependent [214, 216-218]. IL-1β has 
also previously been suggested to affect Ih, however, regulation of Ih by IL-1β has 
not yet specifically been addressed [105]. At least some of the effects of IL-1β on 
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neuronal cells have been shown to require MyD88 [207], supporting the 
association of MYD88 with the EEG. Tabarean et al. (2006) have demonstrated 
IL-1β induced hyperpolarisation and reduced firing rates in hypothalamic neurons 
and these effects were absent in mice lacking IL-1R and MyD88 – demonstrating 
that these effects require both IL-1R and MyD88 [207].  
Brain mRNA levels of IL-1β, as well as IL-6 and TNFα, have been found to be 
elevated following peripheral lipopolysaccharide (LPS) administration in rodents 
[109-114], and peripheral LPS administration is also known to induce a 
behavioural response presumed to be mediated by elevated pro-inflammatory 
cytokine levels in the brain [204, 219]. As surgical trauma is associated with an 
inflammatory response involving the upregulation of these cytokines , it could 
reasonably be hypothesised that a similar elevation in brain cytokines occurs 
during surgery, however, to date no studies have directly examined the short-term 
effects of surgery on brain cytokines.  
In all of the above mentioned studies investigating the effects of systemic 
inflammation on brain cytokine levels, the inflammatory response was stimulated 
by the administration of an exogenous endotoxin. The inflammatory response to 
surgery however, is induced under sterile conditions as a result of traumatic tissue 
injury. Therefore whether the same effects on brain cytokine levels induced by 
peripheral LPS occur in response to surgical trauma is not known. Elevated IL-6 
and IL-8 levels in cerebrospinal fluid (CSF) following hip replacement surgery 
have been reported, conversely IL-1β, IL-10 and TNFα levels in the CSF have 
been found not to be elevated [220, 221]. A lack of correlation between plasma 
and CSF IL-6 levels was taken to suggest elevated CSF IL-6 levels resulted from 
central IL-6 secretion [221]. Moreover, elevated post-surgical CSF IL-6 levels 
have been found to correlate with sleep disturbances [220], suggesting effects of 
centrally expressed cytokines on neuronal function following surgery. Overall, 
these studies demonstrate elevated cytokine levels in the CNS following surgery, 
and suggest subsequent effects on neuronal functioning. However, cytokine levels 
were only measured pre- and post-operatively (hours to days) in the CSF, 
therefore the extent of any changes in brain cytokine levels within the intra-
operative period remain unclear. Furthermore, IL-1β levels were found not be 
elevated in the CSF following surgery. Therefore, whether brain levels of this 
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cytokine are elevated during surgery, and to what extent if so, is unknown. As 
brain IL1B expression is found to be very low under basal conditions [110], it is 
uncertain if differences in basal levels between individuals would have a 
significant effect on neuronal activity that could result in differences in the EEG. 
It should also be noted that the duration and type of surgical procedure would 
likely affect the extent of any changes in cytokine gene expression, as the extent 
of the inflammatory response is related to the magnitude of surgical trauma [120]. 
IL-10 is a pro-inflammatory cytokine produced by a variety of immune cells, 
monocytes, macrophages and T-helper cells, and has also been demonstrated to be 
constitutively expressed by glial cells in the brain [222]. The primary function of 
IL-10 is to reduce the inflammatory response, this is achieved largely via 
modulation of cytokine release by monocytes and macrophages (reviewed in [223, 
224]). Unlike IL-1β, the electrophysiological effects of IL-10 have not been well-
studied and whether this cytokine has regulatory effects on ion channels and 
receptors is not known. IL-10 inhibits the expression of pro-inflammatory 
cytokines such as IL-1β [225], and has been shown to block the inhibitory effects 
of IL-1β on long-term potentiation in hippocampal cells [226] and to block LPS 
induced behavioural effects in rats [219]. It is therefore suggested variable IL10 
expression might influence the EEG via IL-10 mediated regulation of brain pro-
inflammatory cytokines. Thus the balance between levels of pro- and anti-
inflammatory cytokine levels in the brain may be an important contributing factor 
to the EEG during general anaesthesia.  
While previous studies investigating the influence of cytokines on neuronal 
activity and behaviour support the association of cytokine genes (and mediators of 
cytokine signalling) with the EEG, an alternative explanation is that the identified 
SNPs are tagging functional effects of other nearby genes involved in regulation 
of the EEG. This alternative remains to be investigated. 
 
4.5.2 MYD88 
MYD88 is located on chromosome 3 at 3p22 on the forward strand, spans 
approximately 4.5kb, is alternatively spliced to produce 13 different transcripts, 8 
of which are protein encoding (NCBI Gene ID: 4615) (Ensembl: 
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ENSG00000172936). The strongest association with the EEG and ETDC 
identified in this study was for a single SNP (rs6853), located in the 3' UTR of 
MYD88. In this study rs6853G was present at a frequency of only 7.7% and was 
only found in A/G heterozygotes (15.3% of patients). The observed MAF was 
lower than in the HapMap Caucasian population (MAF 11.5%). One of the 
limitations of this study that is particularly relevant to analysing associations of 
this SNP, is the small sample size (Section 4.6.2). The G allele was found to be 
associated 0.88-fold lower median ETDC (p = 0.0095), 1.39-fold higher median 
spindle amplitude (p = 0.0040) and 1.69-fold higher median spindle amplitude 
relative to ETDC (p = 0.0006). The EEG correlation analysis revealed a modest 
correlation between spindle amplitude and ETDC and rs6853 genotype was found 
to influence this relationship. The relationship between ETDC and BIS was not 
significantly affected by rs8365 genotype.  
Previous studies have reported associations of MYD88 variability with various 
conditions including Bueger disease (a rare vascular disorder) [227], Hogdkin’s 
lymphoma [228] and response to the measles vaccine in adolescents [229]. The 
genomic region harbouring MYD88 (3p22) has also been identified as a putative 
locus for autosomal dominant nocturnal frontal lobe epilepsy [230]. To date no 
associations been MYD88 polymorphisms and the EEG or anaesthesia have been 
reported. 
The SNP rs6853 is located in the 3' UTR of MYD88 and effects on gene 
expression are predicted to underlie the identified association. Gene 3' UTRs 
contain polyadenylation sequences required for the addition of the poly(A) tail 
which is important for mRNA stability and translational efficiency. This region 
also contains binding sites for regulatory factors [231] and may contain target 
sites for regulation by miRNAs [232]. miRNAs are small single stranded RNA 
molecules that are involved in post-transcriptional regulation of gene expression. 
miRNAs recognise and bind to target mRNAs by base-pairing interactions, and 
act to down regulate gene expression either by repressing translation or bringing 
about the cleavage of target mRNAs [233]. They are often transcribed from 
intronic regions and predominantly target untranslated regions, in particular gene 
3' UTRs [234, 235]. Polymorphisms in either miRNAs themselves, or in the target 
region to which they bind, might therefore influence gene expression by 
disrupting binding interactions between the miRNA and target region. 
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Accordingly, polymorphisms in the 3' UTR region have previously been 
associated with a variety of conditions and have been shown to affect expression 
of associated genes [236-240]. 
An alternative to the above suggestion is that rs6853 might not be functional itself, 
and instead be tagging the effects of a functional SNP in MYD88, or in another 
nearby gene. Using Haploview, downloaded data for the HapMap Caucasian 
population, and the haplotypes block definition of Gabriel et al. (2002), rs6853 
was found to lie in a 29 kb LD block that encompasses all of MYD88 along with 
the upstream gene ACAA1 (Acetyl-CoA Acyltransferase 1) and part of DLEC1 
(Deleted in Lung and Esophageal Cancer 1) (Appendix; Figure 6.28a). 
The rs6853G allele is only found on two rare haplotypes in HapMap Caucasians 
and tags several other SNPs not present on any other haplotypes (Appendix; 
Figure 6.28b). The free online tool F-SNP (http://compbio.cs.queensu.ca/F-SNP/) 
[241] was used to search for predicted functional SNPs in this block. Four non-
synonymous SNPs with functional effects were predicted in or near MYD88, 
however, the MAF for each of these polymorphisms was <1%. F-SNP did not 
predict any functional effects for rs6853. Six SNPs with functional effects were 
predicted in or near ACAA1. Of these six SNPs, two had MAFs >5% in the 
HapMap Caucasian population, and a further two had MAFs of 1 to 5%. One of 
these SNPs – rs156265G>C (Glu172Asp), a non-synonymous coding SNP – is 
present at a frequency of 8.5% in the HapMap Caucasian population. F-SNP 
predicted functional effects of this SNP on mRNA splicing, transcriptional 
regulation and deleterious effects on protein coding. This SNP has previously 
been reported to be associated with the effects of endotoxin exposure on asthma 
risk in children, however, rs156265 was not found to be in LD with any SNPs in 
MYD88 [242]. Another SNP in this block, rs5875 (MAF = 11.5%), is located in 
the ACAA1 3' UTR. F-SNP predicted a functional effect of rs5875 on transcription 
factor binding. This SNP is in perfect LD with rs6853 it is possible rs6853 is 
tagging the functional effects of rs5875, or another nearby functional SNP. 
ACAA1 (NCBI Gene ID: 30) encodes an enzyme required for fatty acid β-
oxidation in peroxisomes and is expressed throughout the body in a diverse array 
of tissues, including the brain (GeneNote Version 2.3 [243]). Based on the role of 
MYD88 in cytokine signalling and the previously reported finding that some IL-1β 
cytokine effects on neuronal cells require functional MYD88 [207], MYD88 is 
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proposed as a more probable candidate for the association with the EEG, however 
an underlying association with ACAA1 cannot be ruled out. 
 
4.5.3 IL1B  
Two SNPs in Il1B (rs1143627, rs16944) were associated with spindle amplitude 
and spindle amplitude relative to ETDC. IL1B  spans approximately 7 kb, is 
comprised of six coding exons and is located in an interleukin gene cluster on the 
reverse strand of chromosome 2 at 2q14 (NCBI Gene ID: 3553).  
SNPs rs1143627 (−31T>C) and rs16944 (−511C>T) have been extensively 
studied and have been associated with various and diverse diseases including 
psoriatic arthritis [244], schizophrenia [245, 246], febrile seizures [247], and 
breast, lung and gastric cancer [248-250]. Associations of either of these SNPs, or 
other IL1B polymorphisms, with the EEG have not been previously reported.  
LD analysis in Haploview demonstrated that rs1143627 and rs16944 are in near 
perfect LD (D’ = 1.0, r2 = 0.98) (Section 3.8.2), indicating they have not been 
separated by recombination and each near perfectly tags the other. LD between 
rs1143627 and rs16944 was very similar in this sample and the HapMap 
Caucasian population (Table 3.8). Both SNPs are located upstream of the gene 5' 
end in a 3 kb haplotype block, no other genes are located in this block (Appendix; 
Figure 6.29). 
The SNP rs1143627 is located in the 1L1B TATA box [249] and has been 
identified as a transcription factor binding site for several transcription factors by 
ChIP-seq [251]. Furthermore, electrophoretic mobility shift assays have also 
revealed differential protein binding to the DNA region harbouring rs1143627 
[250, 252]. Using promoter reporter assays, Lind et al. (2010) have reported 
higher expression levels from the T allele than the C allele [252], and 2.2 times 
higher expression from the from the T allele has also been reported using in vitro 
allele-specific transcript quantification [253]. Allelic differences in protein 
binding at rs16944 have failed to be identified [250, 254], suggesting that the 
association of rs16944 is due to its high LD with rs1143627.  
Based on these previous studies, the effects of variant rs1143627 on the EEG are 
suggested to be due to by differential transcription factor binding and 
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consequently altered gene expression, and that rs16944 is likely tagging the 
functional effects of rs1143627. In this study, the “low expression” variant 
(rs1143627C), was observed at a frequency of 38.1%, similar to the HapMap 
Caucasian population (36.3%). Associations were observed in all three models for 
rs1143627C, and the strongest association was identified in the over-dominant 
model (p = 0.0092 and p = 0.0072) (Table 3.16, Table 3.18). Given the predicted 
function of this polymorphism on gene expression, the relevance of the 
association in the over-dominant model is unclear, although the effect of 
rs1143627 genotype may potentially be influenced by synergistic effects with 
other functional variants. 
 
4.5.4 IL10  
In the present study, a single SNP in IL10 (rs1800896) was found to be associated 
with delta frequency (p = 0.0176). IL10 is comprised of 5 exons, spans 5.1 kb and 
is located on the reverse strand of chromosome 1 at 1q31-q32 (NCBI Gene ID: 
3586) [255].  
SNP rs1800896 (−1082G>A) is one of three well studied SNPs located in the 
proximal promoter region of IL10, the other two being rs1800871 (−819C>T) and 
rs1800872 (−592C>A) [256]. IL10 promoter SNPs and SNP haplotypes have been 
associated with various diseases including graft-versus-host disease [257, 258], 
advanced liver disease [259], and Alzheimer’s disease [260-262].  
The association of rs1800896 identified in this study is suggested to be 
attributable to differences in IL10 gene expression. Reuss et al. (2002) have 
studied the function of IL10 promoter polymorphisms and found that rs1800896A 
confers optimal binding ability for the negative transcriptional regulator PU.1. 
Accordingly, the presence of the A allele has been found to lead to lower 
transcriptional activity and thereby lower IL-10 production than the G allele [256, 
263]. The two IL10 SNPs genotyped in this study (rs1800896 and rs1800871) and 
a third SNP (rs1800872), have previously been demonstrated to be complete LD 
and are found in only three possible haplotype combinations in Caucasians; GCC, 
ACC and ATA [256, 264, 265]. The ATA haplotype has been associated with 
lower transcriptional activity than the GCC haplotype, and the ATA/ATA 
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homozygous genotype with lower IL-10 production in whole blood cell cultures 
relative to all other genotypes [265]. In the present study, patients homozygous for 
the “high expression” variant (rs1800896G) were found to have a lower median 
delta frequency than A/G heterozygotes (0.67-fold, p = 0.0055), however, no 
significant difference was found between G/G and A/A homozygotes. 
In addition to confirming the putative association identified in this study, a more 
comprehensive investigation of other IL10 promoter polymorphisms is suggested. 
In addition to proximal-promoter SNPs, SNPs in the distal promoter region, and 
microsatellites in both the distal and proximal promoter regions (IL10.R (CA)n 
and IL10.G (CA)n, respectively), have also been suggested to affect gene 
expression and susceptibility to a variety of diseases [266, 267] and might also 
influence the EEG. 
 
 
4.6 Study limitations and confounding factors 
4.6.1 Number of SNPs genotyped 
A large scale study, such as GWAS, was beyond the scope of this project and only 
a limited number of SNPs were able to be included, limiting the amount of 
genotyping data able to be generated. Alternative feasible genotyping approaches 
include high resolution melting and RT-PCR based methods, however, these 
approaches would also have limited the number of SNPs genotyped and would 
also require tests to be performed in duplicate. The advantage of using PCR-RFLP 
over other such methods, was that it allowed DNA to be conserved as part of the 
larger study as tests were only performed once unless the genotyping result was 
unclear. 
As only two to three SNPs per gene were genotyped in this study, only a small 
proportion of the genetic variability in each candidate gene was examined, 
potentially limiting the power of the approach to identify genes associated with 
the EEG. For example, only three SNPs in a single GABAA receptor gene were 
examined for associations in this study. The GABRA2 SNPs genotyped are only 
three of 25 SNPs previously associated with beta oscillations by Edenberg et al. 
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(2004). The HapMap project contains information on over 150 GABRA2 SNPs, 
and almost 3000 SNPs are listed in or near GABRA2 in NCBI dbSNP. 
Furthermore, there are an additional 5 genes encoding α subunits and numerous 
genes encoding other GABAA receptor subunits. Therefore the potential 
contribution of the vast majority of GABAA receptor variability to the EEG is yet 
to be explored. 
An alternative approach would have been to perform a more comprehensive 
analysis of a single gene using a SNP tagging approach. Such an approach may 
possibly have been more likely to detect potential associations in a single gene 
and provide a more refined picture. However, as no studies investigating genetic 
differences contributing to the EEG during general anaesthesia have yet been 
reported, the approach taken provided the advantage of giving a broader picture, 
and enabled identification of a number of genes putatively associated with the 
EEG that could be subject to more intense study in further work. 
 
4.6.2 Multiple testing problem 
The large number of statistical tests performed introduces the problem of multiple 
testing resulting in an increased likelihood of false positive results. This issue is 
addressed in section 4.3.1. 
 
4.6.3 Sample size 
This study included a total 125 participants. Samples from all patients were 
included in the PCR-RFLP genotyping, and only 100 were sent to AGRF for 
genotyping by MassARRAY. This small to moderate sample size often resulted in 
only a small number of patients homozygous (or even heterozygous) for the minor 
allele, hence limiting statistical power. For example, rs6853G was observed at a 
frequency of 7.7% and only 15 patients, all of whom were A/G heterozygous, 
were found to carry the G allele. In order to confirm the presently reported 
associations, these results need to be replicated in a larger sample. This may also 
help clarify the mode of effect of the examined SNPs, as associations were 
reported for several SNPs in more than one effect model.  
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4.6.4 Ancestry of participants 
The participants included in this study were of mixed descent which may 
confound the association results. Because of the small sample size, performing 
statistical tests on each population group would markedly reduce statistical power 
and therefore all participants were pooled together. The study sample does 
however provide a reasonable subset of the New Zealand population which is 
approximately 68% European, 9% Asian, and 22% Maori and Polynesian [268].  
 
4.6.5 Surgical procedures 
Patients included in this study underwent one of three major categories of surgery; 
general (37%), gynaecological (51%) and orthopaedic (12%). The high proportion 
of gynaecological patients also introduced a sex bias into the study  
(82% of participants were female). The diversity of surgical procedures 
undertaken by participants potentially introduces an additional confounding factor. 
Different surgical procedures may cause different levels of trauma to the body, 
this may be particularly relevant to effects of cytokines on neuronal activity. As 
with ethnicity, the small sample size limited the ability to perform separate 
analysis, and due to limitations of the software, such confounding factors were not 
able to be incorporated into the non-parametric tests used. 
 
4.6.6 Effect sizes and clinical relevance 
The effect sizes for significant associations identified in this study were small – 
ranging from a fold-difference of 0.77 to 1.55. With such small effects, these 
SNPs are not likely to be clinically relevant or have useful clinical application. 
The association of numerous SNPs in various genes, each with small affect, 
suggests that the EEG during general anaesthesia is regulated by numerous genes 
in different pathways, each with a small effect.   
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4.7 Conclusions  
This study identified a number of SNPs in a variety of genes putatively associated 
with the EEG during general anaesthesia with desflurane. Associations were 
identified for SNPs in genes with a variety of different functions and effect sizes 
were small, suggesting that the EEG during general anaesthesia is regulated by 
numerous genes in different pathways, possibly with an additive effect.  
Putative associations with spindle amplitude (or relative spindle amplitude) were 
identified for five genes with four distinct types of function; ion channels (HCN2), 
neurotransmitter signalling (GABRA2), neuronal component recycling (SGIP1), 
and cytokine signalling (MYD88 and IL1B). This prompts the suggestion that 
individual differences in the EEG during general anaesthesia may not only be 
attributable to variability in genes directly involved in the generation of 
synchronised EEG activity – such as ion channels and neurotransmitter signalling 
– but also to other pathways involved in regulating neuronal cell components 
involved in generating the synchronised EEG. Furthermore, two of the genes 
associated with spindle amplitude have previously been associated with resting 
theta and beta power (SGIP1 and GABRA2, respectively), suggesting that the 
effects of some genetic loci on the EEG may not be restricted to single frequency 
bands.  
Anaesthetic agents are thought to influence the inflammatory response following 
surgery by modulating cytokine release, resulting in a slight immune suppression 
following surgery (Section 1.7.3). The present study suggests that in addition to 
anaesthetics affecting cytokine release, cytokines themselves might play a role in 
regulating neuronal activity during general anaesthesia. This effect is predicted to 
be due to cytokine mediated modulation of neuronal activity, occurring via 
cytokine effects on ion channel function or neurotransmitter signalling. In 
particular, the present study suggests genetic differences in MYD88 and IL1B 
might underlie some of the variability in spindle wave activity during general 
anaesthesia. It is speculated that cytokine mediated effects on the EEG involve 
upregulation of cytokines in the brain, mirroring the peripheral inflammatory 
response to surgery. However, at present, the effect of surgical trauma on brain 
cytokine levels remains uncertain. If the effect of cytokines on the EEG indeed 
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involves the upregulation of brain cytokine levels, the type and duration of 
surgical procedure undertaken will likely influence this effect as the inflammatory 
response is influenced by the extent of surgical trauma. 
Further work needs to be undertaken to verify the reported associations in a larger 
more homogeneous patient sample, and a more comprehensive investigation of 
SNPs in strongly associated genes is suggested. In particular, further investigation 
of the influence of MYD88 on the EEG during general anaesthesia is suggested. 
Functional MYD88 variants are yet to be identified and it also remains to be 
determined if MYD88 is indeed responsible for the reported association with the 
EEG. While the role of MYD88 in cytokine signalling is presumed to underlie the 
reported associations, the mechanism by which this gene affects the EEG remains 
to be elucidated. The effect of surgery on brain cytokine levels also needs to be 
clarified. As differential gene expression is speculated to underlie the reported 
associations, it is hypothesised brain mRNA levels of the associated genes may 
correlate with EEG activity, however this is yet to be determined.  
Despite the widespread use of qEEG monitors in anaesthesia monitoring, this 
study is the first that I am aware of investigating genetic contributors to individual 
variability in the EEG during general anaesthesia. While no SNPs with likely 
clinical applications were identified, the results presented here lend support for 
further, more comprehensive work investigating genetic polymorphisms 
associated with EEG variability during general anaesthesia. In the future, 
improved understanding of the genetic factors influencing the EEG during general 
anaesthesia will hopefully lead to improved use of the EEG and BIS monitors in 
anaesthesia monitoring and improved patient outcomes. 
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6 Appendix 
  
 
 
 
6.1 Buffers and other recipes 
5 M GITC solution  
295.4 g  GITC   
2.5 g N-Lauroylsarcosine sodium salt (sarkosyl) 
3.9 g  Tri-sodium citrate 
3.6 ml 2-mercaptoethanol  
280 ml DEPC treated MiliQ H20 
 
TE buffer    
10 mM Tris 
1 mM EDTA   
 
CTAB/NaCl   
10%  CTAB  
0.7 M  NaCl 
 
x10 Sodium borate gel running buffer 
56 g Boric Acid 
10 g Sodium Hydroxide 
 Made up to 2 l with distilled water 
 
x6 Loading buffer  
30% Glycerol 
0.02% Bromophenol Blue 
0.02% Xylene Cyanole 
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6.2 EEG data 
Table 6.1: Processed EEG data supplied by the anaesthetist (part 1).  
ID ETDC (%) 
BIS 
value 
Spindle 
frequency 
(Hz) 
Spindle 
amplitude 
(Log(µV)) 
Delta 
frequency 
(Hz) 
Delta 
amplitude 
(Log(µV)) 
Relative 
spindle 
amplitude 
1 7.51 25.00 8.500 1.979 0.750 6.878 0.263 
2 7.62 28.00 7.125 2.245 2.250 5.746 0.295 
3 7.78 41.80 7.750 1.495 0.625 4.895 0.192 
4 4.03 44.30 8.375 2.252 0.500 4.411 0.559 
5 4.91 30.00 7.250 1.708 0.625 6.547 0.348 
6 6.35 44.60 15.500 0.580 0.500 5.550 0.091 
7 6.18 30.60 10.250 1.390 0.500 7.134 0.225 
8 6.69 56.25 8.875 1.129 0.500 7.322 0.169 
9 3.59 42.20 9.625 1.745 0.875 6.234 0.486 
10 4.82 35.50 10.125 2.043 0.500 5.458 0.424 
11 5.63 − 11.250 1.785 0.625 8.317 0.317 
12 3.53 38.80 9.875 2.477 0.625 5.917 0.702 
13 4.11 42.40 10.250 1.934 0.625 5.371 0.471 
14 6.18 29.30 8.125 2.019 1.125 5.541 0.327 
15 5.81 25.20 8.250 2.164 0.500 7.119 0.373 
16 4.66 45.60 10.750 2.330 0.625 5.307 0.500 
17 4.34 40.10 9.125 2.364 0.750 6.306 0.545 
18 5.35 43.20 11.875 3.043 0.500 4.405 0.569 
19 7.96 37.00 15.875 1.036 0.500 6.980 0.130 
20 7.06 40.80 8.000 1.302 0.875 6.317 0.184 
21 7.36 30.30 9.000 1.099 0.875 6.311 0.149 
22 6.61 34.90 8.000 1.428 0.750 5.562 0.216 
23 7.62 38.20 7.500 1.453 0.750 5.608 0.191 
24 5.83 42.70 16.375 1.020 0.750 5.517 0.175 
25 4.53 45.40 10.250 1.928 0.500 5.832 0.426 
26 6.21 28.30 7.625 1.263 1.125 6.346 0.203 
27 5.49 39.10 13.875 0.726 0.750 4.358 0.132 
28 2.12 29.70 8.750 1.790 0.500 5.462 0.844 
29 4.60 40.30 9.875 2.477 0.625 5.917 0.538 
30 5.58 56.10 11.875 1.951 0.750 5.229 0.350 
31 4.45 48.00 9.750 2.700 1.000 5.936 0.607 
33 5.40 21.90 8.625 1.606 1.250 6.932 0.297 
34 6.88 31.20 7.500 1.342 0.625 5.564 0.195 
35 4.75 31.60 7.875 2.521 0.500 7.323 0.531 
36 3.61 54.80 11.125 2.579 0.500 4.405 0.714 
37 4.56 46.40 9.875 1.987 0.875 5.222 0.436 
38 6.03 40.60 10.000 1.031 0.500 5.825 0.171 
39 7.30 39.30 9.750 1.886 0.875 5.929 0.258 
40 4.35 58.80 12.875 2.181 0.500 5.629 0.501 
41 4.95 41.30 11.500 2.174 0.500 7.430 0.439 
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Table 6.1 cont.: Processed EEG data (part 2). 
ID ETDC (%) 
BIS 
value 
Spindle 
frequency 
(Hz) 
Spindle 
amplitude 
(Log(µV)) 
Delta 
frequency 
(Hz) 
Delta 
amplitude 
(Log(µV)) 
Relative 
spindle 
amplitude 
42 5.04 24.00 7.500 1.331 0.875 7.518 0.264 
43 6.67 28.80 7.125 1.017 0.750 5.945 0.153 
44 6.89 32.50 8.875 1.129 0.500 7.322 0.164 
45 5.15 45.00 9.875 2.426 1.000 5.121 0.471 
46 4.96 52.80 10.375 2.772 0.500 4.859 0.559 
47 4.71 29.60 10.375 2.394 0.625 6.127 0.508 
48 5.96 26.70 7.125 2.290 0.750 6.102 0.384 
49 6.66 36.50 10.375 1.829 0.625 7.407 0.275 
50 4.91 45.00 7.375 0.951 0.500 3.585 0.194 
51 5.58 55.10 13.000 1.622 0.500 5.116 0.291 
52 3.78 43.00 9.000 1.544 0.500 4.637 0.409 
53 6.10 25.10 8.375 1.967 1.125 5.809 0.323 
54 5.54 35.30 8.250 1.881 0.500 6.968 0.339 
55 4.44 26.80 7.500 0.879 1.375 7.080 0.198 
56 5.03 31.00 7.500 1.748 0.500 5.641 0.348 
58 5.38 40.00 8.250 1.191 0.750 5.478 0.221 
59 8.01 44.70 10.625 1.653 0.500 3.832 0.206 
60 5.95 35.00 10.125 1.371 0.750 7.346 0.230 
62 3.92 33.20 9.375 2.324 1.125 5.316 0.593 
63 3.95 55.30 10.250 2.097 0.750 4.780 0.531 
64 5.67 25.40 16.500 0.191 0.500 6.307 0.034 
65 5.46 23.70 10.250 1.680 0.500 7.097 0.308 
66 5.34 56.00 11.375 2.313 0.625 5.064 0.433 
67 4.71 56.60 12.000 1.623 0.500 4.539 0.345 
68 5.13 33.00 8.750 1.732 0.875 6.014 0.338 
69 6.41 27.00 9.625 2.194 0.750 6.742 0.342 
70 8.70 38.30 9.000 1.018 0.625 6.279 0.117 
71 4.88 52.27 13.000 3.231 0.500 5.434 0.662 
72 4.81 48.40 9.500 3.062 0.500 5.131 0.636 
73 5.62 34.16 9.375 1.996 1.000 7.091 0.355 
74 7.61 60.22 7.875 1.705 0.500 5.167 0.224 
75 5.81 26.80 8.750 2.839 0.625 5.543 0.489 
76 5.39 60.19 7.875 1.767 0.875 6.063 0.328 
78 6.47 36.08 8.125 1.813 0.500 7.020 0.280 
79 4.32 0.00 9.000 2.261 0.500 5.611 0.523 
80 6.57 36.00 7.500 1.387 0.500 5.623 0.211 
82 7.64 57.00 9.625 2.312 0.625 5.541 0.303 
83 6.91 30.00 7.375 1.815 0.500 6.475 0.263 
85 9.46 50.41 7.875 0.707 1.250 5.085 0.075 
86 4.26 78.97 9.250 2.635 1.250 6.083 0.619 
87 3.79 − 8.500 2.591 0.750 6.460 0.684 
88 5.76 − 9.000 1.541 0.500 7.021 0.268 
89 4.43 35.00 10.250 1.560 0.875 5.338 0.352 
90 3.68 41.00 8.000 1.622 1.125 5.562 0.441 
91 5.46 50.00 10.125 2.666 0.500 4.446 0.488 
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Table 6.1 cont.: Processed EEG data (part 3). 
ID ETDC (%) 
BIS 
value 
Spindle 
frequency 
(Hz) 
Spindle 
amplitude 
(Log(µV)) 
Delta 
frequency 
(Hz) 
Delta 
amplitude 
(Log(µV)) 
Relative 
spindle 
amplitude 
90 3.68 41.00 8.000 1.622 1.125 5.562 0.441 
91 5.46 50.00 10.125 2.666 0.500 4.446 0.488 
92 6.39 40.00 8.125 1.177 0.500 6.565 0.184 
93 6.75 26.00 7.625 1.860 0.500 6.358 0.276 
94 4.98 33.00 9.625 1.848 1.125 6.603 0.371 
95 5.57 42.00 10.125 1.473 1.000 5.443 0.265 
96 4.56 − 12.250 2.269 0.875 5.221 0.498 
97 4.14 − 9.250 2.435 0.750 5.917 0.588 
99 4.38 43.00 8.500 2.499 0.500 5.529 0.571 
100 4.50 81.04 9.250 1.523 0.625 5.764 0.338 
101 7.96 34.00 8.375 1.907 0.625 5.203 0.240 
102 4.57 − 12.125 2.268 0.750 5.900 0.496 
103 4.66 39.00 9.500 1.994 0.500 5.854 0.428 
104 4.80 48.00 11.375 2.596 0.750 4.697 0.541 
105 4.74 − 7.125 2.056 0.500 6.213 0.434 
106 7.43 − 8.250 1.189 0.750 7.233 0.160 
108 5.18 − 9.250 3.027 0.750 4.948 0.584 
109 6.03 − 8.625 1.440 0.625 5.242 0.239 
110 4.01 − 10.625 2.432 1.125 6.897 0.606 
111 6.68 − 8.750 0.613 0.500 5.319 0.092 
112 6.04 − 10.125 1.393 0.625 5.328 0.231 
114 3.28 − 11.875 2.340 0.875 4.014 0.713 
115 7.44 − 15.875 1.144 0.500 7.138 0.154 
116 − − 11.125 2.059 0.500 5.825 − 
117 7.52 − 9.500 1.323 0.500 7.159 0.176 
118 6.52 − 8.375 2.224 0.500 4.886 0.341 
119 4.34 48.00 11.500 2.379 0.875 5.572 0.548 
120 3.84 42.00 11.375 2.111 1.250 5.232 0.550 
121 4.17 51.00 10.750 2.436 0.750 4.455 0.584 
122 6.38 23.00 9.250 2.545 0.625 7.131 0.399 
123 7.51 25.00 8.250 0.499 0.500 10.222 0.066 
124 − − 9.375 2.713 0.625 5.048 − 
125 − − 10.250 2.930 0.500 4.810 − 
128 5.28 − 9.250 2.675 0.750 6.161 0.507 
130 4.37 − 12.250 2.306 0.500 3.358 0.528 
131 5.01 − 8.750 2.080 0.500 5.907 0.415 
158 7.43 29.20 8.000 1.387 0.500 6.282 0.187 
159 6.03 39.50 15.250 0.512 1.125 6.294 0.085 
163 5.74 − 10.375 1.149 0.750 5.941 0.200 
165 5.96 38.30 8.000 0.674 0.750 6.594 0.113 
167 4.54 40.30 11.375 1.283 0.625 6.006 0.283 
170 6.80 38.90 8.625 1.505 0.625 6.009 0.221 
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Table 6.2: Correlations between EEG traits, ETDC and BIS value. 
Significant p-values are marked with an asterisk (p < 0.05) or double asterisk (p < 0.001), 
respectively. N/A = Assumptions for linear regression model not able to be met. 
Independent 
variable 
Dependent 
variable Intercept Slope r
2   r  p-value n 
ETDC √(BIS value) 7.088 -0.149 0.052 -0.227 0.0230* 100 
 Spindle frequency N/A N/A N/A N/A N/A N/A 
 Spindle amplitude 3.054 -0.222 0.218 -0.467 <0.0001** 122 
 Delta amplitude 4.768 0.202 0.070 0.265 0.0032** 122 
 Log
10 (delta 
frequency) -0.139 -0.006 0.003 -0.058 0.5292 122 
BIS value Spindle frequency N/A N/A N/A N/A N/A N/A 
 Spindle amplitude 1.298 0.012 0.050 0.223 0.0254* 100 
 √ (delta amplitude) 0.941 -0.002 0.220 -0.469 <0.0001** 100 
 Log
10 (delta 
frequency) -0.121 -0.001 0.009 -0.093 0.3564 100 
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6.3 Raw genotyping data 
Table 6.3: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 1a). 
Patient 
ID 
rs1088-
9635 
rs6681-
460 
rs2146-
904 
rs5722-
27 
rs2798-
45 
rs2798-
41 
rs1336-
1609 
1 A/G A/G A/G A/G A/T A/G T/T 
2 A/A G/G G/G A/G A/T A/G C/T 
3 A/A G/G G/G G/G T/T G/G C/T 
4 G/G A/G A/G A/G A/T A/G C/T 
5 A/G A/G A/G G/G T/T G/G T/T 
6 G/G A/A A/A A/G A/T A/G T/T 
7 A/A G/G G/G G/G T/T – T/T 
8 A/G A/G A/G A/A A/T A/G T/T 
9 A/G A/G A/G G/G T/T G/G T/T 
10 A/A G/G G/G A/A A/A A/A T/T 
11 G/G A/A A/A A/G A/T A/G C/T 
12 G/G A/A A/A G/G T/T G/G T/T 
13 G/G A/A A/A G/G T/T G/G T/T 
14 A/G A/G A/G A/G A/T A/G C/T 
15 A/G A/G A/G G/G T/T G/G C/T 
16 A/G A/G A/G A/G A/A A/A C/T 
17 A/A G/G G/G A/A A/A A/A T/T 
18 A/A G/G G/G A/G A/A A/G T/T 
19 A/A G/G G/G A/G A/T A/G T/T 
20 A/A G/G G/G G/G T/T G/G T/T 
21 A/G G/G G/G A/A A/T A/G C/T 
22 A/G A/G A/G G/G A/T A/G T/T 
23 A/G G/G G/G A/A A/T A/G T/T 
24 G/G A/G A/G G/G T/T G/G T/T 
25 A/A G/G G/G A/G A/T A/G T/T 
26 A/G A/G A/G G/G T/T G/G C/T 
27 A/A G/G G/G G/G A/T G/G T/T 
28 A/G A/G A/G A/G A/T A/G T/T 
29 A/G A/G G/G G/G A/T A/A T/T 
30 A/G A/G A/G A/A A/A A/A C/T 
31 A/A – G/G G/G T/T G/G T/T 
33 A/G A/G A/G A/G A/T A/G C/T 
34 – – – A/G A/T A/G C/C 
35 G/G A/A A/A A/G A/T A/G T/T 
36 A/G A/G A/G A/G A/T A/G T/T 
37 A/G G/G G/G A/G A/A A/G C/T 
38 A/G A/G A/G G/G T/T G/G C/C 
39 A/A G/G A/G A/G A/T A/G C/C 
40 G/G A/A A/A A/G A/T A/G T/T 
41 A/G A/G A/G A/G A/T A/G T/T 
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Table 6.3 cont.: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 1b). 
Patient 
ID 
rs1318-
7565 
rs7501-
581 
rs8066-
527 
rs8066-
269 
rs7254-
543 
rs8736-
34 
1 G/T C/C C/C G/G C/C T/T 
2 G/T G/G C/T G/G C/C T/T 
3 G/T C/G C/C G/G C/C T/T 
4 T/T C/G C/T G/G C/C T/T 
5 G/G C/G C/C G/G A/A G/T 
6 G/G C/C C/C G/G A/C G/T 
7 G/G C/C C/C G/G A/A T/T 
8 G/G C/C C/T G/G A/C G/T 
9 G/G C/C C/T G/G A/C G/T 
10 G/G G/G C/C G/G A/A G/G 
11 G/T C/C C/T G/G C/C G/T 
12 G/G C/G C/T – C/C T/T 
13 G/G C/C C/T G/G A/A G/T 
14 G/T C/C C/C G/G A/C T/T 
15 T/T C/C C/C G/G C/C T/T 
16 G/T C/C T/T G/G A/C G/T 
17 G/G C/C T/T G/G A/C G/T 
18 G/T C/C C/T G/G C/C T/T 
19 T/T G/G C/C G/G A/A G/T 
20 G/T C/C C/T G/G A/C G/T 
21 T/T G/G C/C – C/C T/T 
22 T/T C/G C/C G/G A/A T/T 
23 G/G G/G C/C – C/C G/T 
24 G/G C/G C/C G/G A/C T/T 
25 G/G C/C C/C – A/A G/T 
26 G/T C/G C/T – C/C T/T 
27 G/T C/G C/T – A/C G/T 
28 G/T C/G C/C – A/C G/G 
29 G/G C/C C/T – C/C T/T 
30 G/T C/G C/C – C/C G/T 
31 G/G C/G C/T – C/C T/T 
33 G/T G/G T/T – C/C T/T 
34 T/T C/G C/T G/G C/C G/T 
35 G/G C/G C/C – A/C G/G 
36 G/G C/G C/T – C/C T/T 
37 T/T C/G C/T – A/A G/T 
38 T/T C/C C/T – C/C T/T 
39 T/T C/C C/T – A/C T/T 
40 G/G C/C C/C – C/C T/T 
41 G/G G/G C/T – C/C G/T 
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 Table 6.3 cont.: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 2a). 
Patient 
ID 
rs1088-
9635 
rs6681-
460 
rs2146-
904 
rs5722-
27 
rs2798-
45 
rs2798-
41 
rs1336-
1609 
42 G/G A/A A/A G/G A/T G/G T/T 
43 A/A G/G G/G A/G T/T G/G T/T 
44 A/A G/G G/G A/G A/T A/G T/T 
45 A/G A/G A/G A/G A/T A/G C/T 
46 A/A G/G G/G A/G A/T A/G T/T 
47 A/A G/G A/G G/G T/T G/G T/T 
48 G/G A/A A/A G/G T/T G/G T/T 
49 A/G A/G A/G A/G A/T A/G C/C 
50 A/A G/G G/G A/G T/T G/G T/T 
51 A/A G/G G/G A/G A/T A/G C/T 
52 A/G A/G A/G A/G A/T A/G T/T 
53 A/A G/G G/G A/G A/T A/G T/T 
54 A/A G/G A/G G/G T/T G/G C/T 
55 A/G A/G A/G A/G A/T A/G C/T 
56 A/G A/G A/G A/G A/T A/G T/T 
58 A/G A/G A/G A/G A/T A/G T/T 
59 A/G A/G A/G G/G T/T G/G C/T 
60 A/G A/G A/G A/G A/T A/G C/T 
62 A/G A/G A/G A/G A/T A/G T/T 
63 G/G A/A A/A A/G A/T A/G T/T 
64 A/G A/G A/G G/G T/T G/G – 
65 A/G A/G A/G A/A A/T A/G T/T 
66 A/G A/G A/G A/G A/T A/G T/T 
67 A/A G/G G/G G/G A/T G/G C/T 
68 A/A G/G G/G A/G A/T A/G T/T 
69 A/G A/G A/G A/G A/T G/G T/T 
70 A/G A/G A/G G/G A/T A/G T/T 
71 A/G A/G A/G G/G A/T A/G C/T 
72 A/A G/G G/G A/G A/T A/G T/T 
73 A/A G/G G/G G/G T/T G/G T/T 
74 A/G G/G G/G A/G T/T G/G – 
75 A/G G/G G/G A/G A/T A/G C/T 
76 A/G A/G A/A A/G A/T A/G T/T 
78 G/G A/A A/A A/G A/T A/G T/T 
79 A/A G/G G/G G/G A/A G/G T/T 
80 A/A G/G G/G A/G A/T A/G C/T 
82 G/G A/A A/A A/A A/A A/A T/T 
83 A/A G/G G/G G/G T/T G/G C/T 
85 A/G A/G A/G A/G A/T A/G C/T 
86 G/G A/A A/A G/G T/T G/G T/T 
87 A/A G/G G/G A/G A/T A/G C/T 
88 A/G A/G A/G G/G T/T G/G T/T 
89 A/A G/G G/G A/A A/A A/A C/T 
90 A/A G/G G/G G/G T/T G/G T/T 
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Table 6.3 cont.: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 2b). 
Patient 
ID 
rs1318-
7565 
rs7501-
581 
rs8066-
527 
rs8066-
269 
rs7254-
543 
rs8736-
34 
42 G/G C/C C/T – A/C G/T 
43 G/G C/C C/T G/G C/C T/T 
44 G/T C/C C/C – A/C G/T 
45 G/T C/C T/T – A/C G/G 
46 G/T G/G C/C – A/C G/T 
47 G/G C/G C/T – A/C G/T 
48 G/G C/G T/T G/G A/C T/T 
49 T/T C/C C/C – A/C G/T 
50 G/T C/C C/T – A/C G/T 
51 T/T C/C C/C – A/A G/T 
52 G/T C/G T/T – A/C G/T 
53 G/T C/G C/T – A/C T/T 
54 G/T C/C C/T – C/C G/G 
55 G/T C/G C/C – A/C G/T 
56 G/G C/C C/T – A/C G/G 
58 G/G C/G T/T – A/C T/T 
59 T/T G/G C/C – A/C G/G 
60 T/T C/C C/C – A/A G/T 
62 G/G C/C T/T – C/C T/T 
63 G/G C/G C/C – C/C T/T 
64 T/T C/G C/C – C/C G/T 
65 G/G C/G C/T – C/C T/T 
66 G/G C/G C/T – C/C T/T 
67 T/T C/G C/T – A/C G/G 
68 G/G G/G T/T – A/C G/T 
69 G/G C/C C/T – C/C T/T 
70 G/G C/C C/C – C/C T/T 
71 T/T C/C T/T – C/C – 
72 T/T C/G C/C G/G A/A G/T 
73 G/G C/C C/T – A/A T/T 
74 – C/G – – – – 
75 G/T C/G C/C – C/C G/T 
76 G/G C/C C/C – C/C T/T 
78 G/G C/C C/T – A/A G/T 
79 G/G C/G C/C – C/C T/T 
80 G/T C/G T/T – C/C T/T 
82 G/G C/C C/C – C/C T/T 
83 T/T G/G C/T – A/C G/T 
85 G/T C/G C/T – A/A G/T 
86 G/G C/C C/C – C/C G/T 
87 T/T C/G T/T – A/C G/G 
88 G/G C/C C/C – A/A G/T 
89 G/T G/G C/C – C/C T/T 
90 G/T C/G C/T – C/C G/G 
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Table 6.3 cont.: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 3a). 
Patient 
ID 
rs1088-
9635 
rs6681-
460 
rs2146-
904 
rs5722-
27 
rs2798-
45 
rs2798-
41 
rs1336-
1609 
91 A/G A/G A/G G/G T/T G/G T/T 
92 A/G A/G A/G G/G T/T G/G T/T 
93 A/G A/G A/G A/G A/T A/G T/T 
94 A/A G/G G/G G/G T/T G/G T/T 
95 A/A G/G G/G G/G T/T G/G T/T 
96 A/A G/G G/G G/G A/T G/G C/T 
97 A/A G/G G/G A/A A/A A/A C/T 
99 G/G A/A A/A G/G T/T G/G C/C 
100 A/A G/G G/G A/G A/A A/A T/T 
101 G/G A/A A/A G/G T/T G/G T/T 
102 G/G A/A A/A G/G A/T G/G C/T 
103 A/A G/G G/G A/A A/A A/A C/T 
104 G/G A/A A/A A/G A/T A/G T/T 
105 G/G A/A A/A G/G T/T G/G C/T 
106 A/G A/G A/G A/G A/A A/G T/T 
108 A/G A/G A/G A/G A/T A/G T/T 
109 A/G A/G A/G G/G T/T G/G T/T 
110 G/G A/A A/A A/A A/A A/A C/T 
111 A/G G/G G/G A/G A/T A/G T/T 
112 A/A G/G G/G A/A A/A A/A T/T 
114 A/A G/G G/G A/G A/T A/G C/T 
115 A/A G/G G/G A/A T/T G/G T/T 
116 G/G A/A A/A G/G T/T G/G C/T 
117 A/A G/G G/G A/A A/A A/A C/C 
118 A/G A/G A/G G/G T/T G/G C/C 
119 A/G G/G G/G G/G T/T G/G C/T 
120 A/A G/G G/G A/A A/A A/A T/T 
121 A/G A/G A/G A/A A/A A/A T/T 
122 A/G A/G A/G A/G A/T A/A T/T 
123 A/G A/G A/G A/G A/T A/G C/T 
124 A/G G/G A/G G/G T/T G/G C/T 
125 A/G A/G G/G A/A A/A A/A T/T 
128 A/G G/G A/G A/A A/A A/A C/T 
130 A/A A/A A/G A/G A/T A/G C/T 
131 A/G A/A A/G G/G T/T G/G C/T 
158 A/A G/G G/G G/G T/T G/G T/T 
159 A/G A/G A/A A/G A/T A/G C/T 
163 A/G G/G G/G A/G T/T – C/T 
165 A/A G/G G/G G/G T/T G/G C/C 
167 A/G A/G A/G A/G A/T A/G – 
170 A/G A/G A/G A/G A/A A/G T/T 
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Table 6.3 cont.: Raw genotyping results for SNPs genotyped by PCR-RFLP (part 3b). 
Patient 
ID 
rs1318-
7565 
rs7501-
581 
rs8066-
527 
rs8066-
269 
rs7254-
543 
rs8736-
34 
91 T/T C/G C/T – C/C T/T 
92 G/T G/G C/T – A/C G/G 
93 G/G G/G T/T – A/C G/T 
94 G/G C/G T/T – A/C G/G 
95 G/T C/C C/T – – G/T 
96 G/T C/G C/C – C/C G/G 
97 T/T C/G C/C – A/C G/G 
99 T/T C/C C/T – C/C T/T 
100 G/G C/G C/C – A/C G/T 
101 G/G C/C T/T – C/C G/T 
102 T/T C/G C/C – C/C T/T 
103 G/T C/G T/T – A/A T/T 
104 G/T C/C C/C – C/C T/T 
105 T/T C/C C/T – C/C G/T 
106 G/G C/G T/T – – T/T 
108 G/G C/G C/T – C/C T/T 
109 G/T C/C C/T – C/C T/T 
110 T/T C/G C/C – A/C G/G 
111 G/T C/C C/C – C/C G/T 
112 G/T G/G C/C – C/C T/T 
114 T/T G/G C/C – C/C G/T 
115 G/T C/G C/T – A/A G/T 
116 T/T C/G C/T – A/A G/T 
117 G/T C/G C/C – C/C T/T 
118 T/T G/G C/C – C/C G/T 
119 G/T C/C C/C – C/C T/T 
120 G/G C/G C/T – A/C G/T 
121 G/G C/C T/T – A/C G/T 
122 G/T C/G C/C – A/A G/G 
123 G/T C/C T/T – C/C G/T 
124 G/T C/G C/C – A/C G/T 
125 G/G C/C C/C – C/C T/T 
128 G/T C/G C/C – A/C G/T 
130 G/T C/G C/T – A/C G/T 
131 G/T C/C C/C – A/A T/T 
158 G/G G/G C/C – – G/T 
159 G/T C/C C/T – C/C T/T 
163 G/T C/G – – – – 
165 T/T G/G C/C – C/C T/T 
167 G/T C/G C/T – – T/T 
170 G/G C/C C/T – C/C G/T 
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Table 6.4: Raw genotyping results for genotyped by MassARRAY. Data supplied by 
AGRF (part 1a). 
Patient 
ID 
rs8192-
284 
rs2794-
521 
rs1800-
871 
rs1800-
896 
rs1143-
634 
rs1143-
627 rs16944 
1 A/A C/T C/C A/G C/C T/T G/G 
2 A/C C/T C/C A/G C/T C/T A/G 
3 A/A C/T C/C A/G C/C C/T A/G 
4 A/C C/T C/C A/G C/C C/T A/G 
5 A/A T/T C/C G/G C/T C/T A/G 
7 A/A T/T C/T A/G C/C C/T A/G 
8 A/C T/T C/C G/G C/C T/T G/G 
9 A/C T/T C/T A/G C/C C/C A/A 
10 A/A T/T T/T A/A C/C C/C A/A 
11 A/A C/T C/C G/G T/T T/T G/G 
13 A/C T/T C/T A/A C/C T/T G/G 
14 A/A T/T C/C A/G C/C C/T A/G 
16 A/C T/T C/C G/G C/C C/T A/G 
18 A/A T/T C/T A/G C/C T/T G/G 
19 A/C T/T T/T A/A C/C T/T G/G 
20 A/A C/T C/T A/G C/C C/C A/A 
21 A/A T/T C/C G/G C/C C/T A/G 
22 C/C T/T C/T A/G C/C T/T G/G 
23 A/C T/T C/C A/G C/C T/T G/G 
24 A/A C/T T/T A/A C/C T/T G/G 
25 A/C T/T C/C G/G C/T T/T G/G 
26 A/A C/T C/C G/G C/T T/T G/G 
27 C/C T/T C/C G/G C/C T/T G/G 
29 A/C T/T C/C A/G C/C C/T A/G 
30 A/C C/T C/C A/G C/T C/T A/G 
33 A/C T/T C/C A/G C/C C/T A/G 
34 A/C T/T C/T A/A C/C C/T A/G 
35 A/C T/T C/C G/G C/T C/T A/G 
36 A/A T/T C/T A/G C/C C/T A/G 
37 C/C T/T C/T A/G C/C C/T A/G 
38 A/C C/T C/C G/G C/C T/T G/G 
39 A/A – C/T A/A C/C – A/G 
40 A/C C/T C/C G/G C/C C/T A/G 
42 C/C T/T C/C A/G C/T C/C A/A 
43 A/A C/T C/C G/G C/C C/C A/A 
44 A/A C/T C/C G/G C/C C/C A/A 
45 A/A – C/C A/G C/C C/T A/G 
47 A/C C/C C/C G/G C/C T/T G/G 
49 C/C C/T C/C A/G C/C C/T A/G 
51 A/A T/T C/T A/A C/C C/C A/G 
52 A/C T/T C/C G/G C/T T/T G/G 
53 C/C C/T C/C A/A C/T T/T G/G 
54 C/C C/T C/T A/A C/C C/T A/G 
55 A/C T/T C/C A/G C/C C/T A/G 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 1b). 
Patient 
ID rs6853 
rs2069-
762 
rs3804-
100 
rs1800-
629 
rs1799-
971 
rs1049-
9563 
rs1146-
6004 
1 A/A T/T T/T A/A A/A T/T C/C 
2 A/A G/T T/T G/G A/G T/T C/C 
3 A/A G/T T/T A/A A/A C/T C/C 
4 A/A T/T T/T G/G A/A T/T C/C 
5 A/A G/T T/T G/G A/G C/T C/C 
7 A/A G/G T/T G/G G/G T/T C/C 
8 A/A G/T T/T A/G A/G T/T C/C 
9 A/A G/T T/T G/G A/A T/T C/C 
10 A/A G/G T/T G/G A/G T/T C/C 
11 A/A G/T T/T G/G A/G C/T C/C 
13 A/A T/T C/T A/G A/A T/T C/C 
14 A/A G/T T/T G/G A/A T/T C/C 
16 A/A G/T T/T G/G A/A T/T C/C 
18 A/G – T/T G/G A/A – – 
19 A/A G/T C/T G/G A/G T/T C/C 
20 A/A G/G T/T G/G A/A T/T C/C 
21 A/A T/T T/T G/G A/A C/T C/C 
22 A/A T/T C/T G/G A/G T/T C/C 
23 A/A G/T C/T G/G A/G T/T C/C 
24 A/A G/G T/T G/G A/G – C/C 
25 A/A T/T T/T G/G A/A T/T C/C 
26 A/A T/T T/T G/G A/A T/T C/C 
27 A/A T/T T/T G/G A/A T/T C/C 
29 A/A T/T T/T A/G A/G T/T C/C 
30 A/A T/T C/T G/G A/A T/T C/C 
33 A/A T/T T/T G/G A/A C/T C/C 
34 A/G T/T T/T G/G A/A T/T C/C 
35 A/A G/T T/T A/G A/A T/T C/C 
36 A/G T/T T/T G/G A/A T/T C/C 
37 A/A T/T T/T G/G A/G T/T C/C 
38 A/A G/T T/T G/G A/G T/T C/C 
39 A/A – T/T A/G A/A – – 
40 A/G T/T T/T G/G A/A C/T C/C 
42 A/G G/T T/T G/G A/A T/T C/C 
43 A/A G/G T/T G/G A/A T/T C/C 
44 A/A G/T T/T G/G A/A T/T C/C 
45 A/G T/T T/T A/G A/A T/T C/C 
47 A/A G/T T/T G/G A/A C/T C/C 
49 A/A G/T T/T A/G A/A T/T C/C 
51 A/A G/T T/T G/G A/A T/T C/C 
52 A/A G/T T/T G/G A/A C/T C/C 
53 A/A T/T T/T G/G A/A T/T C/C 
54 A/A G/G T/T G/G A/A T/T C/C 
55 A/A G/T T/T A/G A/A T/T C/C 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 1c). 
Patient 
ID 
rs4986-
790 
rs4986-
791 rs6265 
rs5543-
44 
rs5802-
53 
rs1146-
6314 
rs1800-
469 
1 A/A C/C G/G C/G C/T G/G C/C 
2 A/A C/C A/G G/G C/C G/G C/C 
3 A/A C/C G/G G/G C/C G/G C/T 
4 A/A C/C G/G G/G C/C G/G T/T 
5 A/G C/T G/G G/G C/C G/G C/C 
7 A/A C/C G/G G/G C/C G/G C/C 
8 A/A C/C G/G C/G C/T G/G C/C 
9 A/G C/T A/G C/G C/T G/G C/C 
10 A/A C/C A/G G/G C/C G/G C/T 
11 A/A C/T G/G C/G C/T G/G C/T 
13 A/A C/C G/G G/G C/C G/G C/C 
14 A/A C/C G/G G/G C/C G/G C/T 
16 A/A C/C G/G C/G C/T G/G C/T 
18 A/A C/T A/A G/G C/C G/G C/C 
19 A/A C/C A/G G/G C/C G/G C/C 
20 A/A C/C G/G G/G C/C G/G C/T 
21 A/A C/C G/G C/G – G/G C/C 
22 A/A C/C A/G G/G C/C G/G C/T 
23 A/A C/C G/G G/G C/C G/G C/T 
24 A/A C/C A/G G/G C/C G/G C/T 
25 A/A C/C G/G C/C T/T G/G C/T 
26 A/A C/C A/G G/G C/C G/G C/T 
27 A/A C/C G/G G/G C/C G/G T/T 
29 A/A C/C G/G C/G C/T G/G C/T 
30 A/A C/C G/G C/G C/T G/G C/C 
33 A/A C/C A/G G/G C/C G/G C/T 
34 A/A C/C G/G G/G C/C G/G C/C 
35 A/A C/C G/G G/G C/C G/G C/T 
36 A/G C/T G/G G/G C/C G/G C/T 
37 A/A C/C A/G G/G C/C G/G T/T 
38 A/A C/C G/G G/G C/C G/G C/C 
39 A/A – G/G G/G C/C G/G C/T 
40 A/A C/C G/G C/G C/T G/G T/T 
42 A/A C/C G/G C/G C/T G/G C/C 
43 A/A C/C G/G G/G C/C G/G C/C 
44 A/A C/C A/G C/G C/T G/G T/T 
45 – C/T G/G C/G C/T G/G C/T 
47 A/A C/C G/G G/G C/C G/G C/C 
49 A/G C/T G/G G/G C/C G/G C/C 
51 A/A C/C G/G G/G C/C G/G C/T 
52 A/A C/C G/G G/G C/C G/G C/C 
53 A/A C/C A/G G/G C/C G/G C/T 
54 A/A C/C G/G G/G C/C G/G C/T 
55 A/A C/C A/G G/G C/C G/G C/T 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 2a). 
Patient 
ID 
rs8192-
284 
rs2794-
521 
rs1800-
871 
rs1800-
896 
rs1143-
634 
rs1143-
627 rs16944 
56 C/C T/T C/T A/A C/C C/C A/A 
58 A/A C/T C/C A/A C/C C/T A/G 
59 A/A C/C C/T A/G C/C T/T G/G 
60 A/C T/T C/T A/A C/C C/T A/G 
64 – C/T C/C A/G C/C C/T A/G 
65 C/C C/C C/T A/G C/C C/T A/G 
66 A/A C/T C/C A/G C/C T/T G/G 
67 A/A T/T C/C A/G C/T C/T A/G 
68 C/C C/C C/T A/G C/T T/T G/G 
69 A/A T/T C/T A/A C/C C/T A/G 
70 A/C C/T C/C A/G C/C T/T G/G 
71 A/A T/T C/C A/A C/C T/T G/G 
72 C/C T/T C/C A/G C/C C/T A/G 
73 A/C T/T C/C A/G C/T T/T G/G 
74 – C/T C/C G/G C/C – A/G 
75 C/C C/C C/T A/G C/T T/T G/G 
76 C/C T/T C/T A/G C/T T/T G/G 
78 A/A T/T C/C A/G C/C C/T A/G 
80 C/C T/T C/T A/A C/C C/T A/G 
82 A/C C/C C/C A/G C/C C/T A/G 
83 A/A T/T C/T A/A C/C T/T G/G 
85 A/C T/T T/T A/A C/C T/T G/G 
86 C/C T/T C/C A/G C/T C/T A/G 
87 A/C T/T T/T A/A C/C C/T A/G 
88 A/A C/T C/C G/G C/C C/C A/A 
89 A/C T/T C/T A/A C/C C/T A/G 
90 A/C T/T C/C A/G C/C C/C A/A 
91 A/A T/T C/T A/A C/C C/T A/G 
93 A/C C/T C/C A/G C/T C/T A/G 
94 A/C T/T C/T A/G C/C C/T A/G 
95 A/A C/T C/C A/A C/C T/T G/G 
96 A/A T/T T/T A/A C/T C/T A/G 
97 A/A C/T T/T A/A C/C C/T A/G 
99 A/A C/T C/T A/A C/C C/T A/G 
100 A/A T/T T/T A/A C/C T/T G/G 
101 A/C C/C C/T A/A C/C T/T G/G 
102 C/C T/T C/T A/G C/C C/C A/A 
104 A/C T/T C/C A/G C/C C/T A/G 
108 A/A T/T C/C A/G C/T C/T A/G 
111 A/C C/T C/C A/A C/C C/T A/G 
112 A/C T/T C/T A/A C/C C/C A/A 
114 A/A T/T T/T A/A C/C C/T A/G 
116 A/A T/T C/C G/G C/T T/T G/G 
117 A/A C/T C/C G/G C/C T/T G/G 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 2b). 
Patient 
ID rs6853 
rs2069-
762 
rs3804-
100 
rs1800-
629 
rs1799-
971 
rs1049-
9563 
rs1146-
6004 
56 A/A T/T T/T G/G A/A T/T C/C 
58 A/A – T/T G/G A/A – – 
59 A/A G/T C/T G/G A/G T/T C/C 
60 A/A G/T T/T G/G A/G T/T C/C 
64 A/A G/G T/T A/G A/A T/T – 
65 A/A G/T T/T G/G A/A – C/C 
66 A/A G/T T/T G/G A/A C/C C/C 
67 A/A G/T T/T G/G A/A T/T C/C 
68 A/G G/T T/T A/G A/G C/T C/C 
69 A/A T/T T/T A/G A/A T/T C/C 
70 A/A G/G C/T G/G A/A T/T C/C 
71 A/G – T/T G/G A/A – – 
72 A/A G/T T/T G/G A/G T/T C/C 
73 A/A T/T T/T G/G A/A T/T C/C 
74 A/A – T/T G/G A/A – – 
75 A/G G/T T/T A/G A/G C/T C/C 
76 A/A T/T T/T G/G A/A – C/C 
78 A/A T/T T/T G/G A/A T/T C/C 
80 A/A T/T T/T G/G A/A T/T C/C 
82 A/A G/G T/T G/G A/G T/T C/C 
83 A/A G/G C/T G/G A/A C/T C/C 
85 A/A T/T T/T G/G A/A T/T C/C 
86 A/A G/T C/T A/G A/A T/T C/C 
87 A/A G/T T/T G/G A/A T/T C/C 
88 A/A T/T C/T G/G A/A C/T C/C 
89 A/G G/T C/T G/G A/A T/T C/C 
90 A/G G/G T/T G/G A/G C/T C/C 
91 A/A T/T T/T G/G A/G C/T C/C 
93 A/A T/T T/T G/G A/A T/T C/C 
94 A/A G/T C/T G/G A/G C/T C/C 
95 A/A G/T T/T G/G A/A T/T C/C 
96 A/A G/G C/T G/G A/A C/T C/C 
97 A/A T/T T/T G/G A/G T/T C/C 
99 A/G T/T T/T G/G A/A C/T C/C 
100 A/A G/T T/T G/G A/A T/T C/C 
101 A/A T/T T/T A/G A/A T/T C/C 
102 A/A G/G T/T G/G A/A T/T C/C 
104 A/A G/T C/T A/G G/G C/T C/C 
108 A/G T/T T/T G/G A/A T/T C/C 
111 A/A G/T C/T G/G A/A T/T C/C 
112 A/A G/T C/T G/G A/A T/T C/C 
114 A/A T/T T/T G/G A/G T/T C/C 
116 A/A G/T T/T A/G A/A C/T C/C 
117 A/A T/T T/T G/G A/A T/T C/C 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 2c). 
Patient 
ID 
rs4986-
790 
rs4986-
791 rs6265 
rs5543-
44 
rs5802-
53 
rs1146-
6314 
rs1800-
469 
56 A/A C/C G/G G/G C/C G/G C/T 
58 A/A C/C G/G G/G C/C G/G C/C 
59 A/A C/C A/G G/G C/C G/G C/C 
60 A/A C/C G/G G/G C/C G/G C/C 
64 A/A C/C G/G C/G C/C G/G T/T 
65 A/A C/C A/G C/C T/T G/G C/C 
66 A/A C/C G/G C/G C/T G/G C/T 
67 A/A C/C A/G G/G C/C G/G T/T 
68 A/A C/C G/G G/G C/C G/G C/T 
69 A/A C/C G/G G/G C/C G/G C/T 
70 A/A C/C G/G C/G C/T G/G C/T 
71 A/A C/C G/G G/G C/C G/G C/C 
72 A/A C/C G/G G/G C/C G/G T/T 
73 A/A C/C A/A C/G C/T G/G C/C 
74 – C/C G/G G/G C/C G/G C/C 
75 A/A C/C G/G G/G C/C G/G C/T 
76 A/A C/C G/G C/G C/C G/G C/C 
78 A/A C/C G/G G/G C/C G/G C/C 
80 A/A C/C G/G G/G C/C G/G C/T 
82 A/A C/C G/G G/G C/C G/G C/T 
83 A/A C/C A/A G/G C/C G/G T/T 
85 A/A C/C G/G – T/T G/G C/C 
86 A/A C/C G/G G/G C/C G/G T/T 
87 A/A C/C A/G G/G C/C G/G C/C 
88 A/A C/C A/G G/G C/C G/G C/C 
89 A/A C/C G/G C/G C/T G/G C/T 
90 A/A C/C G/G G/G C/C G/G T/T 
91 A/A C/C G/G C/G C/T G/G C/C 
93 A/A C/C G/G C/G C/T G/G C/T 
94 A/A C/C G/G G/G C/C G/G T/T 
95 A/A C/C G/G C/G C/T G/G C/T 
96 A/G C/T G/G G/G C/C G/G C/T 
97 A/A C/C A/G G/G C/C G/G C/T 
99 A/A C/C G/G G/G C/C G/G C/C 
100 A/A C/C A/A G/G C/C G/G C/T 
101 A/A C/C G/G G/G C/C G/G C/T 
102 A/A C/C G/G C/G C/T G/G C/T 
104 A/A C/C G/G G/G C/C G/G C/T 
108 A/A C/C A/G C/G C/T G/G C/C 
111 A/G C/T A/G C/C T/T G/G C/C 
112 A/A C/C G/G G/G C/C G/G C/T 
114 A/A C/C G/G G/G C/C G/G C/T 
116 A/A C/C G/G G/G C/C G/G C/T 
117 A/A C/C A/G C/G C/T G/G C/T 
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Table 6.4 cont.: Raw genotyping results for genotyped by MassARRAY (part 3). 
Patient 
ID 
rs8192-
284 
rs2794-
521 
rs1800-
871 
rs1800-
896 
rs1143-
634 
rs1143-
627 rs16944 
118 C/C T/T C/C A/G C/C T/T G/G 
120 A/A T/T C/T A/G C/C C/T A/G 
121 A/C C/T C/C A/G C/T C/T A/G 
122 A/C T/T C/T A/A C/C T/T G/G 
123 A/C T/T C/T A/A C/C C/C A/A 
158 A/A T/T C/T A/A C/C C/T A/G 
159 A/A T/T C/T A/G T/T T/T G/G 
163 A/A C/C C/C A/G C/T T/T G/G 
165 A/A C/T T/T A/A C/C C/T A/G 
167 A/A C/T C/C A/G C/T T/T G/G 
170 A/A T/T C/C A/G C/T C/T A/G 
Patient 
ID rs6853 
rs2069-
762 
rs3804-
100 
rs1800-
629 
rs1799-
971 
rs1049-
9563 
rs1146-
6004 
118 A/A G/T T/T G/G A/G T/T C/C 
120 A/G T/T T/T A/G A/A C/T C/C 
121 A/A T/T T/T G/G A/A C/T C/C 
122 A/G G/G C/C G/G A/A T/T C/C 
123 – T/T T/T A/G A/A – C/C 
158 A/A T/T T/T G/G A/A T/T C/C 
159 A/A – T/T G/G A/A – – 
163 A/A T/T T/T G/G A/A T/T  
165 A/A G/T T/T G/G A/G T/T C/C 
167 A/A T/T C/T A/G A/A – – 
170 A/A T/T T/T G/G A/A T/T C/C 
Patient 
ID 
rs4986-
790 
rs4986-
791 rs6265 
rs5543-
44 
rs5802-
53 
rs1146-
6314 
rs1800-
469 
118 A/A C/C G/G G/G C/C – C/C 
120 A/A C/C G/G C/G C/T G/G C/T 
121 A/A C/C G/G C/G C/T G/G C/T 
122 A/A C/C A/A G/G C/C G/G C/T 
123 A/G C/T G/G G/G C/C G/G C/C 
158 A/A C/C G/G G/G C/C G/G C/T 
159 A/A C/C G/G C/G C/C G/G C/C 
163 A/A C/T A/G C/G C/C G/G C/C 
165 A/A C/C G/G G/G C/C G/G C/T 
167 A/A C/C A/G G/G C/C G/G T/T 
170 A/A C/C G/G G/G C/C G/G C/C 
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6.4 Sequencing results 
GGAGAAATACTGGGCCAACCTGACTAGGATGCTAGCAAACTTTTGAATTCAGCATATAATTTAT
CTTGTAAATGTGACTATTTTAGAAAAAACAAAATACATTTGTGGAGAGCACCACACAATTAACT
TCATTCAGATTTGGCATTTGGATCTTGGCTTTTCT[A]GAGATCCCATTTCTAATGATATCTTA
TTCTGGGCTTTTTTTTCATCATTATTAAAGTCACCCTTTACTTTCCTTCTGCCTTTGAAGTTAC
AATCTCGTCAGTTCAAAGTCTTTTTAGAGCACTTAACAGAAAATTTAATCAAAACGCTGAGCCA
AATTTCAGCTAAAAAGTTATTAGCGTCACTGGAAATTGTGAGTCA  
Figure 6.1: Sequence of PCR product amplified for SNP rs10889635 (SGIP1). 
Sequencing product size was 363 bp, 1 bp shorter than the expected 364 bp. The position of 
rs10889635 is indicated and shown in bold. Sample sequenced was determined to be A/A 
homozygous both by sequencing and PCR-RFLP. 
 
 
 
 
Figure 6.2: BLAST nucleotide alignment of rs10889635 (SGIP1) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown.  
>ref|NW_001838579.2| Homo sapiens chromosome 1 genomic contig, 
alternate assembly HuRef SCAF_1103279188432, whole genome 
shotgun sequence 
Length=32841984 
Features in this part of subject sequence: 
SH3-containing GRB2-like protein 3-interacting protein 1 
Score = 660 bits (357), Expect = 0.0 
Identities = 362/364 (99%), Gaps = 2/364 (1%) 
Strand=Plus/Minus
Query 2 GGAGAAATA-CTGGGCCAACCTGACTAGGATGCTAGCAAACTTTTGAATTCAGCATATAA 60 
||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16610096 GGAGAAATATCTGGGCCAACCTGACTAGGATGCTAGCAAACTTTTGAATTCAGCATATAA 16610037 
Query 61 TTTATCTTGTAAATGTGACTATTTTAGAAAAAACAAAATACATTTGTGGAGAGCACCACA 120 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16610036 TTTATCTTGTAAATGTGACTATTTTAGAAAAAACAAAATACATTTGTGGAGAGCACCACA 16609977
Query 121 CAATTAACTTCATTCAGATTTGGCATTTGGATCTTGGCTTTTCTAGAGATCCCATTTCTA 180 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16609976 CAATTAACTTCATTCAGATTTGGCATTTGGATCTTGGCTTTTCTAGAGATCCCATTTCTA 16609917 
Query 181 ATGATATCTTATTCTGGGCttttttttCATCATTATTAAAGTCACCCTTTACTTTCCTTC 240 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16609916 ATGATATCTTATTCTGGGCTTTTTTTTCATCATTATTAAAGTCACCCTTTACTTTCCTTC 16609857 
Query 241 TGCCTTTGAAGTTACAATCTCGTCAGTTCAAAGTCTTTTTAGAGCACTTAACAGAAAATT 300 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16609856 TGCCTTTGAAGTTACAATCTCGTCAGTTCAAAGTCTTTTTAGAGCACTTAACAGAAAATT 16609797 
Query 301 TAATCAAAACGCTGAGCCAAATTTCAGCTAAAAAGTTATTAGCGTCACTGGAAATTGTGA 360 
||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct 16609796 TAATCAAAACGCTGAGCCAAATTTCAGCTAAAAAGTTATTAGCGTCACTGGAAAT-GTGA 16609738 
Query 361 GTCA 364 
|||| 
Sbjct 16609737 GTCA 16609734 
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GAGGAAGATTCAGGATACAGCCATCCTATTTTTAAGGTTCAATGATTGCAGACTCTTAAAAGGC
TTACAGATTCAACCTGACTTTTATGTCTTGATCCCACTCTATGATGCCTGATGCCAAAATTCCC
ATGGCAGCTCAATTCCTTGTTAAGCTAGGAAGCAAGCAG[G]GGTGTAATCAGAGCACGAAACC
TTC  
Figure 6.3: Sequence of PCR product amplified for SNP rs6681460 (SGIP1). 
Sequencing product size was 193 bp as expected. The position of rs6681460 is indicated and 
shown in bold. Sample sequenced was determined to be G/G homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
 
Figure 6.4: BLAST nucleotide alignment of rs6681460 (SGIP1) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
  
>ref|NW_001838579.2| Homo sapiens chromosome 1 genomic contig, 
alternate assembly HuRef SCAF_1103279188432, whole genome 
shotgun sequence 
Length=32841984 
Features in this part of subject sequence: 
SH3-containing GRB2-like protein 3-interacting protein 1 
Score = 351 bits (190), Expect = 1e-94 
Identities = 192/193 (99%), Gaps = 0/193 (0%) 
Strand=Plus/Minus 
Query 1 GAGGAAGATTCAGGATACAGCCATCCTATTTTTAAGGTTCAATGATTGCAGACTCTTAAA 60 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16562353 GAGGAAGATTCAGGATACAGCCATCCTATTTTTAAGGTTCAATGATTGCAGACTCTTAAA 16562294 
Query 61 AGGCTTACAGATTCAACCTGACTTTTATGTCTTGATCCCACTCTATGATGCCTGATGCCA 120 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 16562293 AGGCTTACAGATTCAACCTGACTTTTATGTCTTGATCCCACTCTATGATGCCTGATGCCA 16562234 
Query 121 AAATTCCCATGGCAGCTCAATTCCTTGTTAAGCTAGGAAGCAAGCAGGGGTGTAATCAGA 180 
||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct 16562233 AAATTCCCATGGCAGCTCAATTCCTTGTTAAGCTAGGAAGCAAGCAGGGATGTAATCAGA 16562174 
Query 181 GCACGAAACCTTC 193 
||||||||||||| 
Sbjct 16562173 GCACGAAACCTTC 16562161
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TTTCAGATGCACCCTGTATATTTACTGTTGATC[A]TGGAACTCGTGCCACTGAAAATTTTTAA
GTGACTATATTCAAAAACAGCAGGTTGCATGACAGTTTCTCAGTGAAGAGGTTCAAAAAAGGTG
AGATGCTATTGCTTTGTGAATTTACAAAGGAAAGAATAATTTAACTGCTCAGAATTACATGTCC
GGTCACTGCTT  
Figure 6.5: Sequence of PCR product amplified for SNP rs2146904 (SGIP1). 
Sequencing product size was 201 bp as expected. The position of rs2146904 is indicated and 
shown in bold. Sample sequenced was determined to be A/A homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
 
Figure 6.6: LAST nucleotide alignment of rs2146904 (SGIP1) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
  
>ref|NT_032977.9| Homo sapiens chromosome 1 genomic contig, 
GRCh37.p5 Primary Assembly 
Length=90908613 
Features in this part of subject sequence: 
SH3-containing GRB2-like protein 3-interacting protein 1 
Score = 363 bits (196), Expect = 5e-98 
Identities = 198/199 (99%), Gaps = 0/199 (0%)
Strand=Plus/Plus 
Query 3 TCAGATGCACCCTGTATATTTACTGTTGATCATGGAACTCGTGCCACTGAAAATTTTTAA 62 
||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct 37132223 TCAGATGCACCCTGTATATTTACTGTTCATCATGGAACTCGTGCCACTGAAAATTTTTAA 37132282 
Query 63 GTGACTATATTCAAAAACAGCAGGTTGCATGACAGTTTCTCAGTGAAGAGGTTCAAAAAA 122 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 37132283 GTGACTATATTCAAAAACAGCAGGTTGCATGACAGTTTCTCAGTGAAGAGGTTCAAAAAA 37132342 
Query 123 GGTGAGATGCTATTGCTTTGTGAATTTACAAAGGAAAGAATAATTTAACTGCTCAGAATT 182 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 37132343 GGTGAGATGCTATTGCTTTGTGAATTTACAAAGGAAAGAATAATTTAACTGCTCAGAATT 37132402 
Query 183 ACATGTCCGGTCACTGCTT 201 
||||||||||||||||||| 
Sbjct 37132403 ACATGTCCGGTCACTGCTT 37132421
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TTACGGGTGCTGGAGACTGGAAAAAGCATCCAGTTTGGTTGCTGTGGAGCAACATGCATATTGG
ATTAGAAAATTGTGCCAAAAACTCCCACTGATGAGAATTCATAGGTGCCCCACACT[G]TGACA
AACACTTATATGATTCTCCTCTTTCCTGTTTACTGCAAATTCTGCCTTAAGGCTTCTTTTCAAG
ACTCAGAAGCCACTAATTATAAAGGAAAGGGCAGTTAATTGGCA 
Figure 6.7: Sequence of PCR product amplified for SNP rs572227 (GABRA2). 
Sequencing product size was 234 bp as expected. The position of rs572227 is indicated and 
shown in bold. Sample sequenced was determined to be G/G homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
 
Figure 6.8: BLAST nucleotide alignment of rs572227 (GABRA2) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
  
>ref|NW_001838903.1| Homo sapiens chromosome 4 genomic contig, 
alternate assembly HuRef SCAF_1103279187004, whole genome 
shotgun sequence 
Length=8800796 
Features flanking this part of subject sequence: 
123291 bp at 5' side: gamma-aminobutyric acid receptor 
subunit gamma-1 precursor 
812 bp at 3' side: gamma-aminobutyric acid receptor subunit 
alpha-2 precursor 
Score = 433 bits (234), Expect = 7e-119 
Identities = 234/234 (100%), Gaps = 0/234 (0%) 
Strand=Plus/Minus 
Query 1 TTACGGGTGCTGGAGACTGGAAAAAGCATCCAGTTTGGTTGCTGTGGAGCAACATGCATA 60 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 5948072 TTACGGGTGCTGGAGACTGGAAAAAGCATCCAGTTTGGTTGCTGTGGAGCAACATGCATA 5948013 
Query 61 TTGGATTAGAAAATTGTGCCAAAAACTCCCACTGATGAGAATTCATAGGTGCCCCACACT 120 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 5948012 TTGGATTAGAAAATTGTGCCAAAAACTCCCACTGATGAGAATTCATAGGTGCCCCACACT 5947953 
Query 121 GTGACAAACACTTATATGATTCTCCTCTTTCCTGTTTACTGCAAATTCTGCCTTAAGGCT 180 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 5947952 GTGACAAACACTTATATGATTCTCCTCTTTCCTGTTTACTGCAAATTCTGCCTTAAGGCT 5947893 
Query 181 TCTTTTCAAGACTCAGAAGCCACTAATTATAAAGGAAAGGGCAGTTAATTGGCA 234 
|||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 5947892 TCTTTTCAAGACTCAGAAGCCACTAATTATAAAGGAAAGGGCAGTTAATTGGCA 5947839
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TGCCATGTTTGTCACAGGTTTTCTTAATGAACTACATTTACAAATGGCAACTTCTGATAAAGGA
TAACAGATTAAGTTCAGTGTCAATTTTGACCAGATATTAAAACTCACAACTCTCTAAACTTCCT
TGATATTAACTACTGAACTAATTAATATCCCAGTAGCTTCTGGAG[T]TTCTAAGAGATAATGC
ACTCTGTGTTTTTGCAGAGGAAG  
Figure 6.9: Sequence of PCR product amplified for SNP rs279845 (GABRA2). 
Sequencing product size was 213 bp as expected. The position of rs279845 is indicated and 
shown in bold. Sample sequenced was determined to be T/T homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
 
Figure 6.10: BLAST nucleotide alignment of rs279845 (GABRA2) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
 
 
  
ref|NT_006238.11| Homo sapiens chromosome 4 genomic contig, 
GRCh37.p5 Primary Assembly 
Length=9041845 
Features in this part of subject sequence: 
gamma-aminobutyric acid receptor subunit alpha-2 precursor
gamma-aminobutyric acid receptor subunit alpha-2 precursor
Score = 394 bits (213), Expect = 2e-107 
Identities = 213/213 (100%), Gaps = 0/213 (0%) 
Strand=Plus/Plus
Query 1 TGCCATGTTTGTCACAGGTTTTCTTAATGAACTACATTTACAAATGGCAACTTCTGATAA 60 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 6032454 TGCCATGTTTGTCACAGGTTTTCTTAATGAACTACATTTACAAATGGCAACTTCTGATAA 6032513 
Query 61 AGGATAACAGATTAAGTTCAGTGTCAATTTTGACCAGATATTAAAACTCACAACTCTCTA 120 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 6032514 AGGATAACAGATTAAGTTCAGTGTCAATTTTGACCAGATATTAAAACTCACAACTCTCTA 6032573 
Query 121 AACTTCCTTGATATTAACTACTGAACTAATTAATATCCCAGTAGCTTCTGGAGTTTCTAA 180 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 6032574 AACTTCCTTGATATTAACTACTGAACTAATTAATATCCCAGTAGCTTCTGGAGTTTCTAA 6032633 
Query 181 GAGATAATGCACTCTGTGTTTTTGCAGAGGAAG 213 
||||||||||||||||||||||||||||||||| 
Sbjct 6032634 GAGATAATGCACTCTGTGTTTTTGCAGAGGAAG 6032666 
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CCTCTCTGTTCCTATCCATACAT[G]TTTTTTCTTGGATTAATTCTCAGGCTATTATTTTCTAT
GGCTAATGTCTCCTACCCATTTCTGACCTTCTAGTCTTACTATTTTCTTGGAGTTTGAGAGTAT
AAATAGACAGCTACTGAGAAGTAGAAAGGTTGGACCAGTTTTCTGACT 
Figure 6.11: Sequence of PCR product amplified for SNP rs279841 (GABRA2). 
Sequencing product size was 174 bp as expected. The position of rs279841 is indicated and 
shown in bold. Sample sequenced was determined to be G/G homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
>ref|NT_006238.11| Homo sapiens chromosome 4 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=9041845  
 
Features in this part of subject sequence:  
gamma-aminobutyric acid receptor subunit alpha-2 precursor  
gamma-aminobutyric acid receptor subunit alpha-2 precursor  
 
Score = 316 bits (171), Expect = 4e-84  
Identities = 173/174 (99%), Gaps = 0/174 (0%)  
Strand=Plus/Plus 
 
Query 1  CCTCTCTGTTCCTATCCATACATGTTTTTTCTTGGATTAATTCTCAGGCTATTATTTTCT 60 
 |||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||  
Sbjct 6043644  CCTCTCTGTTCCTATCCATAGATGTTTTTTCTTGGATTAATTCTCAGGCTATTATTTTCT 6043703  
 
Query 61  ATGGCTAATGTCTCCTACCCATTTCTGACCTTCTAGTCTTACTATTTTCTTGGAGTTTGA 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 6043704  ATGGCTAATGTCTCCTACCCATTTCTGACCTTCTAGTCTTACTATTTTCTTGGAGTTTGA 6043763  
 
Query 121  GAGTATAAATAGACAGCTACTGAGAAGTAGAAAGGTTGGACCAGTTTTCTGACT 174 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 6043764  GAGTATAAATAGACAGCTACTGAGAAGTAGAAAGGTTGGACCAGTTTTCTGACT 6043817  
Figure 6.12: BLAST nucleotide alignment of rs279841 (GABRA2) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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ATTCCCTCTGCGTCTCTGAAACCCACTGGATTAGCTAAAGGAAGCAAAA[T]GTGCTGCCAAAC
CCACCAGTCACTCAGCAGGGGAGCCCCGGCGTCTGAAGAGCTTCAAGACTCCCGAATGTCCCAA
AACATCTGTTTCAGATACAAGCATTGCCTCCCTGCCCATAGCCTCTTCAAAGGAAATCTTGCCC
TG 
Figure 6.13: Sequence of PCR product amplified for SNP rs13361609 (HCN1) 
Sequencing product size was 192 bp as expected. The position of rs13361609 is indicated and 
shown in bold. Sample sequenced was determined to be T/T homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
ref|NT_006576.16| Homo sapiens chromosome 5 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=46395641  
 
Features flanking this part of subject sequence:  
1218 bp at 5' side: potassium/sodium hyperpolarization-
activated cyclic nucle...  
 
Score = 355 bits (192), Expect = 8e-96  
Identities = 192/192 (100%), Gaps = 0/192 (0%)  
Strand=Plus/Plus  
 
Query 1  ATTCCCTCTGCGTCTCTGAAACCCACTGGATTAGCTAAAGGAAGCAAAATGTGCTGCCAA 60 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45687413 ATTCCCTCTGCGTCTCTGAAACCCACTGGATTAGCTAAAGGAAGCAAAATGTGCTGCCAA 45687472 
  
Query 61  ACCCACCAGTCACTCAGCAGGGGAGCCCCGGCGTCTGAAGAGCTTCAAGACTCCCGAATG 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45687473  ACCCACCAGTCACTCAGCAGGGGAGCCCCGGCGTCTGAAGAGCTTCAAGACTCCCGAATG 45687532  
 
Query 121  TCCCAAAACATCTGTTTCAGATACAAGCATTGCCTCCCTGCCCATAGCCTCTTCAAAGGA 180 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45687533  TCCCAAAACATCTGTTTCAGATACAAGCATTGCCTCCCTGCCCATAGCCTCTTCAAAGGA 45687592  
 
Query 181  AATCTTGCCCTG 192  
 ||||||||||||  
Sbjct 45687593  AATCTTGCCCTG 45687604  
Figure 6.14: BLAST nucleotide alignment of rs13361609 (HCN1) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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TCACCAACAAAGAGGCCATTATCAACTTGGAGTCTCAAAGCTGATTTTCTCCACCTCTTTAGCA
AGAAATTCAGTGAAATTCTGGAAATGAAATTACACACGATTATAAATGAGATTATTATTATTAT
TGTCTCTGAGTGAATTAAGATGCATAAATTGGGTTAAAGGGGTTTCCTCTTTATAATTATTTTT
ACC[G]TACCGATTTACAAAACTCCACAGTTC  
Figure 6.15: Sequence of PCR product amplified for SNP rs13187565 (HCN1) 
Sequencing product size was 222 bp as expected. The position of rs13187565 is indicated and 
shown in bold. Sample sequenced was determined to be G/G homozygous by both sequencing 
and PCR-RFLP. 
 
 
 
>ref|NT_006576.16| Homo sapiens chromosome 5 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=46395641  
 
Features flanking this part of subject sequence:  
11148 bp at 5' side: potassium/sodium hyperpolarization- 
activated cyclic nucle...  
 
Score = 405 bits (219), Expect = 1e-110  
Identities = 221/222 (99%), Gaps = 0/222 (0%)  
Strand=Plus/Plus 
  
Query 1  TCACCaacaaagaggccattatcaacttggagtctcaaagctgattttctccacctcttt 60 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45697343  TCACCAACAAAGAGGCCATTATCAACTTGGAGTCTCAAAGCTGATTTTCTCCACCTCTTT 45697402 
 
Query 61  agcaagaAATTCAGTGAAATTCTGGAAATGAAATTACACACGATTATAAATGAGATTATT 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45697403 AGCAAGAAATTCAGTGAAATTCTGGAAATGAAATTACACACGATTATAAATGAGATTATT 45697462  
 
Query 121 ATTATTATTGTCTCTGAGTGAATTAAGATGCATAAATTGGGTTAAAGGGGTTTCCTCTTT 180 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 45697463  ATTATTATTGTCTCTGAGTGAATTAAGATGCATAAATTGGGTTAAAGGGGTTTCCTCTTT 45697522  
 
Query 181  ATAATTATTTTTACCGTACCGATTTACAAAACTCCACAGTTC 222  
 |||||||||||||||||| |||||||||||||||||||||||  
Sbjct 45697523 ATAATTATTTTTACCGTAGCGATTTACAAAACTCCACAGTTC 45697564  
Figure 6.16: BLAST nucleotide alignment of rs13187565 (HCN1) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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GTGGTGCAGCCTTAGGTGAGTGAACAACGCCCAGGGTTGAAGGGCTCAGCAAGTGAGGGGTGGT
GATGGAGGTCATCCGACCCATCCCGCCGCCTCTCCGCAGTGGCGCAAGCGCCCCAAAATCTCCG
GAGAGGGAACTGA[C/G]TGACCCACTAGGTTCCGCCGTGTCTACCTCTCGCAGATGTTGGGGA
AGTGCTT  
Figure 6.17: Sequence of PCR product amplified for SNP rs7501581 (CACNA1G). 
Sequencing product size was 195 bp, 1 bp shorter than the expected 196 bp. The position of 
rs7501581 is indicated and shown in bold. Sample sequenced was determined to be C/G 
heterozygous by both sequencing and PCR-RFLP. 
 
 
 
ref|NT_010783.15| Homo sapiens chromosome 17 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=44983201  
 
Features flanking this part of subject sequence:  
3496 bp at 5' side: spermatogenesis-associated protein 20  
2107 bp at 3' side: voltage-dependent T-type calcium channel 
subunit alpha-1G...  
 
Score = 333 bits (180), Expect = 4e-89  
Identities = 191/196 (97%), Gaps = 1/196 (1%)  
Strand=Plus/Plus  
 
Query 1  GTGGTGCAGCCTTAGGTGAGTGAACAACGCCCAGGGTTGAAGGGCTCAGC-AAGTGAGGG 59 
 |||||||||||||||| ||||||||||||||||||| ||| || |||||| |||||||||  
Sbjct 13910671  GTGGTGCAGCCTTAGGAGAGTGAACAACGCCCAGGGGTGATGGCCTCAGCAAAGTGAGGG 13910730 
  
Query 60  GTGGTGATGGAGGTCATCCGACCCATCCCGCCGCCTCTCCGCAGTGGCGCAAGCGCCCCA 119 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13910731  GTGGTGATGGAGGTCATCCGACCCATCCCGCCGCCTCTCCGCAGTGGCGCAAGCGCCCCA 13910790  
 
Query 120  AAATCTCCGGAGAGGGAACTGACTGACCCACTAGGTTCCGCCGTGTCTACCTCTCGCAGA 179 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13910791  AAATCTCCGGAGAGGGAACTGACTGACCCACTAGGTTCCGCCGTGTCTACCTCTCGCAGA 13910850  
 
Query 180  TGTTGGGGAAGTGCTT 195  
 ||||||||||||||||  
Sbjct 13910851  TGTTGGGGAAGTGCTT 13910866  
Figure 6.18: BLAST nucleotide alignment of rs7501581 (CACNA1G) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown.  
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CCCAGGTAGGCG[C/T]GAGTGGACCAGCCATCTGGCCCCCCCACCTCCAGCTGAGGAACCTCT
GGGCAAGGTTAACACAGCCTGAGCCAGGGTACCTCTGTGCCAAGCAAGTGCTAGGCACACTACA
TGGGTTCCTCTTGTGCCCCTTGGAGGTGGGTATCATCTT  
Figure 6.19: Sequence of PCR product amplified for SNP rs8066527 (CACNA1G). 
Sequencing product size was 163 bp in length, 3 bp shorter than the expected 169 bp. The 
position of SNP rs8066527 is indicated and shown in bold. Sample sequenced was determined 
to be C/T heterozygous by both sequencing and PCR-RFLP. 
 
 
 
ref|NT_010783.15| Homo sapiens chromosome 17 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=44983201  
 
Features in this part of subject sequence:  
voltage-dependent T-type calcium channel subunit alpha-1G...  
 
Score = 296 bits (160), Expect = 4e-78  
Identities = 162/163 (99%), Gaps = 0/163 (0%)  
Strand=Plus/Plus  
 
Query 1  CCCAGGTAGGCGCGAGTGGACCAGCCATCTGGcccccccACCTCCAGCTGAGGAACCTCT 60 
 |||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13967021  CCCAGGTAGGAGCGAGTGGACCAGCCATCTGGCCCCCCCACCTCCAGCTGAGGAACCTCT 13967080  
 
Query 61  GGGCAAGGTTAACACAGCCTGAGCCAGGGTACCTCTGTGCCAAGCAAGTGCTAGGCACAC 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13967081  GGGCAAGGTTAACACAGCCTGAGCCAGGGTACCTCTGTGCCAAGCAAGTGCTAGGCACAC 13967140  
 
Query 121  TACATGGGTTCCTCTTGTGCCCCTTGGAGGTGGGTATCATCTT 163 
 |||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13967141  TACATGGGTTCCTCTTGTGCCCCTTGGAGGTGGGTATCATCTT 13967183  
Figure 6.20: BLAST nucleotide alignment of rs8066527 (CACNA1G) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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CTCCGTCTTGTCCGTTCACTCCCAGCCAGCAGATACCAGCTACATCCTGCAGCTTCCCAAAGAT
GCACCTCATCTGCTCCAGCCCCACAGC[G]CCCCAACCTGGGGCACCATCCCCAAACTGCCCCC
ACCAGGACGCTCCCCTTTGGCTCAGAGGCCACTCAGGCGCCAGGTGAGCAGATGTGGAAAGGCA
GGCACAGGCCTGGGGGCTGGACCCTCTGCTGCTGGTGATGACCTGTGTT  
Figure 6.21: Sequence of PCR product amplified for SNP rs8066269 (CACNA1G). 
Sequencing product size was 239 bp as expected. The position of SNP rs8066269 is indicated 
and shown in bold. Sample sequenced was determined to be G/G homozygous by both 
sequencing and PCR-RFLP. 
 
 
 
ref|NT_010783.15| Homo sapiens chromosome 17 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=44983201  
 
Features in this part of subject sequence:  
voltage-dependent T-type calcium channel subunit alpha-1G...  
 
Score = 442 bits (239), Expect = 8e-122  
Identities = 239/239 (100%), Gaps = 0/239 (0%)  
Strand=Plus/Plus 
 
Query 1  CTCCGTCTTGTCCGTTCACTCCCAGCCAGCAGATACCAGCTACATCCTGCAGCTTCCCAA 60 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13975874  CTCCGTCTTGTCCGTTCACTCCCAGCCAGCAGATACCAGCTACATCCTGCAGCTTCCCAA 13975933  
 
Query 61  AGATGCACCTCATCTGCTCCAGCCCCACAGCGCCCCAACCTGGGGCACCATCCCCAAACT 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13975934  AGATGCACCTCATCTGCTCCAGCCCCACAGCGCCCCAACCTGGGGCACCATCCCCAAACT 13975993  
 
Query 121  GCCCCCACCAGGACGCTCCCCTTTGGCTCAGAGGCCACTCAGGCGCCAGGTGAGCAGATG 180 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13975994  GCCCCCACCAGGACGCTCCCCTTTGGCTCAGAGGCCACTCAGGCGCCAGGTGAGCAGATG 13976053  
 
Query 181  TGGAAAGGCAGGCACAGGCCTGGGGGCTGGACCCTCTGCTGCTGGTGATGACCTGTGTT 239 
 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 13976054  TGGAAAGGCAGGCACAGGCCTGGGGGCTGGACCCTCTGCTGCTGGTGATGACCTGTGTT 13976112  
Figure 6.22: BLAST nucleotide alignment of rs8066269 (CACNA1G) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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GGCCTCTCCTCCCTCGTAC[A/C]CCCCACCCCAGTGGGAGCCCACAAGGACAGGGCCTGCCCC
ATCCCCTCCACTCTGGGCTGTGGCTCTAAGCAGCACGTCCCACTCTAGGGGCTCAGGGCAGGGA
CAGTGACTCATCCAAGGTCCCGCCGTGGAGGGCAGAGCTGAAGGAGTGAGAAGGAGCTGCTGAC
ATGGAA  
Figure 6.23: Sequence of PCR product amplified for SNP rs7254543 (HCN1). 
Sequencing product was 194 bp in length as expected. The position of rs725454 is shown in 
indicated and shown in bold. Sample sequenced was determined to be A/C heterozygous by 
both sequencing and PCR-RFLP. 
 
 
 
>ref|NT_011255.14| Homo sapiens chromosome 19 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=7286004  
 
Features flanking this part of subject sequence:  
3209 bp at 5' side: basigin isoform 1 precursor  
3967 bp at 3' side: potassium/sodium hyperpolarization-
activated cyclic nucle...  
 
Score = 348 bits (188), Expect = 1e-93  
Identities = 192/194 (99%), Gaps = 0/194 (0%)  
Strand=Plus/Plus  
 
Query 1  GGCCTCTCCTCCCTCGTACACCCCACCCCAGTGGGAGCCCACAAGGACAGGGCCTGCCCC 60 
 ||||||||||||||| ||| ||||||||||||||||||||||||||||||||||||||||  
Sbjct 525786  GGCCTCTCCTCCCTCTTACCCCCCACCCCAGTGGGAGCCCACAAGGACAGGGCCTGCCCC 525845  
 
Query 61  ATCCCCTCCACTCTGGGCTGTGGCTCTAAGCAGCACGTCCCACTCTAGGGGCTCAGGGCA 120 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 525846  ATCCCCTCCACTCTGGGCTGTGGCTCTAAGCAGCACGTCCCACTCTAGGGGCTCAGGGCA 525905  
 
Query 121  GGGACAGTGACTCATCCAAGGTCCCGCCGTGGAGGGCAGAGCTGAAGGAGTGAGAAGGAG 180 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 525906  GGGACAGTGACTCATCCAAGGTCCCGCCGTGGAGGGCAGAGCTGAAGGAGTGAGAAGGAG 525965  
 
Query 181  CTGCTGACATGGAA 194  
 ||||||||||||||  
Sbjct 525966  CTGCTGACATGGAA 525979  
Figure 6.24: BLAST nucleotide alignment of rs7254543 (HCN1) sequencing product 
(Query) against the human genome. 
The most highly significant alignment is shown. 
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ACTGAAGGGGGTTCTTTTATGTTCACCCTGGGAAGATGTCAGGCCGGGCAGGTCGCCAGAGCCC
CAGGGCTCGCGGCTGGGAGCAGGGAGGAGGCGGGACCCGCACGGCACGAGAACCGCCCA[T]GC
CTGGCAGTGGGAGAAGCAGAAAGACGCCTCCTGCAGGCGCCGGCAGAACCCGCAAGTCACAAGG
GAGGCTGTG  
Figure 6.25: Sequence of PCR product amplified for SNP rs873634 (HCN2). 
Sequencing product size was 199 bp in length as expected. The position of rs873634 is 
indicated and shown in bold. Sample sequenced was determined to be T/T homozygous by 
both sequencing and PCR-RFLP. 
 
 
 
>ref|NT_011255.14| Homo sapiens chromosome 19 genomic contig, 
GRCh37.p5 Primary Assembly  
Length=7286004  
 
Features flanking this part of subject sequence: 
5653 bp at 5' side: basigin isoform 1 precursor  
1519 bp at 3' side: potassium/sodium hyperpolarization-
activated cyclic nucle...  
 
Score = 366 bits (198), Expect = 4e-99  
Identities = 198/198 (100%), Gaps = 0/198 (0%)  
Strand=Plus/Minus  
 
Query 2  CTGAAGGGGGTTCTTTTATGTTCACCCTGGGAAGATGTCAGGCCGGGCAGGTCGCCAGAG 61 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 528427 CTGAAGGGGGTTCTTTTATGTTCACCCTGGGAAGATGTCAGGCCGGGCAGGTCGCCAGAG 528368  
 
Query 62  CCCCAGGGCTCGCGGCTGGGAGCAGGGAGGAGGCGGGACCCGCACGGCACGAGAACCGCC 121 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 528367 CCCCAGGGCTCGCGGCTGGGAGCAGGGAGGAGGCGGGACCCGCACGGCACGAGAACCGCC 528308  
 
Query 122  CATGCCTGGCAGTGGGAGAAGCAGAAAGACGCCTCCTGCAGGCGCCGGCAGAACCCGCAA 181 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct 528307 CATGCCTGGCAGTGGGAGAAGCAGAAAGACGCCTCCTGCAGGCGCCGGCAGAACCCGCAA 528248  
 
Query 182  GTCACAAGGGAGGCTGTG 199  
 ||||||||||||||||||  
Sbjct 528247 GTCACAAGGGAGGCTGTG 528230  
Figure 6.26: BLAST nucleotide alignment of rs873634 (HCN2) sequencing product 
(Query) against the human genome.  
The most highly significant alignment is shown. 
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6.5 Haploview and haplotype phasing results 
Table 6.5: Haploview quality control data for genotyped SNPs.  
a. SNPs genotyped by PCR-RFLP; b. SNPs genotyped by MassARRAY. ObsHET = observed 
heterozygosity, PredHET = predicted heterozygosity, HWpval = HWE p-value, %Geno =  
% of samples successfully genotyped. Rating indicates SNPs that failed control checks on 
MAF (MAF < 0.05) or adherence to HWE (p < 0.05). 
a. 
SNP ID Obs- HET 
Pred- 
HET 
HW-
pval %Geno MAF Alleles Rating 
 rs10889635 0.476 0.483 0.9820 99.2 0.407 A:G  
 rs6681460 0.407 0.468 0.1881 98.4 0.374 G:A  
 rs2146904 0.427 0.473 0.3558 99.2 0.383 G:A  
 rs572227 0.472 0.475 1 100 0.388 G:A  
 rs279845 0.496 0.486 0.9985 100 0.416 T:A  
 rs279841 0.472 0.472 1 98.4 0.382 G:A  
 rs13187565 0.371 0.487 0.0117 99.2 0.419 G:T BAD 
 rs13361609 0.328 0.362 0.3904 97.6 0.238 T:C  
 rs7501581 0.432 0.465 0.5135 100 0.368 C:G  
 rs8066527 0.398 0.457 0.2022 98.4 0.354 C:T  
 rs8066269 0 0 1 20 0 G:G BAD 
 rs873634 0.443 0.456 0.8509 97.6 0.352 T:G  
 rs7254543 0.336 0.435 0.0219 95.2 0.319 C:A BAD 
         b. 
SNP ID Obs- HET 
Pred- 
HET 
HW-
pval %Geno MAF Alleles Rating 
 rs8192284 0.371 0.461 0.0793 98 0.361 A:C  
 rs2794521 0.320 0.367 0.2911 98 0.242 T:C  
 rs1800871 0.343 0.397 0.2563 100 0.273 C:T  
 rs1800896 0.475 0.490 0.8754 100 0.429 A:G  
 rs1143634 0.232 0.236 1 100 0.136 C:T  
 rs1143627 0.495 0.472 0.8342 98 0.381 T:C  
 rs16944 0.515 0.471 0.4985 100 0.379 G:A  
 rs6853 0.153 0.141 1 99 0.077 A:G  
 rs2069762 0.419 0.461 0.4827 93.9 0.360 T:G  
 rs3804100 0.172 0.174 1 100 0.096 T:C  
 rs1800629 0.192 0.205 0.7546 100 0.116 G:A  
 rs1799971 0.253 0.25 1 100 0.146 A:G  
 rs10499563 0.236 0.225 1 89.9 0.129 T:C  
 rs11466004 0 0 1 90.9 0 T:T BAD 
 rs4986790 0.072 0.070 1 98 0.036 A:G  
 rs4986791 0.112 0.106 1 99 0.056 C:T  
 rs6265 0.232 0.278 0.1922 100 0.167 G:A  
 rs554344 0.286 0.287 1 99 0.173 G:C  
 rs580253 0.235 0.266 0.3819 99 0.158 C:T  
 rs11466314 0 0 1 99 0 G:G BAD 
 rs1800469 0.475 0.466 1 100 0.369 C:T  
 
6 | Appendix  179 
 
 
 
Table 6.6: Haplotype phasing results as determined by the EM algorithm in 
SNPAnalzyer 1.2A (part 1). Haplotype phase was determined for three-SNP haplotypes in 
SGIP1, GABRA2 and IL1B, haplotypes assignments for each sample are shown (H1 and H2).  
Prob. = probability of the haplotype being correctly phased. 
ID 
SGIP1 GABRA2 IL1B 
H1 H2 Prob. H1 H2 Prob. H1 H2 Prob. 
1 AGG GAA 49.88 GTG AAA 49.70 CTG CTG 100 
2 AGG AGG 100.00 GTG AAA 49.70 TTG CCA 45 
3 AGG AGG 100.00 GTG GTG 100.00 CTG CCA 50 
4 GAA GGG 49.85 GTG AAA 49.70 CTG CCA 50 
5 AGG GAA 49.88 GTG GTG 100.00 TTG CCA 45 
6 GAA GAA 100.00 GTG AAA 49.70 − − − 
7 AGG AGG 100.00 − − − CTG CCA 50 
8 AGG GAA 49.88 ATG AAA 50.00 CTG CTG 100 
9 AGG GAA 49.88 GTG GTG 100.00 CCA CCA 100 
10 AGG AGG 100.00 AAA AAA 100.00 CCA CCA 100 
11 GAA GAA 100.00 GTG AAA 49.70 TTG TTG 100 
12 GAA GAA 100.00 GTG GTG 100.00 − − − 
13 GAA GAA 100.00 GTG GTG 100.00 CTG CTG 100 
14 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
15 AGG GAA 49.88 GTG GTG 100.00 − − − 
16 AGG GAA 49.88 GAA AAA 100.00 CTG CCA 50 
17 AGG AGG 100.00 AAA AAA 100.00 − − − 
18 AGG AGG 100.00 GAG AAA 49.93 CTG CTG 100 
19 AGG AGG 100.00 GTG AAA 49.70 CTG CTG 100 
20 AGG AGG 100.00 GTG GTG 100.00 CCA CCA 100 
21 AGG GGG 100.00 ATG AAA 50.00 CTG CCA 50 
22 AGG GAA 49.88 GAA GTG 47.59 CTG CTG 100 
23 AGG GGG 100.00 ATG AAA 50.00 CTG CTG 100 
24 GAA GGG 49.85 GTG GTG 100.00 CTG CTG 100 
25 AGG AGG 100.00 GTG AAA 49.70 CTG TTG 100 
26 AGG GAA 49.88 GTG GTG 100.00 CTG TTG 100 
27 AGG AGG 100.00 GTG GAG 100.00 CTG CTG 100 
28 AGG GAA 49.88 GTG AAA 49.70 − − − 
29 AGG GAG 43.84 GTA GAA 100.00 CTG CCA 50 
30 AGG GAA 49.88 AAA AAA 100.00 TTG CCA 45 
31 − − − GTG GTG 100.00 − − − 
33 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
34 − − − GTG AAA 49.70 CTG CCA 50 
35 GAA GAA 100.00 GTG AAA 49.70 TTG CCA 45 
36 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
37 AGG GGG 100.00 GAG AAA 49.93 CTG CCA 50 
38 AGG GAA 49.88 GTG GTG 100.00 CTG CTG 100 
39 AGG AGA 100.00 GTG AAA 49.70 − − − 
40 GAA GAA 100.00 GTG AAA 49.70 CTG CCA 50 
41 AGG GAA 49.88 GTG AAA 49.70 − − − 
42 GAA GAA 100.00 GTG GAG 100.00 CCA CTA 100 
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Table 6.6 cont.: Haplotype phasing results (part 2). 
ID 
SGIP1 GABRA2 IL1B 
H1 H2 Prob. H1 H2 Prob. H1 H2 Prob. 
43 AGG AGG 100.00 GTG ATG 100.00 CCA CCA 100 
44 AGG AGG 100.00 GTG AAA 49.70 CCA CCA 100 
45 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
46 AGG AGG 100.00 GTG AAA 49.70 − − − 
47 AGG AGA 100.00 GTG GTG 100.00 CTG CTG 100 
48 GAA GAA 100.00 GTG GTG 100.00 − − − 
49 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
50 AGG AGG 100.00 GTG ATG 100.00 − − − 
51 AGG AGG 100.00 GTG AAA 49.70 CCG CCA 100 
52 AGG GAA 49.88 GTG AAA 49.70 CTG TTG 100 
53 AGG AGG 100.00 GTG AAA 49.70 CTG TTG 100 
54 AGG AGA 100.00 GTG GTG 100.00 CTG CCA 50 
55 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
56 AGG GAA 49.88 GTG AAA 49.70 CCA CCA 100 
58 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
59 AGG GAA 49.88 GTG GTG 100.00 CTG CTG 100 
60 AGG GAA 49.88 GTG AAA 49.70 CTG CCA 50 
62 AGG GAA 49.88 GTG AAA 49.70 − − − 
63 GAA GAA 100.00 GTG AAA 49.70 − − − 
64 AGG GAA 49.88 GTG GTG 100.00 CTG CCA 50 
65 AGG GAA 49.88 ATG AAA 50.00 CTG CCA 50 
66 AGG GAA 49.88 GTG AAA 49.70 CTG CTG 100 
67 AGG AGG 100.00 GTG GAG 100.00 TTG CCA 45 
68 AGG AGG 100.00 GTG AAA 49.70 CTG TTG 100 
69 AGG GAA 49.88 GAG ATG 39.67 CTG CCA 50 
70 AGG GAA 49.88 GAA GTG 47.59 CTG CTG 100 
71 AGG GAA 49.88 GAA GTG 47.59 CTG CTG 100 
72 AGG AGG 100.00 GTG AAA 49.70 CTG CCA 50 
73 AGG AGG 100.00 GTG GTG 100.00 CTG TTG 100 
74 AGG GGG 100.00 GTG ATG 100.00 − − − 
75 AGG GGG 100.00 GTG AAA 49.70 CTG TTG 100 
76 GAA AGA 49.86 GTG AAA 49.70 CTG TTG 100 
78 GAA GAA 100.00 GTG AAA 49.70 CTG CCA 50 
79 AGG AGG 100.00 GAG GAG 100.00 − − − 
80 AGG AGG 100.00 GTG AAA 49.70 CTG CCA 50 
82 GAA GAA 100.00 AAA AAA 100.00 CTG CCA 50 
83 AGG AGG 100.00 GTG GTG 100.00 CTG CTG 100 
85 AGG GAA 49.88 GTG AAA 49.70 CTG CTG 100 
86 GAA GAA 100.00 GTG GTG 100.00 TTG CCA 45 
87 AGG AGG 100.00 GTG AAA 49.70 CTG CCA 50 
88 AGG GAA 49.88 GTG GTG 100.00 CCA CCA 100 
89 AGG AGG 100.00 AAA AAA 100.00 CTG CCA 50 
90 AGG AGG 100.00 GTG GTG 100.00 CCA CCA 100 
91 AGG GAA 49.88 GTG GTG 100.00 CTG CCA 50 
92 AGG GAA 49.88 GTG GTG 100.00 − − − 
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Table 6.6 cont.: Haplotype phasing results (part 3). 
ID 
SGIP1 GABRA2 IL1B 
H1 H2 Prob. H1 H2 Prob. H1 H2 Prob. 
93 AGG GAA 49.88 GTG AAA 49.70 TTG CCA 45 
94 AGG AGG 100.00 GTG GTG 100.00 CTG CCA 50 
95 AGG AGG 100.00 GTG GTG 100.00 CTG CTG 100 
96 AGG AGG 100.00 GTG GAG 100.00 TTG CCA 45 
97 AGG AGG 100.00 AAA AAA 100.00 CTG CCA 50 
99 GAA GAA 100.00 GTG GTG 100.00 CTG CCA 50 
100 AGG AGG 100.00 GAA AAA 100.00 CTG CTG 100 
101 GAA GAA 100.00 GTG GTG 100.00 CTG CTG 100 
102 GAA GAA 100.00 GTG GAG 100.00 CCA CCA 100 
103 AGG AGG 100.00 AAA AAA 100.00 − − − 
104 GAA GAA 100.00 GTG AAA 49.70 CTG CCA 50 
105 GAA GAA 100.00 GTG GTG 100.00 − − − 
106 AGG GAA 49.88 GAG AAA 49.93 − − − 
108 AGG GAA 49.88 GTG AAA 49.70 TTG CCA 45 
109 AGG GAA 49.88 GTG GTG 100.00 − − − 
110 GAA GAA 100.00 AAA AAA 100.00 − − − 
111 AGG GGG 100.00 GTG AAA 49.70 CTG CCA 50 
112 AGG AGG 100.00 AAA AAA 100.00 CCA CCA 100 
114 AGG AGG 100.00 GTG AAA 49.70 CTG CCA 50 
115 AGG AGG 100.00 ATG ATG 100.00 − − − 
116 GAA GAA 100.00 GTG GTG 100.00 CTG TTG 100 
117 AGG AGG 100.00 AAA AAA 100.00 CTG CTG 100 
118 AGG GAA 49.88 GTG GTG 100.00 CTG CTG 100 
119 AGG GGG 100.00 GTG GTG 100.00 − − − 
120 AGG AGG 100.00 AAA AAA 100.00 CTG CCA 50 
121 AGG GAA 49.88 AAA AAA 100.00 TTG CCA 45 
122 AGG GAA 49.88 AAA GTA 49.74 CTG CTG 100 
123 AGG GAA 49.88 GTG AAA 49.70 CCA CCA 100 
124 AGG GGA 37.49 GTG GTG 100.00 − − − 
125 AGG GAG 43.84 AAA AAA 100.00 − − − 
128 AGG GGA 37.49 AAA AAA 100.00 − − − 
130 AAG AAA 100.00 GTG AAA 49.70 − − − 
131 GAA AAG 49.67 GTG GTG 100.00 − − − 
158 AGG AGG 100.00 GTG GTG 100.00 CTG CCA 50 
159 GAA AGA 49.86 GTG AAA 49.70 TTG TTG 100 
163 AGG GGG 100.00 − − − CTG TTG 100 
165 AGG AGG 100.00 GTG GTG 100.00 CTG CCA 50 
167 AGG GAA 49.88 GTG AAA 49.70 CTG TTG 100 
170 AGG GAA 49.88 GAG AAA 49.93 TTG CCA 45 
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Table 6.7: Summary of quality control data for haplotype phase reconstruction 
performed using the EM algorithm in SNPAnalyzer 1.2A.  
Minimum, maximum and mean of haplotype call probabilities are shown together with 
percentage of samples that met the 90% probability threshold (Passed).  
Gene n Min.  probability 
Max. 
probability 
Mean 
probability Passed  
SGIP1 123 37% 100% 78% 56% 
GABRA2 123 40% 100% 75% 51% 
IL1B 97 45% 100% 75% 51% 
 
 
6.6 HapMap haplotypes and haplotype blocks 
The following LD plots and haplotypes were constructed in Haploview using 
downloaded HapMap data (V3/R27/CEU) and the haplotype block definitions  
of Gabriel et al. (2002) [134]. For LD plots, the value in each square corresponds 
level of LD between SNP loci in D’ – for example, a value of 94 corresponds to  
D’ = 0.94, and empty squares correspond to D’ = 1. Dark black squares indicate 
high levels of LD between SNP loci, and white and pale grey squares weaker LD. 
 
Table 6.8: Comparison of haplotypes and their frequencies constructed for SNPs 
genotyped in this study with the HapMap Caucasian population.  
a. SGIP1 haplotypes, 1 = rs10889635, 2 = rs6681460, 3 = rs2146904; b. GABRA2 haplotypes, 
1 = rs572227, 2 = 279845, 3 = rs279841; c. IL1B haplotypes, 1 = rs1143634, 2 = rs1143627 
and 3 = rs16944. N/P = haplotype not present in HapMap Caucasians. 
a. SGIP1 Genotyped HapMap b. GABRA2 Genotyped HapMap 
 1 2 3 HF HF  1 2 3 HF HF 
 A G G 0.558 0.509  G T G 0.530 0.491 
 G A A 0.350 0.453  A A A 0.343 0.432 
 G G G 0.043 0.004  G A G 0.048 0.030 
 A G A 0.022 0.017  G T A 0.009 N/P 
 A A G 0.009 N/P  G A A 0.025 0.017 
 G A G 0.008 0.009  A T G 0.045 0.021 
 G G A 0.007 N/P       
 A A A 0.004 0.009 c. IL1B Genotyped HapMap 
       1 2 3 HF HF 
       C T G 0.490 0.470 
       C C A 0.368 0.321 
       T T G 0.126 0.171 
       T C A 0.011 0.034 
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Figure 6.27: LD plot showing the haplotype block structure of GABRA2.  
SNPs genotyped by PCR-RFLP in this study are circled. SNPs previously associated with 
GABRA2 mRNA levels [171] are marked with square boxes (rs279871 was not in the 
HapMap Caucasian database).   
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Figure 6.28: Haplotype block structure and haplotypes for MYD88 and surrounding 
genomic region.  
a. LD plot for MYD88 and surrounding genomic region. rs6853 (circled) is located in a 29 kb 
haplotype block encompassing all of MYD88 (indicated by a black square) along with ACAA1 
and part of DLEC1. b. rs6853G (circled) is present on two rare haplotypes located in a 29 kb 
haplotype in Caucasians.  
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Figure 6.29: LD plot showing gene and haplotype block structure of IL1B and 
surrounding genomic region.  
Genotyped SNPs are circled.  
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Figure 6.30: LD plot showing gene and haplotype block structure of IL10.  
rs1800896 (circled) is located in a 7 kb haplotype block encompassing all of IL10.  
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6.7 Association analysis results 
Table 6.9: Effect of SNP genotypes on spindle amplitude.  
Significant (p < 0.05), and highly significant (p < 0.01), p-values are marked by an asterisk 
and double asterisk, respectively. 
SNP Test Genotype n Median  (95% CI) 
Fold 
Diff. p-value 
rs6681406 AA vs. AG AA 21 2.18 (1.93-2.43) 1.25 0.0158* 
(SGIP1)  AG 50 1.74 (1.51-1.98)   
 AA vs. GG AA 21 2.18 (1.93-2.43) 1.23 0.0206* 
  GG 52 1.77 (1.50-1.99)   
 AG vs. GG  AG 50 1.74 (1.51-1.98) 0.98 0.7863 
  GG 52 1.77 (1.50-1.99)   
rs279841 AA vs. AG AA 18 2.32 (1.95-2.44) 1.29 0.0262* 
(GABRA2)  AG 58 1.80 (1.61-1.99)   
 AA vs. GG AA 18 2.32 (1.95-2.44) 1.28 0.0141* 
  GG 47 1.81 (1.54-2.06)   
 AG vs. GG  AG 58 1.80 (1.61-1.99) 0.99 0.8467 
  GG 47 1.81 (1.54-2.06)   
rs1143627 CC vs. CT CC 13 1.54 (1.13-1.75) 0.78 0.0118* 
(IL1B)  CT 48 1.97 (1.68-2.25)   
 CC vs. TT CC 13 1.54 (1.13-1.75) 0.91 0.3358 
  TT 36 1.69 (1.32-1.93)   
 CT vs. TT  CT 48 1.97 (1.68-2.25) 1.17 0.0488* 
  TT 36 1.69 (1.32-1.93)   
rs16944 AA vs. AG AA 12 1.47 (1.13-1.75) 0.78 0.0129*  
(IL1B)  AG 51 1.89 (1.71-2.25)   
 AA vs. GG AA 12 1.47 (1.13-1.75) 0.87 0.3230 
  GG 36 1.69 (1.32-1.93)   
 AG vs. GG  AG 51 1.89 (1.71-2.25) 1.12 0.0568 
  GG 36 1.69 (1.32-1.93)   
rs6853 AG vs. AA AG 15 2.43 (1.62-2.84) 1.39 0.0040** 
(MYD88)  AA 83 1.75 (1.54-1.88)   
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Table 6.10: Effect of SNP genotypes on relative spindle amplitude. 
Significant (p < 0.05), and highly significant (p < 0.01), p-values are marked by an asterisk 
and double asterisk, respectively. 
SNP Test Genotype n Median  (95% CI) 
Fold 
Diff. p-value 
rs6681406 AA vs. AG AA 20 0.48 (0.32-0.53) 1.55 0.0115* 
(SGIP1)  AG 49 0.31 (0.24-0.35)   
 AA vs. GG AA 20 0.48 (0.32-0.53) 1.41 0.0261* 
  GG 51 0.34 (0.23-0.42)   
 AG vs. GG  AG 49 0.31 (0.24-0.35) 0.91 0.8307 
  GG 51 0.34 (0.23-0.42)   
rs873634 GG vs. GT GG 16 0.43 (0.34-0.53) 1.48 0.0164* 
(HCN1)  GT 52 0.29 (0.24-0.41)   
 GG vs. TT GG 16 0.43 (0.34-0.53) 1.30 0.0540 
  TT 51 0.33 (0.26-0.42)   
 GT vs. TT GT 52 0.29 (0.24-0.41) 0.88 0.3732 
  TT 51 0.33 (0.26-0.42)   
rs1143627 CC vs. CT CC 13 0.27 (0.16-0.44) 0.77 0.0724 
(IL1B)  CT 48 0.35 (0.29-0.49)   
 CC vs. TT CC 13 0.27 (0.16-0.44) 1.04 0.8985 
  TT 35 0.26 (0.20-0.34)   
 CT vs. TT  CT 48 0.35 (0.29-0.49) 1.35 0.0145* 
  TT 35 0.26 (0.20-0.34)   
rs16944 AA vs. AG AA 12 0.27 (0.16-0.44) 0.79 0.1073 
(IL1B)  AG 51 0.34 (0.29-0.47)   
 AA vs. GG AA 12 0.27 (0.16-0.44) 1.04 0.9223 
  GG 35 0.26 (0.20-0.34)   
 AG vs. GG  AG 51 0.34 (0.29-0.47) 1.31 0.0220* 
  GG 35 0.26 (0.20-0.34)   
rs6853 AG vs. AA AG 15 0.49 (0.35-0.57) 1.69 0.0006** 
(MYD88)  AA 82 0.29 (0.24-0.33)   
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Table 6.11: Effect of SNP genotypes on ETDC. 
Significant (p < 0.05), and highly significant (p < 0.01), p-values are marked by an asterisk 
and double asterisk, respectively. 
SNP Test Genotype n Median  (95% CI) 
Fold 
Diff. p-value 
rs7501581 GG vs. CG GG 19 6.39 (4.96-7.36) 1.29 0.0075** 
(CACNA1G)  CG 52 4.95 (4.56-5.49)   
 GG vs. CC GG 19 6.39 (4.96-7.36) 1.14 0.1071 
  CC 51 5.62 (5.04-6.03)   
 CG vs. CC CG 52 4.95 (4.56-5.49) 0.88 0.0383* 
  CC 51 5.62 (5.04-6.03)   
rs2794521 CC vs. CT CC 8 5.78 (4.71-7.96) 0.97 0.6764 
(CRP)  CT 31 5.96 (5.57-6.68)   
 CC vs. TT CC 8 5.78 (4.71-7.96) 1.12 0.0739 
  TT 57 5.18 (4.80-5.62)   
 CT vs. TT CT 31 5.96 (5.57-6.68) 1.15 0.0306* 
  TT 57 5.18 (4.80-5.62)   
rs6853 AG vs. AA AG 15 5.04 (4.35-5.35) 0.88 0.0095** 
(MYD88)  AA 82 5.71 (5.46-6.1)   
rs1800469 TT vs. CT TT 13 4.71 (4.26-5.67) 0.84 0.0634 
(TGF1B)  CT 46 5.58 (4.82-6.10)   
 TT vs. CC TT 13 4.71 (4.26-5.67) 0.79 0.0126* 
  CC 39 5.95 (5.39-6.66)   
 CT vs. CC CT 46 5.58 (4.82-6.10) 0.84 0.2408 
  CC 39 5.95 (5.39-6.66)   
  
Table 6.12: Effect of rs7501581 (CACNA1G) on relationship between BIS and ETDC.  
a. Linear regression analysis results for √BIS value vs. ETDC categorised by rs7501581 
genotype. b. p-values for differences in slope and intercept between lines. Significant (p < 
0.05), and highly significant (p < 0.01), p-values are marked by an asterisk and double 
asterisk, respectively. 
a. Model Genotype/s n Intercept Slope r2 r  p-value 
 R G/G 16 6.396 -0.080 0.024 -0.155 0.5663 
  C/G + C/C 84 7.067 -0.136 0.040 -0.200 0.0693 
 D G/G + C/G 55 6.725 -0.099 0.025 -0.158 0.2492 
  C/C 45 7.734 -0.243 0.126 -0.112 0.0169* 
 OD C/C + G/G 61 7.558 -0.226 0.122 -0.349 0.0058** 
  C/G 39 6.568 -0.053 0.006 -0.076 0.6458 
 
b. 
Model Genotype/s p-value for difference in intercept 
p-value for difference 
in slope  
 R G/G vs. C/G + C/C 0.1786 0.7765 
 D G/G + C/G vs. C/C 0.2476 0.2804 
 OM C/C + G/G vs. C/G 0.8393 0.1990 
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Table 6.13: Effect of rs6853 (MYD88) genotype on relationship of ETDC with spindle 
amplitude and BIS value.  
a. Linear regression analysis results for spindle amplitude (Spindle A.) vs. ETDC, and √BIS 
value vs. ETDC, categorised by res6853 genotype. b. p-values for differences in slope and 
intercept between lines. Significant (p < 0.05), and highly significant (p < 0.01), p-values are 
marked by an asterisk and double asterisk, respectively. 
a. ETDC vs. Genotype n Intercept Slope r2 r  p-value 
 Spindle A. A/A 82 0.019 -0.183 0.172 -0.415 0.0001** 
  A/G 15 2.177 2.764 0.001 0.028 0.9208 
 √BIS A/A 82 -0.5836 -0.1348 0.038 -0.194 0.1075 
  A/G 15 9.097 7.059 0.394 0.627 0.0163 
 
b. 
ETDC vs. Test p-value for difference in intercept 
p-value for difference 
in slope  
 Spindle A. A/A vs. A/G 0.0087** 0.2139 
 √BIS A/A vs. A/G 0.4216 0.8594 
 
Table 6.14: Effect of rs1800896 (IL10) genotype on delta frequency. 
Significant (p < 0.05), and highly significant (p < 0.01), p-values are marked by an asterisk 
and double asterisk, respectively. 
SNP Test Genotype n Median  (95% CI) 
Fold 
Diff. p-value 
rs1800896 GG vs. AG GG 19 0.50 (0.05-0.63) 0.67 0.0055** 
(IL10)  AG 47 0.75 (0.63-0.88)   
 GG vs. AA GG 19 0.50 (0.05-0.63) 0.79 0.1385 
  AA 33 0.63 (0.50-0.75)   
 AG vs. AA AG 47 0.75 (0.63-0.88) 1.19 0.0935 
  AA 33 0.63 (0.50-0.75)   
 
 
 
